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Résumé 
Les cyclodipeptides et leurs dérivés, les dicétopipérazines (DKP), constituent une large classe de métabolites 
secondaires aux activités biologiques remarquables qui sont essentiellement synthétisés par des microorganismes. 
Les voies de biosynthèse de certaines DKP contiennent des synthases de cyclodipeptides (CDPS), une famille 
d’enzymes récemment identifiée. Les CDPS ont la particularité de détourner les ARNt aminoacylés de leur rôle 
essentiel dans la synthèse protéique ribosomale pour les utiliser comme substrats et ainsi catalyser la formation 
des deux liaisons peptidiques de différents cyclodipeptides. Le travail de thèse présenté dans ce manuscrit a pour 
objectif de caractériser la nouvelle famille des CDPS. Dans un premier temps, la caractérisation tant structurale 
que mécanistique de la première CDPS identifiée, AlbC de Streptomyces noursei, est présentée. Puis, les résultats 
obtenus avec trois autres CDPS, chacune de ces enzymes ayant des caractéristiques adéquates pour approfondir 
l’étude de la famille des CDPS, sont décrits. Ainsi, la CDPS Ndas_1148 de Nocardiopsis dassonvillei a permis 
d’étendre nos connaissances sur les bases moléculaires de la spécificité des CDPS. La CDPS AlbC-IMI de S. sp. IMI 
351155 est un bon modèle pour analyser l’interaction de chacun des deux substrats nécessaires à la formation 
d’un cyclodipeptide. Enfin, la caractérisation de la CDPS Nvec-CDPS2 chez l’animal Nematostella vectensis a permis 
de fournir le premier exemple d’enzyme d’origine animale impliquée dans la synthèse peptidique non ribosomale.     
Abstract 
Cyclodipeptides and their derivatives, the diketopiperazines (DKPs), constitute a large class of secondary 
metabolites with noteworthy biological activities that are mainly synthesized by microorganisms. The biosynthetic 
pathways of some DKPs contain cyclodipeptide synthases (CDPSs), a newly defined family of enzymes. CDPSs hijack 
aminoacyl-tRNAs from their essential role in ribosomal protein synthesis to catalyze the formation of the two 
peptide bonds of various cyclodipeptides. The aim of the work presented in this thesis manuscript is to 
characterize the CDPS family. At first, the structural and mechanistic characterization of the first identified CDPS, 
AlbC of Streptomyces noursei, is presented. Then, the results obtained with three other CDPSs, each of which 
having suitable properties to increase our understanding of the CDPS family, are described. The CDPS Ndas_1148 
of Nocardiopsis dassonvillei extends our knowledge of the molecular bases of the CDPS specificity. The CDPS AlbC-
IMI of S. sp. IMI 351155 is a good model to analyze the interaction of each of the two substrates required for the 
formation of a cyclodipeptide. Finally, the characterization of the CDPS Nvec-CDPS2 from Nematostella vectensis 
provides the first example of enzymes of animal origin involved in nonribosomal peptide synthesis. 
Mots-clés :  
cyclodipeptide synthase (CDPS), diketopiperazine (DKP), nonribosomal biosynthesis, peptide bond, aminoacyl-
tRNA, secondary metabolite  
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Abbreviations 
aaRS Aminoacyl-tRNA synthetase 
aa-tRNA Aminoacyl-tRNA 
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Introduction 
Natural products have been the source of most of the active ingredient of 
medicines. Analysis of the sources of new and approved drugs for the treatment of 
human diseases indicates that natural products always play a highly significant role 
in the drug discovery and development process. Almost half of the drugs approved 
since 1994 are based on natural products. In the past decade, with the development 
of the combinatorial chemistry, many pharmaceutical companies put an emphasis on 
high1throughput screening of synthetic libraries and decrease the research into 
natural products (Harvey 2008; Li and Vederas 2009). This has been because of the 
perceived disadvantages of natural products, such as difficulties in access and supply, 
and complexities of natural product chemistry since many effective natural 
compounds cannot be easily obtained by the chemical synthesis pathway. 
Nevertheless, the rapid development of biotechnologies in recent years renews the 
interest of natural products in the drug discovery. Untapped biological resources, 
biological screening methods, robotic separation with structural analysis, metabolic 
engineering, and synthetic biology offer exciting technologies for new natural 
product drug discovery (Li and Vederas 2009). A significant number of natural 
product drugs are actually produced by microbes. Numerous microbial metabolites 
have been found to have interesting pharmaceutical activities such as antimicrobial 
and antitumor activities. 
In the bioactive natural compounds, there is an important class of molecules 
called “diketopiperazines (DKPs)” which consist of cyclodipeptides and their 
derivatives. They are commonly biosynthesized by a large variety of organisms, 
including mammals (De Carvalho and Abraham 2012). The ability of microorganisms 
to produce DKPs is widespread and published data have shown that about 90% of 
Gram1negative bacteria produce them (Fenical 1993). In view of the potential medical 
value of such molecules, research on DKPs is always an active domain. However, a 
lot of DKPs with complex modifications cannot be easily obtained through the 
6 
chemical synthesis approach. It is thus important to decipher their biosynthetic 
pathways. Some cyclodipeptides have been reported to be synthesized by dedicated 
nonribosomal peptide synthetases (NRPSs) which are large multimodular 
biocatalysts. The structure and the catalytic mechanism of NRPSs will specially be 
described in the section “bibliographic studies”. 
The research team named “Enzymology and non ribosomal peptide 
biosynthesis”, directed by Dr Muriel Gondry (CEA/DSV/iBiTec1S/SIMOPRO), is 
devoted to studies on the biosynthetic pathways and mechanisms of DKPs. At the 
beginning, in collaboration with another team directed by Jean1Luc Pernodet (IGM, 
CNRS UMR 8621, Université Paris1Sud 11), they isolated the biosynthetic pathway of 
albonoursin (cyclo(MPhe1MLeu)) ( 	) which is a DKP produced by 
Streptomyces noursei and Streptomyces albulus with remarkable bioactivities like 
antibacterial and antitumor activities (Gondry et al. 2001; Lautru et al. 2002). Like 
most secondary metabolite genes in Streptomyces species, the albonoursin 
biosynthetic genes are clustered. The DNA fragment has a length of 3.8 kb containing 
four genes named albA, albB, albC and albD. However, subsequent studies showed 
that only albA, albB and albC are necessary for the biosynthesis of albonoursin (

). albA and albB code the cyclic dipeptide oxidase (CDO), while albC codes a small 
enzyme of 28 kDa, called AlbC. Firstly, the precursor of albonoursin, cyclo(Phe1Leu) 
or indicated as cFL, is synthesized by AlbC; then the CDO catalyzes the formation of 
α,β1unsaturated residues of cyclo(Phe1Leu) to generate albonoursin; the latter is 
released to the culture medium after synthesis () (Lautru et al. 2002). 
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Figure 1: The albonoursin and its biosynthesis (Lautru et al. 2002). (A) Structure of albonoursin, with 
the DKP skeleton shown in orange and the two α,β-dehydrogenations in green. (B) The gene cluster 
composed of albA, albB and albC, and responsible for the biosynthesis of albonoursin. (C) Schema of 
the biosynthetic pathway of albonoursin. 
AlbC catalyzes the formation of cyclodipeptides but it is unrelated to NRPSs or 
other known proteins. In the next few years, other similar proteins to AlbC were 
successively discovered in various bacterial phyla. Until 2009, eight related proteins 
from different bacterial organisms () had been identified and characterized 
(Gondry et al. 2009). They are all composed of 2161249 amino acid residues, 13 of 
which are conserved among them. In addition, further biological analysis 
demonstrated that they all use aminoacyl1tRNAs (aa1tRNAs) as substrates to catalyze 
the formation of cyclodipeptides. These proteins thus form a family of tRNA1
dependent peptide bond1forming enzymes dedicated to the formation of 
cyclodipeptides. They are named “cyclodipeptide synthases (CDPSs)” (Gondry et al. 
2009). However, the primary characterization showed that those CDPSs do not 
synthesize the same cyclodipeptides (). All the eight CDPSs were expressed 
in E. coli. Their culture supernatants were analyzed by LC1MS/MS which is HPLC 
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coupled to mass spectrometry in order to characterize the cyclodipeptides 
synthesized. The results showed that AlbC produced twelve cyclodipeptides, 
including the principal products cFL and cFF. Thus, AlbC can incorporate into 
cyclodipeptides various nonpolar residues, such as phenylalanine, leucine, tyrosine 
and methionine, and to a much lesser extent alanine and valine. Indeed, the ten 
possible cyclodipeptides composed of phenylalanine, leucine, tyrosine and 
methionine are all synthesized in detectable amounts by AlbC. Almost all of the 
compounds produced by other CDPSs are combinations of the same four amino 
acids, with the restriction that cyclodipeptides synthesized by Rv2275 always contain 
tyrosine, and those synthesized by the other CDPSs almost always contain leucine 
(). 
 
Figure 2: Eight characterized CDPSs to date (in bold) from different bacterial phyla shown in the form 
of phylogenetic tree. 
AlbC
Streptomyces noursei
Rv2275
Mycobacterium
tuberculosis
Jk0923
Corynebacterium jeikeium
Plu0297
Photorhabdus
luminescens
PSHaeC06
Staphylcoccus haemolyticus
YvmC
Bacillus subtilis
YvmC
Bacillus
licheniformis
YvmC
Bacillus 
thuringiensis
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Figure 3: Histogram of the amounts of the various cyclodipeptides synthesized by eight recombinant 
CDPSs in E. coli (Gondry et al. 2009). cXX corresponds to an unidentified cyclodipeptide of the same 
molecular mass as cLL. 
Cyclodipeptide formation is often the first step in the synthesis of more 
complex DKPs that are obtained after tailoring reactions (Gardiner et al. 2004; Loria 
et al. 2008). This appears also to be the case for the CDPS1synthesizing 
cyclodipeptides because the CDPS genes in prokaryotes are generally organized into 
operon1like structures and some of the proteins encoded by these operons could play 
a role in modifying the cyclodipeptide. So far, three proteins encoded by genes 
closely linked to CDPS genes have been experimentally characterized and shown to 
have three different cyclodipeptide1tailoring activities: α,β1dehydrogenation, DKP 
ring oxidation and C1C aryl coupling () (Belin et al. 2012). One of the three 
proteins is the CDO having the α,β1dehydrogenation activity. As previously 
described, it is involved in oxidizing the cFL in the biosynthetic pathway of 
albonoursin (  and  	). Many of the CDPS genes identified in 
databases are closely linked to a gene encoding a cytochrome P450 enzyme (P450). 
P450s constitute a superfamily of heme1containing monooxygenases that dissociate 
molecular oxygen to catalyze numerous reactions on a wide range of structurally 
diverse molecules (Guengerich 2001; Isin and Guengerich 2007). The first evidence of 
a role for a P450 in a CDPS1dependent pathway was provided by the identification of 
10 
the yvmCcypX gene cluster in the pulcherrimin synthesis in B. subtilis ( 
) 
(Tang et al. 2006). The CDPS YvmC catalyzes the formation of cyclo(Leu1Leu) (cLL) 
(Gondry et al. 2009), which is subsequently converted into pulcherriminic acid by 
CypX; the pulcherriminic acid associates with iron (III) to generate pulcherrimin. 
CypX having the cyclodipeptide1tailoring activity belongs to the P450 family. The 
recent biochemical and structural characterization of CYP134A1 (= CypX) has 
provided insight into the oxidation of the DKP ring of cyclodipeptides (Cryle et al. 
2010). The third cyclodipeptide1tailoring identified is CYP121 involved in the 
biosynthetic pathway of mycocyclosin isolated from Mycobacterium tuberculosis 
( ). Genetically, CYP121 is linked to the CDPS Rv2275 in an operon1like 
structure (Cole et al. 1998; Roback et al. 2007). The two proteins constitute the 
metabolic pathway of the DKP mycocyclosin. Rv2275 synthesize cyclo(Tyr1Tyr) (cYY) 
which is then modified by CYP121 having C1C aryl coupling activity. 
Bioinformatic analyses of the genetic environment of putative CDPSs have 
enabled to identify new putative cyclodipeptide1tailoring enzymes such as methyl1
transferases, oxidoreductases, 21oxoglutatarate1dependent oxygenases, acyl1CoA or 
peptideligases, and hypothetical proteins not yet related to any known function. 
These proteins may actually catalyze alternative modifications of the side chains of 
the residues constituting the cyclodipeptide or the cyclodipeptide ring itself (Belin et 
al. 2012). 
11 
 
Figure 4: The CDPS-dependent biosynthetic pathways of albonoursin 1 (A), pulcherrimin 3 (B) and 
mycocyclosin 4 (C) (Belin et al. 2012). 
Nevertheless, our knowledge on the CDPS family and the CDPS1dependent 
biosynthetic pathways of DKPs is still very poor. It is important to understand their 
molecular mechanisms in order to, in the long run, apply this knowledge to the 
production of molecules that have new or improved biological and pharmacological 
activities. 
My Ph.D project mainly consists of characterization of some CDPSs of interest, 
elucidation of their molecular bases on catalysis and on substrate specificity, as well 
as preliminary work on the catalytic process of CDPSs. This work can be achievable 
thanks to the existence of new CDPSs in the nature, some of which are good study 
models. 
This thesis manuscript will begin with bibliographic studies on DKPs and the 
known peptide bond1forming biocatalysts ( ). The result part will be 
12 
divided into four chapters ( ). The   will be dedicated to a 
published work on structural and mechanic characterization of AlbC, which 
provides insight into the interaction between the CDPS and its aa1tRNA substrates, 
as well as the catalytic mechanism. In the  , I will introduce a new CDPS 
Ndas_1148 from Nocardiopsis dassonvillei characterized in the laboratory. The 
characteristics of Ndas_1148 allow us to better understand the molecular bases of the 
substrate specificity. In the , I will introduce another CDPS, named AlbC1
IMI, freshly identified from Streptomyces sp. IMI 351155. AlbC1IMI is used in my 
work as a CDPS model to study the catalytic mechanism. The  concerns our 
published work on Nvec1CDPS2 which is the first eukaryotic CDPS identified in the 
sea anemone Nematostella vectensis. Finally, we will conclude the whole work and 
present the perspectives of studies on CDPSs. 
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1 BIBLIOGRAPHIC STUDIES 
1.1 Natural Diketopiperazines (DKPs) 
Cyclodipeptides and their derivatives DKPs have been detected in a variety of 
natural resources. They constitute a large class of secondary metabolites synthesized 
predominantly by microorganisms. Recently, the interest in these compounds has 
significantly increased because of their diverse and remarkable bioactivities (Prasad 
1995; Martins and Carvalho 2007; Huang et al. 2010), such as antibacterial (Magyar et 
al. 1996; Cain et al. 2003; Kohn and Widger 2005), antifungal (Ström et al. 2002; 
Musetti et al. 2007), antiviral (Rodriguez and Carrasco 1992), antitumor (Kanoh et al. 
1999; Williams et al. 1999; Kanzaki et al. 2004; Jia et al. 2005), immunosuppressive 
(Waring and Beaver 1996) and anti1inflammatory (Minelli et al. 2012) activities. Some 
DKPs are found to play physiological roles like in quorum1sensing (Holden et al. 
1999; Degrassi et al. 2002; Park et al. 2006; Li et al. 2011; Ortiz1Castro et al. 2011), in 
plant1growth regulatory (Ortiz1Castro et al. 2011), and in central nervous system 
(Minelli et al. 2009). In this part, I will introduce the DKP family, their physiological 
roles, their biological and pharmacological activities, and some applications or 
potential applications of DKPs in medical and pharmaceutical domains. 
1.1.1 DKP family 
DKPs are a class of cyclic organic compounds and characterized by a common 
motif: the DKP nucleus, which is heterocycle piperazine12.51dione, also known as 
dioxopiperazine. This nucleus presents two cis amide bonds. The general structure of 
DKPs is shown in . 
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Figure 5: General structure of DKPs. R1 and R2 represent variable lateral chains. 
When the groups R1 and R2 correspond to side chains of amino acids,  
these DKPs are named cyclodipeptides. They are from the cyclization of two amino 
acids resulting from the formation of two peptide bonds. The cyclodipeptides can be 
of cis or trans conformation, depending on whether the constituting amino acids are 
of identical or different configuration. 
1.1.1.1 Natural abundance of DKPs 
DKPs are ubiquitous in nature. They are produced in numerous prokaryotic 
and eukaryotic organisms forming a large family of natural products although these 
molecules are a relatively unexplored class of bioactive peptides.  
A lot of DKPs have been isolated in prokaryotes of various species like 
Streptomyces noursei (Khokhlov and Lokshin 1963), Pseudomonas aeruginosa (Jayatilake 
et al. 1996), Lactobacillus reuteri (Li et al. 2011) and Salinispora arenicola (Schultz et al. 
2008). Besides, DKPs are also produced by plants and by several eukaryotic 
microorganisms such as yeasts, lichens and fungus (Prasad 1995). Some examples are 
shown in  . Numerous DKPs are isolated from marine microorganisms, 
sponges, see stars, tunicates (ascidians), and red algae (Huang et al. 2010). Finally, 
one DKP, cyclo(His1Pro), has been shown to be present in mammals. This DKP was 
demonstrated to be present in human (hypothalamus, stomach and esophagus), 
monkey (hypothalamus and spinal cord), rat and mouse (hypothalamus, cerebellum 
and cortex) (Prasad 1995).  
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Table 1: Some simple cyclodipeptides that occur naturally in the protist and plant kingdoms (Prasad 
1995). 
A significant structural diversity of DKPs is associated with the variety of their 
natural sources, which I will detail in the following section. 
1.1.1.2 Structural diversity of DKPs 
Structures of DKPs vary a lot from simple cyclodipeptides to very complicated 
derivatives. Some examples are shown in  . In most cases, amino acids 
incorporated in DKPs are of L1configuration. In this thesis, the configuration of amino 
acids constituting the cyclodipeptides will not be specified except for those of D1
configuration. All amino acids are not similarly incorporated to form cyclodipeptides. 
They are often composed of hydrophobic and aromatic amino acids especially the 
leucine (cyclo(Leu1Pro)), the valine (cyclo(MAla1Val) (	) (Holden et al. 1999), 
the proline, the tyrosine (cyclo(Pro1Tyr)) (Holden et al. 1999), the phenylalanine 
(cyclo(Phe1Pro)) (Li et al. 2011), and the tryptophan (cyclo(Trp1Phe)). Several charged 
and polar amino acids are also present in DKPs, such as the serine (gliotoxine (

)), and the histidine (cyclo(His1Pro)). Several unusual amino acids are also found 
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in some DKPs, such as the δ–hydroxyl1leucine in cyclomarazines A and B (
), and the norvaline (Nva) in cyclo(41methyl1D1Pro1Nva) () (Adamczeski 
et al. 1995). 
Besides the different types of amino acids, various chemical modifications to 
cyclodipeptides also enrich the diversity of DKPs. The modification can be 
introduced to DKP nuclei or to their side chains. The most common chemical 
modifications are the methylation like cyclo(41methyl1D1Pro1Nva) ( ), the 
hydroxylation like bicyclomycin ( ), the nitration like the phytotoxin 
thaxtomin A (), and the presence of double bonds like albonoursin (
). 
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Figure 6: Examples of DKP structures. The DKP-producing species are indicated in italics. 
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1.1.1.3 Physiological roles of DKPs 
Although the DKPs are ubiquitous in nature and more and more DKPs are 
being discovered, knowledge to their physiological roles is still limited. In this part, I 
will introduce several known physiological roles of some DKPs. 
1.1.1.3.1 Cell0to0cell communication: Quorum sensing 
Communication between cells via diffusible chemicals is a general phenomenon 
virtually found in all living organisms. It has been intensively studied in bacteria in 
the last two decades. One of the best1known examples is quorum sensing. A number 
of bacteria associated with eukaryotic hosts employ quorum sensing systems to sense 
their population density thereby modulating the expression of sets of genes involved 
in physiological responses associated with survival, propagation, and/or virulence 
(Salmond et al. 1995; de Kievit and Iglewski 2000; Henke and Bassler 2004). 
In Gram1negative bacteria, the most universal cell1cell signaling mechanism 
occurs via the production and response to a class of small diffusible molecules called 
N1acylhomoserine lactones (AHLs). However, DKPs are identified in cell1free culture 
supernatants of some Gram1negative bacteria. Cyclo(MAla1Val) and cyclo(Pro1Tyr) 
were found in Pseudomonas aeruginosa, Proteus mirabilis, Citrobacter freundii and 
Enterobacter agglomerans (cyclo(MAla1Val) only) (Holden et al. 1999). Although these 
two DKPs were absent from Pseudomonas fluorescens and Pseudomonas alcaligenes, a 
third DKP, cyclo(Phe1Pro) was isolated from both pseudomonas (Holden et al. 1999). 
The three DKPs were revealed capable of activating or antagonizing a LuxR1based 
AHL biosensor or other LuxR1based quorum1sensing systems. Although the 
physiological role of these DKPs has yet to be established, their activity suggests the 
existence of cross talk among bacterial signalling systems (Holden et al. 1999). 
Furthermore, the study of G. Degrassi et al. demonstrated that plant growth1
promoting Pseudomonas putida WCS358 produced at least four different 
cyclodipeptides (cyclo(Pro1Tyr), cyclo(Pro1Leu), cyclo(Phe1Pro), and cyclo(Val1Leu)), 
and some of them potentially cross1talked with the quorum sensing LuxI and LuxR 
homologs (Degrassi et al. 2002). It was found that three DKPs (cyclo(Pro1Val), 
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cyclo(Phe1Pro), and cyclo(Pro1Tyr)) from Pseudomonas aeruginosa were involved in 
plant growth promotion by this symbiotic bacterium (Ortiz1Castro et al. 2011). The 
observation that quorum1sensing1regulated bacterial production of DKPs modulates 
auxin signaling and plant growth promotion establishes an important function for 
DKPs mediating prokaryote/eukaryote transkingdom signaling (Ortiz1Castro et al. 
2011). In addition, cyclo(Phe1Pro) was found produced by Vibrio vulnificus and 
related Vibrio spp. (V. cholera, V.  parahaemolyticus, and V. harveyi) (Park et al. 2006). 
Vibrio vulnificus is an opportunistic human pathogen that causes severe wound 
infection and primary septicemia (Strom and Paranjpye 2000). The study suggests 
that cyclo(Phe1Pro) is a signal molecule controlling the expression of genes important 
for the pathogenicity of Vibrio spp. by activating the quorum sensing bioindicator 
(Park et al. 2006). If methods could be developed to interfere with quorum sensing 
systems of Gram1negative pathogens, a novel means of controlling their 
pathogenicity might be possible (Hartman and Wise 1998). 
In Gram1positive bacteria are also isolated DKPs participating in interspecies 
cell1to1cell communication. In the work of Jingru Li et al., they showed that the 
human vaginal isolate Lactobacillus reuteri RC114 produced cyclo(Pro1Pro) and 
cyclo(Tyr1Pro) as the signaling molecules that are able to interfere with the 
staphylococcal quorum sensing system agr, a key regulator of virulence genes (Li et 
al. 2011). Their work contributes to a better understanding of interspecies cell1to1cell 
communication between Lactobacillus and staphylococcus, and provides a unique 
mechanism by which endogenous or probiotic strains may attenuate virulence factor 
production by bacterial pathogens. 
1.1.1.3.2 Virulence of pathogenic microorganisms 
So far, certain DKPs are found to be involved in the virulence of pathogenic 
microorganisms such as thaxtomin phytotoxins and gliotoxin. 
Thaxtomin phytotoxins, first reported in 1989, are cyclic dipeptides (2,51
diketopiperazines) formed from the condensation of 41nitrotrytophan and 
phenylalanine groups. Individual thaxtomins differ only in the presence or absence 
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of N1methyl and hydroxyl groups and their respective substitution sites. The great 
interest in the thaxtomins derives mainly from their established roles as virulence 
factors in the common scab of potato disease and their apparent ability to inhibit 
cellulose synthesis in developing plant cells. Common scab is an economically 
important disease that is caused by Streptomyces species, which attack growing tubers 
through immature lenticels and wound sites. All these streptomyces species produce 
the phytotoxin thaxtomin which could be thaxtomin A ( ) or another 
member of the thaxtomin family (Loria et al. 2008). Numerous studies have 
demonstrated that the thaxtomin family is directly associated with the potato 
common scab disease. Firstly, thaxtomin is present in the tissues of infected plants 
and, once extracted and added in healthy tissues, induces symptoms of the common 
scab (King et al. 1992). Then, Healy et al. found that thaxtomin A production was 
abolished in biosynthesis pathway disruption mutants which were avirulent on 
potato tubers. Moreover, introduction of the thaxtomin synthetase cosmid into a 
mutant restored both pathogenicity and thaxtomin A production, demonstrating a 
critical role for thaxtomins in pathogenesis (Healy et al. 2000). In short, the 
generation of thaxtomins by common scab1causing species from diverse geographic 
areas of the world and the quantitative relationship established between phytotoxin 
production and virulence overwhelmingly supports the concept of these toxins as 
pathogenicity determinants (King and Calhoun 2009). 
Gliotoxin ( 
) is an epipolythiodioxopiperazine toxin that is made by 
the filamentous fungus Aspergillus fumigatus. This molecule has several remarkable 
biological activities. One of them under study is its contribution to the virulence of A. 
fumigates (Spikes et al. 2008). In the study of Spikes et al., they tested for gliotoxin 
production and virulence in different animal models. The results showed that 
gliotoxin production correlated positively with virulence in a nonneutropenic mouse 
model of invasive pulmonary aspergillosis and a Drosophila melanogaster model of 
aspergillosis (Spikes et al. 2008). 
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1.1.1.3.3 Iron0binding DKPs 
It is known that all life forms have an absolute requirement for iron to maintain 
their metabolism. For aerobic organisms the concentration of free, aqueous ferric ion 
is limited to 10118 M at neutral pH due to the insolubility of Fe(OH)3. This is the 
driving force for the excretion by microbes of strong iron1chelating agents 
(siderophores) and the expression of high1affinity transport systems, which provide a 
reliable cellular iron supply. Studies showed under iron1deficient growth conditions 
the yeast Rhodotorula pilimanae excreted vast amounts of rhodotorulic acid, a 
cyclodipeptide of δ1N1acetyl1L1δ1N1hydroxyornithine ( ) which is able to 
tightly bind iron (Müller et al. 1985). 
Another DKP capable of binding iron is pulcherriminic acid. Fruit1borne 
Metschnikowia pulcherrima is yeast, which can protect fruits against postharvest rot 
caused by some postharvest pathogens due to its antifungal effects. M. pulcherrima 
produces a red pigment called pulcherrimin ( ) which is a large complex 
formed nonenzymatically from pulcherriminc acid and ferric ions. The antimicrobial 
activity of M. pulcherrimamay is attributed to the formation of pulcherrimin which 
depletes the iron in the medium and creates an environment unsuitable for growth of 
microbes that require iron for growth since iron is essential for the growth of many 
microorganisms (Sipiczki 2006). 
1.1.1.3.4 Effect on the central nervous system 
Cyclo(His1Pro) is the first cyclodipeptide shown to be endogenous to the 
mammalian brain. It is present in central nervous system, body fluids, anuran skins, 
and gastrointestinal system (Prasad 1995; Minelli et al. 2009). This DKP is widely 
studied for its effects on the central nervous system. It might produce analgesia 
(Prasad 1995). Modulation of prolactin secretion, thermoregulation, and stereotypical 
behavior are three biological activities of cyclo(His1Pro) that seem to share a common 
dopaminergic mechanism (Prasad 1995). 
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In conclusion, the physiological role of DKPs in organisms that produce these 
compounds remains poorly documented. However, in most cases, these molecules 
are principally studied for their biological and pharmacological activities. 
1.1.1.4 Biological and pharmacological activities of DKPs 
As freshly mentioned above, DKPs are widely studied because of their 
numerous biological and pharmacological activities such as antibacterial, antiviral, 
antifungal, antitumor, anti1inflammatory, and immunosuppressive activities. Now, 
we will present, through some examples, these remarkable activities of DKPs. 
1.1.1.4.1 Antibiotic DKPs 
Bicyclomycin ( ) is a DKP isolated from streptomyces sapporonensis in 
1972 then from streptomyces aizunensis in 1973 (Bradley et al. 1996). This molecule is a 
clinically useful antibiotic exhibiting activity against a broad spectrum of Gram1
negative bacteria such as Escherichia coli, Klebsiella, Salmonella, Shigella and Citrobacter, 
and against the Gram1positive bacterium, Micrococcus luteus. Bicyclomycin has been 
used to treat diarrhea in humans and bacterial diarrhea in calves and pigs and is 
marketed by Fujisawa (Osaka, Japan) under the trade name Bicozamycin® (Kohn 
and Widger 2005). The structure of bicyclomycin is unique among antibiotics and 
studies showed that it employed a novel mode of action by inhibition of the RNA 
transcription termination factor Rho in Escherichia coli (Zwiefka et al. 1993; Kohn and 
Widger 2005). Rho is a hexameric RNA/DNA helicase/translocase that terminates 
transcription of select genes in bacteria. Bicyclomycin can disrupt the Rhomolecular 
machinery thereby giving rise to a catastrophic effect caused by the untimely 
overproduction of proteins not normally expressed constitutively, thus leading to a 
toxic effect on the cell (Kohn and Widger 2005). A recent study demonstrated that the 
sensibility of E. coli to bicyclomycin could be altered by deletions of different types of 
genes (Tran et al. 2011). Up to now, bicyclomycin is the only known selective 
inhibitor of Rho. 
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Glionitrin A (  ) is a new DKP disulfide with antibiotic1antitumor 
activity isolated from coculture of a mine drainage1derived Sphingomonas bacterial 
strain and a mine drainage1derived Aspergillus fumigatus fungal strain. Glionitrin A 
displayed significant antibiotic activity against a series of microbes including 
methicillin1resistant Staphylococcus aureus. Besides, an in vitro cytotoxicity assay 
revealed that glionitrin A had potent submicromolar cytotoxic activity against four 
human cancer cell lines: HCT1116, A549, AGS, and DU145 (Park et al. 2009). 
1.1.1.4.2 Antiviral DKPs 
A well1known antiviral DKP is gliotoxin ( 
). This molecule has been 
mentioned above about its contribution to the virulence of pathogenic 
microorganisms. Besides its physiological role, gliotoxin is found to be a potent 
inhibitor of poliovirus RNA synthesis via its inhibition to the activity of the 
poliovirus polymerase 3Dpol in vitro (Rodriguez and Carrasco 1992). Gliotoxin is the 
first inhibitor reported of this viral enzyme. The toxicity of gliotoxin is due to the 
presence of a disulphide bridge, which can inactivate proteins via reaction with thiol 
groups, and to the generation of reactive oxygen species by redox cycling (Gardiner 
et al. 2005). 
Moreover, three DKPs ( !") extracted from the fungus Epicoccum 
nigrum showed inhibitory effects on HIV11 replication in C8166 cells (Guo et al. 2009). 
Recently, a novel DKP dimer, aspergilazine A (#), dimerized by two DKP 
units via a rare N11 to C16 linkage, was isolated from the marine1derived fungus 
Aspergillus taichungensis. This DKP dimer showed a weak activity against influenza A 
(H1N1) virus (Cai et al. 2012). 
1.1.1.4.3 Antifungal DKPs 
Ten years ago, Ström et al. firstly reported the production of the antifungal 
DKPs, cyclo(Phe1Pro) and cyclo(Phe1trans141OH1Pro), by lactic acid bacteria (Ström et 
al. 2002). Recently, a new antifungal compound cyclo(Leu1Leu) was identified from 
Lactobacillus plantarum AF1, which was isolated from kimchi, a traditional Korean 
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food which is a well1known lactic acid1fermented vegetable product (Yang and 
Chang 2010). In this study, soybeans treated with different concentration of culture 
supernatant of Lb. plantarum AF1 could partially even totally inhibit the growth of 
Aspergillus flavus, which often germinates in stored cereal grains. Up to now, the 
mechanism of inhibition is still not clear. The end products from kimchi lactic acid 
bacteria, like cyclo(Leu1Leu), may be a promising alternative to chemical 
preservatives as a potential biopreservative which prevent fungal spoilage and 
mycotoxin formation in food and feed (Yang and Chang 2010). 
Moreover, three other antifungal DKPs, cyclo(Phe141hydroxy1Pro), cyclo(Leu141
hydroxy1Pro) and cyclo(Ala141hydroxy1Pro), were extracted from broth culture of the 
grapevine endophyte Alternaria alternata. The three DKPs demonstrate real 
effectiveness in inhibiting the fungus Plasmopara viticola sporulation which causes the 
grapevine downy mildew, one of the most destructive diseases affecting this crop 
(Musetti et al. 2007). 
1.1.1.4.4 Antitumor DKPs 
More and more DKPs have been demonstrated to have antitumor activity. 
However, their modes of action are found very varied. Several examples will be 
introduced in this part to illustrate their antitumor activity. 
As previously mentioned (section $$$$), glionitrin A was also shown to have 
antitumor activity. An in vitro cytotoxicity assay revealed that glionitrin A had potent 
submicromolar cytotoxic activity against four human cancer cell lines: HCT1116, 
A549, AGS, and DU145 (Park et al. 2009). 
The DKP phenylahistin ( %) is a cell cycle inhibitor produced by 
Aspergillus ustus. Phenylahistin exhibits antitumor activity against eight tumor cell 
lines in vitro, and against P388 leukemia and Lewis lung carcinoma cells in vivo  
(Kanoh et al. 1999). The mechanism of action of phenylahistin is not very clear but it 
was elucidated that phenylahistin arrested cells in mitosis by inhibiting tubulin 
polymerization (Kanoh et al. 1999). 
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Recently, a new DKP disulfide, deoxyapoaranotin, was separated from 
Aspergillus sp. KMD 901 and found to have direct cytotoxic and apoptosis1inducing 
effects towards HCT116 colon cancer cell lines (Choi et al. 2011). 
1.1.1.4.5 Other biological activities and applications of DKPs 
Besides the biological activities detailed above, DKPs exhibit some other 
activities. For example, cyclo(His1Pro) is an in vivo anti1inflammatory compound by 
modulating NF1κB and Nrf2 signalling (Minelli et al. 2012). Its cytoprotective/anti1
inflammatory effects can be ascribed to the cross1talk between the suppression of NF1
κB signalling and the activation of Nrf21EpRE/ARE pathway, the former depressing 
the pro1inflammatory response, the latter enhancing the antioxidant defensive 
response (Minelli et al. 2012). Some DKPs exhibit immunosuppressive activity like 
gliotoxin ( 
) (Grovel et al. 2006). Gliotoxin is an immunosuppressive 
cytotoxin produced by numerous environmental or pathogenic fungal species. It is 
thought to play a role in the A. fumigatus virulence by facilitating fungal growth and 
colonization of host tissue through induction of a local or generalized 
immunosuppression (Grovel et al. 2006). Cyclo(Trp1Trp) and cyclo(Trp1Pro) 
specifically block the calcium channels therefore show an interest in the treatment of 
cardiovascular disorders (Milne et al. 1998). Furthermore, several mono1N1
methylated and di1N1methylated DKPs were demonstrated to be able to help the 
passage of baicalin and dopamine across the blood−brain barrier (BBB) by passive 
diffusion. Thereby, the DKPs or cyclodipeptide scaffolds can be considered a novel 
family of brain delivery systems (BBB1shuttles) to transport to the brain drugs and 
other cargos that cannot cross the BBB unaided (Teixidó et al. 2007). 
DKPs display numerous biological and pharmacological activities. These 
properties make it possible to foresee their use in the treatment of pathologies.     
In the first part of this chapter, I introduced the DKP family, their natural 
abundance and structural diversity, some physiological roles, and their biological 
activities which make them a family of molecules important to the research for their 
interest in various applications and treatment. In the study, it is important to find out 
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how these DKPs are produced by organisms. So, in the next part, we will talk about 
the biosynthesis of DKPs. 
1.1.2 Biological mechanisms of DKP formation 
DKPs are commonly biosynthesized from amino acids by different organisms, 
including mammals, and are considered to be secondary functional metabolites or 
side products of terminal peptide cleavage. Up to now, several biosynthetic 
pathways of DKPs have been deciphered. In general, these mechanisms can be 
classified as two types: nonenzymatic pathways and enzymatic pathways.  
1.1.2.1 Nonenzymatic pathways of DKP formation 
Cyclo(His1Pro) has important implications in neurophysiological functions and 
is an endogenous cyclic dipeptide that exists throughout the central nervous system, 
peripheral tissues, and body fluids. In mammals, the DKP cyclo(His1Pro) is derived 
from the nonenzymatic cyclization of the thyrotropin1releasing hormone (TRH, 
pGlu1His1Pro) after cleavage by pyroglutamate aminopeptidase. Miyashita et al. 
proved that cyclo(His1Pro) can emanate from a direct predecessor, that is TRH1Gly 
(pGlu1His1Pro1Gly), form of TRH by pyroglutamate aminopeptidase action, not 
through TRH formation. TRH1Gly is firstly transformed by pyroglutamate 
aminopeptidase to His1Pro1Gly. Nonenzymatic conversion of His1Pro1Gly to 
cyclo(His1Pro) then occurs ( &) (Miyashita et al. 1993). The proline induces 
constraints which promote cis conformation of the peptide bond between the 
histidine and the proline, thereby faciliting the cyclization to generate the DKP 
nucleus. 
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Figure 7: Mechanism of the formation of cyclo(His-Pro) in mammals (Miyashita et al. 1993). 
However, in microorganisms, all the known mechanisms of DKP formation 
involve enzymes. 
1.1.2.2 Enzymatic pathways of DKP formation 
DKPs are commonly considered to be secondary metabolites in organisms. 
Some protease enzymes, such as dipeptidyl peptidases, cleave the terminal ends of 
proteins to generate dipeptides which naturally cyclize to form DKPs. There exist 
two known important enzyme families which can catalyze the formation of DKPs: 
nonribosomal peptide synthetases (NRPSs) and cyclodipeptide synthases (CDPSs). 
Here I will briefly illustrate with examples the roles of the two enzyme families in 
biosynthesis of DKPs. The structures and the catalytic machanisms of NRPSs are 
detailed in this chapter (section $$$) whereas the results of studies on CDPSs are 
presented in the introduction and the   because my thesis work is on 
CDPSs. 
1.1.2.2.1 Formation of DKPs involving NRPSs 
NRPSs are large multimodular biocatalysts that utilize complex regiospecific 
and stereospecific reactions to assemble structurally and functionally diverse 
peptides that have important medicinal applications. NRPSs are not enzymes 
dedicated only to the DKP formation. In contrast, they commonly catalyze the 
H2N CH C
CH2
O
CH2
C
OH
O
H
N CH C
CH2
O
N
NH
N
C
O
H
N CH C
H
OH
O
H2N CH C
CH2
O
N
NH
N
C
O
NH CH C
H
OH
O
HN
N
HN
N
O
O
Pyroglutamate
aminopeptidase
Gly
Glu-His-Pro-Gly His-Pro-Gly
cyclo(His-Pro)
28 
formation of multiple peptide bonds. However, some dipeptides, usually containing 
proline, are sometimes prematurely released then cyclize to form cyclodipeptides as 
side products of the reaction catalyzed by NRPSs. One of examples is the formation 
of cyclo(D1Phe1Pro) as side product during the nonribosomal assembly of '()*
	 by NRPSs (Schwarzer et al. 2001). The antibiotic tyrocidine A is a cyclic 
decapeptide synthesized nonribosomally by three NRPSs, TycA, TycB, and TycC, 
which consist of a total 10 modules, each being responsible for the incorporation of 
one amino acid into the final product (Schwarzer et al. 2001). Phenylalanine and 
proline are the first two amino acids incorporated by TycA. During the second 
reaction of condensation, as the dipeptide D1Phe1Pro is covalently fixed to enzyme, 
the side product cyclo(D1Phe1Pro) is formed due to the cis conformational constraint 
of proline which facilitates the nonenzymatic cyclization thereby the premature 
release of this DKP (+) (Schwarzer et al. 2001). 
 
Figure 8: Formation of the side product cyclo(D-Phe-Pro) during the synthesis of tyrocidine A 
catalyzed by NRPSs (Schwarzer et al. 2001). Three NRPSs, TycA, TycB, and TycC, act in concert to 
synthesize the cyclic decapeptide from the amino acid precursors. TycA comprises one module, TycB 
three, and TycC six modules, each of which is responsible for the incorporation of a cognate amino 
acid into the growing chain. The Te domain (red) at the last module of TycC catalyzes peptide 
cyclization and thereby release of the final product. The D-Phe-Pro intermediate bound to the second 
module is chemically unstable and is released as a side product as the cyclo(D-Phe-Pro). 
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Although the majority of DKPs deriving from NRPSs harbor a proline residue 
at the second amino acid position, such as cyclo(D1Phe1Pro) mentioned above, and 
are proposed to form spontaneously resulting from conformational constraints 
induced by the proline residue (Stachelhaus et al. 1998; Stachelhaus and Walsh 2000; 
Schultz et al. 2008), there are some exceptions. This is the case of the production of 
'(,-* 	 ( ) during the biosynthesis of cyclic heptapeptides 
cyclomarin A by a 71module NRPS from the marine bacterium Salinispora arenicola 
(.) (Schultz et al. 2008).  On the subject of the formation of cyclomarazine A, 
N1methylation of the second residue incorporated induces constraints which 
promote cis conformation of the peptide bond between the two residues, thereby 
faciliting the formation of cyclomarazine A. 
 
Figure 9: Biosynthetic gene cluster organization of cym and proposed biosynthesis of cyclomarin A (1) 
and cyclomarazine A (5) (Schultz et al. 2008). Each arrow represents the direction of transcription of 
an ORF and is color coded to signify enzyme function which is further reflected chemically. NRPS-
related genes are colored blue with enzymatic domain abbreviations as follows:  A, adenylation; T, 
thiolation (peptidyl carrier protein); C, condensation; MT, methyltransferase; and TE, thioesterase. 
Cyclomarazine A
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There exist some NRPSs dedicated to the biosynthesis of cyclodipeptides. 
Several biosynthetic pathways of DKPs involving NRPSs have been isolated in recent 
years. The biosynthetic pathway of the phytotoxin /(,*	 () is firstly 
described in 2000 (Healy et al. 2000). Biosynthesis of this compound involves 
conserved NRPSs, TxtA and TxtB, encoded by the txtA and txtB genes (Healy et al. 
2000). TxtA and TxtB are responsible for production of the N1methylated cyclic 
dipeptide backbone of the toxin, and a P450 monooxygenase named TxtC is required 
for post1cyclization hydroxylation steps (Healy et al. 2002). A nitric oxide synthase 
(NOS) is suggested to function in the nitration of thaxtomin (Loria et al. 2008) (
0). 
 
Figure 10: Biosynthesis pathway of thaxtomin A in Streptomyces acidiscabies (Loria et al. 2008). (a) 
The biosynthesis of thaxtomin A involves NRPSs (TxtA and B), a P450 monooxygenase (TxtC), and a 
nitric oxide synthase (NOS). (b) The genes known or predicted to be involved in thaxtomin A 
biosynthesis are clustered together on the chromosome. Biosynthetic genes are shown in gray, while 
regulatory genes are indicated in red. 
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Another NRPS dedicated to the DKP synthesis is a dimodular NRPS identified 
within a gene cluster of Aspergillus fumigates, aspecies reported to produce 
fumitremorgins and other prenylated alkaloids (Maiya et al. 2006). Fumitremorgins 
are tremorgenic mycotoxins, members of a group of prenylated indole alkaloids 
derived from tryptophan and proline. Some compounds of this group have interest 
in the development of anticancer drugs such as tryprostatin B which is a mammalian 
cell1cycle inhibitor (Zhao et al. 2002). It was found that in A. fumigates, the gene 
Afu8g00170 encoded the NRPS brevianamide synthetase. The DKP brevianamide F 
(cyclo(Trp1Pro)), synthesized by this NRPS, is the precursor of a variety of fungal 
prenylated alkaloids with biological activity, including fumigremorgins A, B and C 
and tryprostatin B (Maiya et al. 2006). Some modification enzyme genes are clustered 
with Afu8g00170 to modify brevianamide F thereby to produce varied prenylated 
alkaloids. For example, Afu8g00170 is clustered with the gene Afu8g00210 encoding 
a prenyltransferase, which is able to prenylate brevianamide F to form tryprostatin B 
(Grundmann and Li 2005; Maiya et al. 2006). There are other examples of 
biosynthesis of DKPs involving NRPSs such as those of sirodesmin (1) and 
gliotoxin ( 
), which are both secondary metabolites made by fungi. The 
biosynthetic gene cluster of sirodesmin is identified in Leptosphaeria maculans 
(Gardiner et al. 2004) (). It is composed of 18 genes among which the gene 
sirP encodes a two1module NRPS involved in the biosynthesis of a precursor of 
sirodesmin, named phomamide (Gardiner et al. 2005) (). Besides, a similar 
gene cluster is identified in the gliotoxin1producing fungus Aspergillus fumigatusby 
genome database searches (Gardiner et al. 2004) ( ). It is composed of 12 
genes, many of which are similar to those in the L. maculans sirodesmin biosynthetic 
gene cluster. The gene gliP is a homologue of sirP, thereby is predicted to encode a 
NRPS responsible for the synthesis of a precursor of gliotoxin, that is cyclo(Phe1Ser) 
(Gardiner et al. 2005) (). 
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Figure 11: Comparison of the sirodesmin and gliotoxin biosynthetic gene clusters from Leptosphaeria 
maculans and Aspergillus fumigatus, respectively (Gardiner et al. 2005). sirP and gliP encoding NRPSs 
involved in biosynthesis of precursors of sirodesmin and gliotoxin respectively are encircled in red 
dotted lines. Genes with obvious homologues in the clusters are coloured. The ‘other’ category 
contains genes encoding cytochrome P450 monooxygenases (GliF, SirB, SirE), a prenyl transferase 
(SirD), an acetyl transferase (SirH), epimerases (SirQ, SirR, SirS), an oxidoreductase (SirO) and a 
hypothetical protein (GliK). 
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Figure 12: Predicted biosynthetic pathways for (a) gliotoxin and (b) sirodesmin (Gardiner et al. 2005). 
The two NRPSs GliP and SirP are encircled by dotted red lines. 
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Besides NRPSs, in the introduction part of this manuscript, we have presented 
another enzyme family called CDPSs dedicated to the biosynthesis of 
cyclodipeptides. 
1.1.2.2.2 Formation of cyclodipeptides by CDPSs 
As described in the introduction of the manuscript, the CDPS family is specially 
involved in the synthesis of cyclodipeptides. Unlike NRPS which is often a huge 
enzyme with multi1modules, the CDPS is always a small enzyme composed of only 
about 200 amino acid residues. They are very different from NRPSs or other known 
enzymes. This thesis is based on studies of the CDPS family. Before our dissection of 
CDPSs, it is necessary to describe all the known biological macromolecules that are 
able to catalyze the peptide bond formation in organisms. 
1.2 Formation of peptide bonds by biocatalysts 
A peptide bond is a covalent bond formed between two molecules when the 
carboxyl group of one molecule reacts with the amino group of the other molecule, 
leading to the release of a molecule of water (H2O). It usually occurs between amino 
acids (). 
 
Figure 13: Formation of a peptide bond between two amino acids. 
Peptide bonds are ubiquitous and important in organisms for the structures of 
many biological molecules such as proteins and numerous peptide derivatives. In 
organisms, peptide bond formation is catalyzed by certain biocatalysts in order to 
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accelerate the reaction since uncatalyzed reaction is very long. There exist in cells 
different synthetic systems to form peptide bonds, which can be divided into two 
types: ribosomal pathway and nonribosomal pathways. The ribosomal pathway 
involving the macromolecule ribosome is the main pathway to synthesize proteins 
and polypeptides by forming multi1peptide bonds. It is one of the most important 
activities in cells to ensure the normal cell metabolism. Formation of peptide bonds 
through nonribosomal pathways can be accomplished by several different enzyme 
families such as NRPSs, CDPSs, Fem1transferases, aminoacyl1tRNA transferases, and 
glutathione synthetase (). No matter which pathway is used to form peptide 
bonds, activation of the carboxyl group is indispensable to bring about the reaction. 
In some cases, such as NRPS pathways, the carboxyl group of amino acid involved in 
the peptide bond formation is activated by ATP thereby forming an intermediate 
aminoacyl adenylate. In other cases, activated amino acid is present in the form of 
aminoacyl1tRNA (aa1tRNA), the formation of which is catalyzed by the aminoacyl1
tRNA synthetase (aaRS).  
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Figure 14: Some tRNAs are involved in primary processes such as cell wall formation, protein labeling 
for degradation, biosynthesis of amino acids and modification of porphyrin and lipids. Now tRNAs 
have been found in secondary metabolism in cyclic peptide formation (von Dohren 2009). 'P1' is a 
recently discovered product created by the P450-mediated oxidation of cyclo(Tyr-Tyr) (Belin et al. 
2009). 
In this part, I will firstly describe the biocatalysts of peptide bond formation 
which involve aa1tRNAs as substrates: ribosome, Fem1transferases, aminoacyl1tRNA 
transferases, CDPS, and a recently discovered transferase named PacB (Zhang et al. 
2011). Before the description of these biocatalysts, aaRSs, enzymes catalyzing the 
aminoacylation of tRNA, will be particularly discussed because of their structural 
homology with our research object CDPSs. This part will then be ended with the 
description of some others biocatalysts of peptide bond formation which function in 
a tRNA1independent manner, in particular the NRPSs. 
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1.2.1 Peptide bond formation involving aa0tRNA 
Above all, we will briefly evoke tRNA and aaRS. Then we will present the 
ribosomal pathway of peptide bond formation, the essential peptide and protein 
synthesis pathway in cells. Finally we will talk about some enzyme families, which 
catalyze the peptide bond formation by using the aa1tRNA as substrate. 
1.2.1.1 Transfer RNA (tRNA) 
Representing the single largest, best1understood class of non1protein coding 
RNA genes found in all living organisms, tRNAs are adaptor molecules composed of 
RNA, typically 73 to 93 nucleotides in length, that are used in protein biosynthesis to 
link the codons in a messenger RNA (mRNA) to the amino acids that they specify 
(Crick 1968). 
tRNAs have cloverleaf secondary structure due to four base1paired stems (
	). The secondary structure folds into a compact L1shaped three1dimensional 
structure via a set of tertiary and triple base1pair interactions, as well as a number of 
magnesium ions that are crucial for folding and stability (Jovine et al. 2000) (

). Generally, tRNA structure contains an acceptor arm, an anticodon arm, a D 
arm, and a TΨC arm (). The acceptor arm is made by the base pairing of the 
5'1terminal nucleotide with the 3'1terminal nucleotide, which contains the CCA 3'1
terminal group used to attach the amino acid. The loop of anticodon arm contains the 
anticodon, which can match with the triplet codon on mRNA. The D arm often 
contains hydrouridines where as the TΨC arm contains the sequence TΨC where Ψ 
is a pseudouridine. 
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Figure 15: Secondary and tertiary  structure of yeast tRNAPhe (Jovine et al. 2000). (A) “Cloverleaf” 
representation of yeast tRNAPhe secondary structure. Different regions of the molecule are indicated 
and colour-coded accordingly. Watson-Crick base-pairs are represented by short black lines, the 
single G4·U69 wobble pair is marked by a black dot. Tertiary interactions are shown as grey lines, 
while arrows indicate stacking of the enclosed nucleotides onto 5′ or 3′ helices. The anticodon and 
the terminal CCA sequence are boxed in red and grey, respectively. Tightly and weakly bound Mg2+ 
are shown as green and white circles, respectively, with green arrows indicating the nucleotides with 
which they interact. The spermine molecule is represented by a red stick, with four dots 
corresponding to its nitrogen atoms (not drawn to scale); grey arrows indicate interactions with the 
RNA. The A14 nucleotide of a symmetry-related molecule is labelled in reverse colours. Modified 
nucleotide name abbreviations are; 2MG, N2-methylguanosine; H2U, dihydrouridine; M2G, N2,N2-
dimethylguanosine; OMC, 2′-O-methylcytidine; OMG, 2′-O-methylguanosine; YG, wybutosine; PSU, 
pseudouridine; 5MC, 5-methylcytidine; 7MG, 7-methylguanosine; 5MU, ribosylthymine; 1MA, 1-
methyladenosine. (B) Ribbon representation of the three-dimensional structure. The structure is 
colour coded as in (A). 
In general, tRNA biogenesis involves the synthesis of the initial transcript, 
followed by processing to remove the 5′ leader, trim the 3′ trailer, add CCA, splice 
introns that may be present, modify multiple nucleoside residues (	), and, 
for eukaryotes, export the tRNA to the cytoplasm, before its use in translation 
(Phizicky and Hopper 2010). tRNA genes are highly transcribed to meet the needs of 
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cells to tRNA. tRNA transcription is a complicated process involving multiple layers 
of regulation (Phizicky and Hopper 2010). Freshly transcribed pre1tRNAs with 
extensions 5’ and 3’ as well as introns need to be processed to generate functional 
tRNA molecules. Maturation on 5’ involves an endoribonuclease RNase P consisting 
of one RNA and a variable number of protein subunits: one in bacteria, four in 
archaea, nine in yeast and ten in mammalian (human, nuclear) RNase P (Kirsebom 
2007). RNase P RNA is the catalytic component in bacteria (Guerrier1Takada et al. 
1983; Torres1Larios et al. 2005) whereas the protein subunit increases the catalytic 
efficiency of the RNA component (Crary et al. 1998; Sun et al. 2006). Maturation of 
the 3’ end of tRNA always requires removal of the 3’ trailer from the original 
transcript, and also often requires the subsequent addition of CCA after the 
nucleotide N73, although, in some bacteria and archaea, some or all tRNA genes have 
encoded CCA (Vogel et al. 2005; Hartmann et al. 2009). 3’ processing involves 
numerous endonucleases and exonucleases, and the mechanism is different among 
the three phyla. Furthermore, although introns occur in only a minority of tRNA 
genes, they are found in all sequenced eukaryotes and archaea, and splicing is 
essential (or nearly essential) in all of these organisms. In this process, introns are 
excised by certain endonucleases, then dissected tRNAsare repaired by special 
ligases (Phizicky and Hopper 2010). Finally, before definitely getting matured and 
functional, tRNAs have to suffer some post1transcriptional modifications on their 
nucleotides (methylated nucleotides, pseudouridines, dihydrouridines and so on) 
( 	). A total of 92 different tRNA modifications are listed in the RNA 
Modification Database (http://biochem.ncsu.edu/RNAmods). In tRNAs, which are 
among the most strongly modified RNAs, most nucleotide modification sites are 
clustered in two sites, one in the structural core of the L1shaped 3D structure and the 
other in the anticodon domain (Grosjean et al. 1996). These modifications have 
different affects on tRNA activity. Some modifications in or around the anticodon 
loop affect translation or growth; many modifications in the main body of the tRNA 
affect tRNA folding or stability; some other modifications at various positions 
specifically affect tRNA identity (Phizicky and Hopper 2010). 
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After those complicated post1transcriptional modifications, matured tRNAs are 
ready to perform their duties as transporter of amino acids by forming aa1tRNAs. 
Loading of amino acids to tRNAs, that is aminoacylation of tRNAs, is performed by 
aminoacyl1tRNA synthetases. 
1.2.1.2 Aminoacyl0tRNA synthetase (aaRS) 
Aminoacyl1tRNA synthetases were first discovered to ligate an amino acid to 
tRNA in 1958 (Hoagland et al. 1958; Martinis et al. 1999). They are the linchpins of 
translation, the link between the worlds of protein and nucleic acid by covalently 
linking an amino acid to a tRNA that contains the triplet anticodon for that amino 
acid. The charged tRNAs are then available for use in polypeptide chain elongation 
on the ribosome or other tRNA1dependent peptide bond formation reactions. In 
addition to their housekeeping role in peptide synthesis, recently, aaRSs have been 
paid attention for their potential pathophysiological implications in tumorigenesis 
(Kim et al. 2011). 
Generally, the ligation of a substrate amino acid to its cognate tRNA proceeds 
in two steps:  
 
The first step involves the activation of an amino acid to aminoacyl1adenylate in 
consumption of one ATP, and the second delivers the activated amino acid to the 
acceptor end of its congate tRNA (Ibba and Söll 2000). This reaction is catalyzed by a 
specific aaRS. There exist 20 aaRSs responsible for the synthesis of the 20 canonical 
aa1tRNA families (Woese et al. 2000). In organisms, an amino acid could be charged 
to several different cognate tRNAs which are called isoacceptors (Saks et al. 1998). 
All the isoacceptors are charged by a single aaRS (Woese et al. 2000). For example, 
transfer of the leucine to its 6 different isoaccepting tRNAs in E. coli is catalyzed by 
aa + ATP + aaRS aaRS•aa-AMP + PPi (1)
aaRS•aa-AMP + tRNA aaRS + aa-tRNA + AMP          (2)
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the same LeuRS. In a word, each aaRS is specific for one amino acid and one or more 
isoaccepting tRNAs. A set of tRNA isoacceptors can be distinguished by their main 
points of contact for aaRS, that is the acceptor arm, the anticodon loop and a few base 
pairs in the T and D stems (Arnez and Moras 1997). 
1.2.1.2.1 Classification of aaRSs 
Although all aaRSs share the same catalytic mechanism, they appear to be 
different from each other in terms of molecular size, quaternary structure and amino 
acid sequence. Overall, aaRSs are divided into two unrelated classes (I and II) based 
on mutually exclusive sequence motifs that reflect distinct active site topologies. In 
addition, each class is divided into subclasses based on additional common features 
among some members of each class (Arnez and Moras 1997; Ibba and Söll 2000). 
Principal features of the two classes of aaRSs and their classification are summarized 
in  . Some exceptions should be noted. LysRS exists in two unrelated forms 
thereby is found as both a class I and a class II aaRS (Arnez and Moras 1997; Ibba and 
Söll 2000; Ambrogelly et al. 2002). Most prokaryotes and all eukaryotes contain a 
class II LysRS, whereas most archaea and a few bacteria contain a less common class 
I LysRS (Ambrogelly et al. 2002). GlyRS exists also in two forms and is classed in two 
different subclasses of class II (Freist et al. 1996). 
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Table 2: Classes of aaRSs and their principal features (Arnez and Moras 1997; Ibba and Söll 2000). 
Both LysRS and GlyRS exist in two unrelated forms, so they are both found in two different subclasses.  
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1.2.1.2.1.1 Class I aaRSs 
As shown in , class I aaRSs share sequence motifs HIGH and KMSKS, 
and have active sites based on the Rossmann fold. This fold is characterized by a 
central β–sheet composed of several β1strands linked by α–helix in the topological 
order β1α1β. 
During the first step of aminoacylation, for example catalyzed by GlnRS (
	), ATPs adopts an extended conformation reminiscent of that found in other 
proteins containing the Rossmann fold. In this catalytic site, the two signature motifs, 
HIGH and KMSKS, interact with the ATP and stabilize the transition state of the 
reaction for amino acid activation. Whereas, in contrast to other aaRS, GlnRS 
(together with ArgRS, GluRS, and LysRS I) requires bound tRNA for amino acid 
activation. One significant consequence of this requirement is that the sequence of 
the tRNA strongly influences the affinity of GlnRS for glutamine (Hong et al. 1996; 
Ibba et al. 1996). The second step involves binding and aminoacylation of tRNA. In 
tRNA binding mode, class I aaRSs approach the acceptor stem of tRNA from the 
minor groove side with the variable loop facing the solvent. In addition, class I aaRSs 
attach amino acids to the 2’1OH of the terminal adenosine of the tRNA.  
Class I aaRSs are furthermore subgrouped to three subclasses. Members of each 
subclass share common enzymatic modules and generally charge the same type 
amino acids onto cognate tRNAs. Thus, the subclass Ia aaRSs process mostly 
aliphatic or sulfphur1containing amino acids except ArgRS and LysRS I; the subclass 
Ib aaRSs require tRNA for activation of charged amino acids, Glu and Gln; whereas 
the assembly of aromatic amino acids (Tyr and Trp) to their cognate tRNAs are taken 
charge by the subclass Ic aaRSs (). In the class I aaRSs, amino acids are bound 
in relatively open and relaxed pockets. 
With regard to the quaternary structure, class I aaRSs are mostly monomeric 
although TyrRS and TrpRS of the subclass Ic are obligate dimmers (Arnez and Moras 
1997). 
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1.2.1.2.1.2 Class II aaRSs 
The Rossmann fold is absent in the class II aaRSs. Instead, their active sites are 
built on a novel antiparallel β–sheet surrounded by α–helix ( 
). Class II 
aaRSs share three conserved sequence motifs (). Motif 1 consists of a long α–
helix linked to a β–strand. Motif 2 comprises two antiparallel β–strands connected by 
a long loop, and motif 3 consists of a β–strand followed immediately by an α–helix. 
Motifs 2 and 3 are part of the active site (
). 
In the first step of aminoacylation, in contrast to class I aaRSs, the ATP exhibits 
a compact conformation: the γ–phosphate folds back over the adenine base. The ATP 
is cradled by the antiparallel β–sheet, which is formed in part by the conserved 
motifs 2 and 3. Amino acids are bound by specific rigid templates in class II aaRSs. 
Motif 2 is involved in the binding of amino acids. In the second step of 
aminoacylation, class II aaRSs, such as AspRS (
), bind tRNA on the major 
groove side. Thus, the variable loop of the tRNA faces the aaRS. Class II aaRSs attach 
amino acids to the 3’1OH of tRNA except PheRS which attaches Phe to the 2’1OH of 
tRNAPhe (Arnez and Moras 1997). 
Class II aaRSs are divided into 3 subclasses (). The class IIa contains five 
aaRSs, which charge small and polar amino acids onto their cognate tRNAs; the class 
IIb aaRSs process charged amino acids; whereas the class IIc aaRSs take charge of 
small amino acids (Ala and Gly) and an aromatic amino acid (Phe). 
Most of class II aaRSs are dimmers (Arnez and Moras 1997). The conserved 
motif 1 participates in the dimer interface. The latter participates in the formation of 
the active site and cooperative coupling upon tRNA binding. Class IIc aaRSs are 
obligate or could be tetramers. For example, PheRS is an (αβ)2 tetramer. 
45 
 
Figure 16: Active-site domains of (A) class I aaRS, e.g. GlnRS, and (B) class II aaRS, e.g. AspRS. Shown 
are ATP and the acceptor ends of cognate tRNAs (red). The locations of the characteristic motifs are 
indicated: in (A), MSK (dark blue), HIGH (red); in (B), motif 1 (red), motif 2 (light blue) and motif 3 
(dark blue). 
1.2.1.2.2 Evolution of aaRSs 
The universal distribution across the phylogenetic tree of the aaRSs suggests 
that they are among the oldest polypeptide families (Ribas de Pouplana and 
Schimmel 2001). 
Aminoacylation of all 20 universal amino acids is partitioned between two 
major aaRS folds (class I and class II). Within each class, the aaRSs with different 
amino acid specificity show distant shared ancestry as revealed by structural, 
sequence, and enzymatic similarity. Within each class, only the catalytic domain is 
conserved among all the members. Each class has its own specific structural fold 
forming the catalytic domain ( ). No evidence for a common ancestor to the 
two classes has been uncovered. Although the aaRSs of two different classes are not 
related by divergent evolution, they are clearly the result of a functional evolutionary 
convergence, as they carry out the same basic biochemical function, that is linking 
specific amino acids to their cognate tRNAs (O'Donoghue and Luthey1Schulten 2003). 
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It was found that two aaRSs from different class can be docked simultaneously 
onto the tRNA acceptor stem by binding opposite sides of the acceptor stem (Ribas 
de Pouplana and Schimmel 2001; Ribas de Pouplana and Schimmel 2001). 
Remarkably, the docking pairs are not arbitrary. These specific pairings linked two 
members of class Ia (IleRS and ValRS) respectively with two members of class IIa 
(ThrRS and SerRS), a member of class Ib (GlnRS) with one of class IIb (AspRS), and 
one from class Ic (TyrRS) with a member of class IIc (PheRS) (Ribas de Pouplana and 
Schimmel 2001). This complementation phenomenon of a pair aaRSs in the tRNA 
binding manner is supposed to be related to a special role of the early aaRSs, which is 
acting as “chaperones” to cover and protect the acceptor end of tRNA therefore to 
preserve aminoacylation probably in a high1temperature environment. Thus, a 
specific primordial chaperone/synthetase pair may have been involved in the 
discrimination between sterically similar amino acids like as tyrosine and 
phenylalanine. The individual members of each pair may have acquired exact amino 
acid specificity. In this way, the primordial chaperone/synthetase pairs would have 
contributed to the final development of the genetic code. As the members of each 
pair gained exact amino acid specificity, and the pairs split apart, new codons would 
have to be assigned to differentiate between similar amino acids (Ribas de Pouplana 
and Schimmel 2001). 
In addition to their aminoacylation role, catalytic domains of aaRSs were found 
in a class of HisRS1like proteins named HisZ which lack aminoacylation activity but 
are involved in histidine biosynthesis (Sissler et al. 1999). Moreover, the overall 
structure of E. coli asparagine synthetase (AsnA) which generates asparagine from 
aspartate is remarkably similar to that of the catalytic domain of yeast AspRS (Ruff et 
al. 1991). The active site architecture and most of the catalytic residues are also 
conserved in both enzymes. They were thereby supposed to have evolved from a 
common ancestor and share a similar chemistry (Nakatsu et al. 1998). In addition, the 
newly discovered cyclodipeptide synthases show structural similarity to the catalytic 
domains of class I aaRSs (Sauguet et al. 2011), which will be detailed in the . 
Recently, a new class of SerRS1like proteins was found structurally related to the 
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catalytic core of atypical SerRS (aSerRS) found only in methanogenic archaea. These 
truncated SerRS homologs acylate carrier proteins by selected amino acids. It is 
speculated that single1domain SerRS1like proteins are ancestors of both thio1
acylating enzymes needed for nonribosomal peptide synthesis and of class II 
synthetases required for ribosomal protein synthesis. Therefore, they provide a link 
between ribosomal and nonribosomal peptide synthesis (Mocibob et al. 2010). These 
observations show that the evolution of aaRSs is probably closely related to the 
evolution of the genetic code, amino acids and their metabolism. 
After presenting the tRNA and the enzymes aaRSs responsible for its 
aminoacylation, we will describe the ribosome with an emphasis on the structure of 
its active site and the catalytic mechanism of peptide bond formation currently 
accepted. 
1.2.1.3 Ribosome 
The ribosome is the protein synthesis factory in the cell. It decodes the genetic 
information carried by mRNA. Considering its important role in protein biosynthesis, 
the ribosome is extensively studied, no matter in structural or in functional aspect, in 
order to understand the catalytic mechanism of the peptide bond formation thereby 
to decrypt how the genetic information is translated to a protein form. 
1.2.1.3.1 Ribosome structure 
The ribosome is the large ribonucleoprotein particle using mRNA as the 
template and tRNAs as substrates to perform the protein synthesis. Ribosomes are 
composed of two subunits, a large one and a small one. Prokaryotic ribosomes and 
eukaryotic ribosomes have significantly different structures and RNA sequences. 
Ribosomes from bacteria consist of a large subunit which has a sedimentation 
coefficient of 50S and a small (30S) subunit, which together compose the 70S 
ribosome; their eukaryotic counterparts are the 60S and 40S subunits and the 80S 
ribosome (Schmeing and Ramakrishnan 2009). Here, we will mainly present 
prokaryotic ribosomes. In prokaryote, the ribosomal 50S subunit consists of 23S RNA 
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(~2900 nucleotides), 5S RNA (~120 nucleotides) and about 34 proteins; the 30S 
subunit consists of 16S RNA (~1500 nucleotides) and about 20 proteins. The 50S 
subunit contains the site of catalysis, the peptidyl transferase center (PTC), which is 
responsible for making peptide bonds and for the hydrolysis of peptidyl1tRNA. The 
30S subunit contains the decoding site, where base1pairing interactions between the 
mRNA codon and the tRNA anticodon determine the selection of the cognate aa1
tRNA. In addition, several protein factors act on the ribosome at various stages of 
translation (Schmeing and Ramakrishnan 2009). The resolution of the ribosome 
structure is the basis for the phasing and molecular interpretation of every 
subsequent structure of the ribosome. During the last ten years, progress has been 
made from low1resolution structures of the 70S ribosome by crystallography 
(Yusupov et al. 2001) to recent high1resolution structures of the 70S ribosome 
(Schuwirth et al. 2005; Selmer et al. 2006). 
The basic architecture of the ribosome is shown in  & (Schmeing and 
Ramakrishnan 2009). The interface between the two subunits consists mainly of RNA. 
The mRNA binds in a cleft of the 30S subunit, where its codons interact with the 
anticodons of the tRNA. The ribosome has three tRNA binding sites: the A site that 
binds the incoming aminoacyl1tRNA, the P site that holds the peptidyl1tRNA 
attached to the nascent polypeptide chain, and the E (exit) site to which the 
deacylated P1site tRNA moves after peptide bond formation before its ejection from 
the ribosome (Schmeing and Ramakrishnan 2009). The whole peptide synthesis 
process occurs on these sites. 
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Figure 17: Structure of the ribosome (Schmeing and Ramakrishnan 2009). A, Top view of the 70S 
ribosome with mRNA and A-P- and E-site tRNAs. B and C, Exploded view of the 30S subunit (B) and 
50S subunit (C). 
1.2.1.3.2 General mechanism of the peptide synthesis by the ribosome 
Bacterial translation can be roughly divided into three main stages: initiation, 
elongation and termination. The overview of bacterial translation is described in 
 (Schmeing and Ramakrishnan 2009) although not every detail is clear up to 
now.  
A
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Initiation requires the ribosome to position by base pairing the initiator, 
formylmethionine (fMet)1tRNAfMet in bacteria, over the start codon of mRNA in the P 
site. The precise positioning requires three initiation factors named IF1, IF2, and IF3 
( +2 *(*). However, exactly how the correct tRNA is selected and the 
roles of these factors still remain unclear. 
Once the translation is successfully initiated, the elongation cycle begins to 
sequentially add amino acids to the polypeptide chain. An elongation cycle can be 
divided into three steps: decoding, peptide bond formation, and translocation 
( 2(*(*). Decoding ensures that the correct aa1tRNA, as dictated by 
the mRNA codon, is selected in the A site. During decoding, aa1tRNA is delivered to 
the A site in a ternary complex with elongation factor Tu (EF1Tu) and GTP. 
Following the GTP hydrolysis by EF1Tu and the dissociation of the factor from the 
ribosome, aa1tRNA accommodates in the A site to prepare for the next step 
concerning the peptide bond formation. During this step, the aminoacyl part of aa1
tRNA reacts with peptidyl1tRNA bound to the P site to form a new peptide bond, 
yielding deacylated tRNA in the P site and A site peptidyl1tRNA extended by one 
amino acid residue. The mechanism of peptide bond formation will be discussed in 
the next part (section $$$$). Before the next round of elongation, the tRNAs and 
mRNA need to move relative to the ribosome. This process is termed translocation. 
During translocation, catalyzed by another elongation factor named EF1G, the mRNA 
normally shifts by precisely one codon. The deacylated tRNA translocates from the P 
site to the E site, whereas the nascent peptidyl1tRNA moves from the A site to the P 
site. In consequence, a new codon is exposed in the A site for the interaction with the 
next aa1tRNA. The deacylated tRNA bound to the E site is released during the 
beginning of the next elongation cycle. 
The elongation cycle continues until an mRNA stop codon moves into the A site, 
signaling the end of the coding sequence. A class I release factor (RF1 or RF2 in 
bacteria) recognizes the stop codon and cleaves the nascent polypeptide chain from 
the P site tRNA, resulting in the release of the newly synthesized protein from the 
ribosome. Then the deacylated tRNAs and mRNA are subsequently released from 
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the ribosome which is then recycled into subunits for a new round of protein 
synthesis to begin in the help of various factors including RF3, EF1G, and the 
ribosome recycling factor (RRF) (+23*)3'*). 
 
Figure 18: Overview of bacterial translation (Schmeing and Ramakrishnan 2009). EF, elongation 
factor; IF, initiation factor; RF, release factor. 
1.2.1.3.3 Mechanism of peptide bond formation 
In this part, we will specially discuss the mechanism of peptide bond formation 
during the elongation cycle of peptide synthesis in the ribosome. As previously 
presented, the peptidyl transferase center (PTC) of the 50S ribosomal subunit is the 
site of catalysis responsible for the peptide bond formation and the hydrolysis of 
peptidyl1tRNA. In fact, the central chemical event in protein synthesis is the 
peptidyl1transferase reaction, in which the α–amino group of the aa1tRNA bound to 
the A site nucleophillically attacks the ester carbon of the peptidyl1tRNA attached to 
the P site to form a new peptide bond (Beringer and Rodnina 2007; Schmeing and 
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Ramakrishnan 2009) ( .). Compared to the uncatalyzed reaction, the 
ribosome increases the rate of this reaction by at least ~1051fold (Sievers et al. 2004). 
 
Figure 19: Schematic of peptide bond formation on the ribosome (Beringer and Rodnina 2007). 
How does the ribosome so efficiently catalyze the peptide formation? Now the 
catalytic mechanism of peptide bond formation on the ribosome is becoming more 
and more clear thanks to the progress in ribosome crystallography, as well as kinetic, 
biochemical, genetic, and computational approaches. It has been proved that no 
general acid/base catalysis involving a group with near1neutral pKa because when 
the reactive α–amine was substituted with a much less reactive hydroxyl, making 
chemistry rate limiting, a pH1independent reaction rate was observed (Bieling et al. 
2006). A comparison of the rate of peptide bond formation by the ribosome and by a 
ribosome free model system suggested that the ribosome accelerated the reaction 
solely by entropic effects (Sievers et al. 2004). In addition, the combined evidence of 
all the studies supports the idea that peptide bond formation on the ribosome is 
driven by a favorable entropy change. The most favorable catalytic mechanism, 
named concerted proton shuttle mechanism, has been proposed (Beringer and 
Rodnina 2007). It is substrate1assisted catalysis of peptide bond formation involving 
a six1membered transition state in which proton shuttling occurs via the 2’1OH of the 
P site peptidyl1tRNA (). In other words, the 2’1OH group of the P site tRNA 
A76 ribose moiety donates its proton to the adjacent leaving 3’1O of A76 and 
simultaneously receives a proton from the nucleophilic –NH2 group of the A site aa1
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tRNA. The presence of this 2’1OH is crucial for the reaction. Substitution of the 2’1OH 
by hydrogen (2’1H) or fluor (2’1F) results in at least a 1061fold reduction in the rate of 
peptide bond formation by the ribosome (Weinger et al. 2004). The ribosome plays an 
important role in the process although it is not involved in chemical catalysis. Certain 
ribosomal residues (C2063, A2451, and U2584) participate in the construction of the 
hydrogen bond network that stabilizes the transition state (0). In addition to 
placing the reactive groups into close proximity and precise orientation to each other, 
the ribosome appears to work by providing an electrostatic environment that reduces 
the free energy for forming the highly polar transition state, shielding the reaction 
against bulk water, helping the proton shuttle forming the leaving group, or a 
combination of these effects. With this preorganized network, the ribosome avoids 
the extensive solvent reorganization that is inevitable in the corresponding reaction 
in solution, resulting in significantly more favorable entropy of activation of the 
reaction on the ribosome (Beringer and Rodnina 2007). 
 
Figure 20: Concerted proton shuttle mechanism of peptide bond formation by the ribosome 
(Beringer and Rodnina 2007). A six-membered transition state is formed between the P site peptidyl-
tRNA (in blue) and the A site aa-tRNA (in red). Ribosomal residues (in green) stabilize the transition 
state by forming a hydrogen bond network via H2O (in gray). 
Although the critical role of aa1tRNAs is playing a central role in protein 
biosynthesis, aa1tRNAs are also involved in other cellular processes ( ) 
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(RajBhandary and Söll 2008). For example, aa1tRNAs are used as substrates for two 
enzyme families which catalyze one peptide bond formation: the Fem transferases 
and the aminoacyl1tRNA1protein transferases. The two enzyme families are 
respectively involved in cell wall formation and protein labeling for degradation. 
Next, we will briefly present the Fem transferases then the aminoacyl1tRNA1protein 
transferases with an emphasis on the L/F transferase. 
1.2.1.4 Fem transferases 
1.2.1.4.1 Biological implication and function 
Cell wall integrity is critical for bacterial survival. Peptidoglycan (murein) is an 
essential and specific structural element of the bacterial cell wall surrounding the 
cytoplasmic membrane. It serves both as a barrier to osmotic pressure by providing a 
mechanical protection against the turgor and a scaffold for attachment of various 
proteins (Ton1That et al. 1998; Dramsi et al. 2008; Vollmer et al. 2008). It is 
particularly abundant in Gram1positive bacteria, which possess a very thick cell wall 
containing around twenty layers of peptidoglycan. The main structural features of 
peptidoglycan are linear glycan strand cross1linked by short peptides. The glycan 
strands are made up of alternating N1acetylglucosamine (GlcNAc) and N1
acetylmuramic acid (MurNAc) residues linked by β11→4 bonds. The D1lactoyl group 
of each MurNAc residue is substituted by a peptide stem whose composition is most 
often (L1Ala)1(γ1D1Glu)1X1(D1Ala)1(D1Ala) in nascent peptidoglycan, where X is often 
meso1diaminopimelic acid (DAP), Lys, or ornithine (Orn) depending on the bacterial 
species (Vollmer et al. 2008; Dare and Ibba 2012). The last D1Ala residue is lost in the 
mature macromolecule. Cross1linking of the glycan strands generally occurs between 
the carboxyl group of D1Ala at position 4 and the amino group of the diamino acidat 
position 3, either directly (most Gram1negative bacteria) or through a short peptide 
bridge (most Gram1positive bacteria) (Vollmer et al. 2008). The peptide bridge varies 
from one to seven amino acid residues, which could be the glycine, or certain L1 or D1
amino acids. Generally, transfer of the glycine and L1amino acids to peptidoglycan 
precursors are ensured by Fem transferases, a family of nonribosomal peptide bond 
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forming enzymes utilizing aa1tRNAs as substrates. In a word, Fem transferases 
transfer the amino acid moiety from aa1tRNA to the pentapeptide of the 
peptidogylycan precursor to form branched peptide chains that link these precursors 
to from the peptidoglycan layer () (Dare and Ibba 2012). The completion of 
these peptide bridges is paramount to the structural integrity of the cell wall. Some 
antibiotics are conceived to damage the integrity of these peptide bridges resulting in 
inadequately linked peptidoglycan and weak cell walls. Therefore, Fem transferases 
have became the subject of studies to develop novel antibiotics (Hegde and Shrader 
2001). The peptide bridges formed by Fem transferases differ among bacterial species 
(Hegde and Blanchard 2003; Dare and Ibba 2012) ( ). For example, in 
Streptomyces aureus, the peptide bridge is composed of five glycines, which are added 
by the proteins FemA, FemB, and FemX (Ehlert et al. 1997; Rohrer et al. 1999). FemX 
catalyzes the addition of the first glycine to the ε–amino group of L1Lys of the 
peptidoglycan precursor lipid II, followed by the addition of two glycines by FemA, 
and two more glycines by FemB (  and  ). All the three Fem 
transferases use Gly1tRNAGly as substrate to donate the glycine. The last step of 
peptidoglycan biosynthesis is performed by transpeptidase (TP) (  and
). 
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Figure 21: Formation of the peptidoglycan layer in some bacterial species involves peptide bridges 
formed by Fem tansferases (Dare and Ibba 2012). Shown is a schematic of cell wall biogenesis, below 
each precursor the amino acid specificity of the Fem enzyme(s) found in the organism listed to the 
left is indicated in the same color text as the precursor used by the enzyme for amino acid transfer. 
 
Figure 22: Primary structure of cross-linked peptidoglycan(Hegde and Blanchard 2003). (A) Primary 
structure of a fragment of S. aureus peptidoglycan. S. aureus peptidoglycan contains L-Lys in the stem 
peptide (diamino acid) and a pentaglycine interchain peptide. S. aureus FemX transfers Gly1 from 
glycyl-tRNA to the ϵ-NH2 group of Lys followed by the addition of Gly2-3 and Gly4-5 by FemA and FemB, 
respectively. The α-NH2 group of the terminal Gly5 is cross-linked to the penultimate d-Ala residue (d-
Ala4) of a neighboring pentapeptide releasing the terminal d-Ala residue (curved arrows). The cross-
linking step is a transpeptidase (TP) reaction. (B) Sequence of interchain peptide bridges in different 
species. 
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1.2.1.4.2 Structures of Fem transferases 
The Fem transferases constitute a family of proteins of 3301450 amino acids that 
have been divided into two classes depending on the presence or absence of a coiled1
coil region of about 60 amino acids. Structures of one member of each class have been 
determined, FemA from S. aureus, and FemX from W. viridescens (Benson et al. 2002; 
Biarrotte1Sorin et al. 2004). S. aureus FemA is the first protein structure solved from 
this family. It consists of an antiparallel coiled1coil domain formed by the helical 
domain and a globular domain that can be separated into two subdomains (domains 
1A and 1B) ( 	). W. viridescens FemX lacking the antiparallel coiled1coil 
region consists of two structurally equivalent domains, separated by a cleft. So the 
two Fem enzymes display a similar structure except the coiled1coil region (). 
The fold of each subdomain of the two Fem enzymes displays a structural similarity 
to that of a large N1acetyltransferase superfamily, the GCN51related N1
acetyltransferase (GNAT) superfamily, which catalyzes the transfer of the acetyl 
group from acetyl coenzyme A to a primary amine (Neuwald and Landsman 1997) 
( ). In addition, the complex structure of W. viridescens FemX with its 
substrate UDP1MurNAc1pentapeptide shows that the binding site of the substrate is 
situated in the clef that separates the two domains (Biarrotte1Sorin et al. 2004). 
 
Figure 23: Structural comparisons of Staphylococcus aureus FemA and Weissella viridescens FemX 
(Mainardi et al. 2008; Dare and Ibba 2012). (A) Sequence and structure of FemA with an additional 
coiled coil absent in FemX. (B) Domains 1A and 1B of W. viridescens FemX. The two proteins can be 
structurally compared to the catalytic domains of the histone acetyltransferase of Tetrahymena 
thermophila (C), and the serotonin acetyltransferase of Ovis ovaries (D). 
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1.2.1.4.3 Catalytic mechanism of Fem transferases 
Since 2003, there is little progress on kinetic and mechanistic characterization of 
Fem transferases. The first related work was effectuated on recombinant Lactobacillus 
viridescens (also known as W. viridescens) FemX that catalyzes the transfer of L1Ala 
from Ala1tRNAAla to UDP1MurNacpentapeptide (UDP1MPP) (Hegde and Shrader 
2001; Hegde and Blanchard 2003). In this work, it was suggested that FemX use a 
sequential kinetic mechanism where both substrates (UDP1MPP and Ala1tRNA) must 
be bound to the enzyme for catalysis to occur ( ) (Hegde and Blanchard 
2003). In addition, the authors proposed a model for the reaction catalyzed by FemX 
that includes the acid/base assistance () (Hegde and Blanchard 2003). UDP1
MPP binds to the free enzyme followed by Ala1tRNA. A ternary complex is 
consequently formed among UDP1MPP, Ala1tRNA and FemX. In the ternary 
complex, nucleophilic attack on the carbonyl of Ala1tRNA generates the zwitterionic, 
tetrahedral intermediate. A general acid participates in the catalysis by assisting in 
protonating the 3’1OH of the tRNA ribose moiety and a general base deprotonates 
the positively charged amine. Ala is thereby transferred to the ε–amino group of L1
Lys of UDP1MPP with the help of the general acid and base (Hegde and Blanchard 
2003). 
 
 
Figure 24: Proposed kinetic and chemical mechanisms for Ala transfer activity by W. viridescens FemX 
(Hegde and Blanchard 2003). 
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1.2.1.5 Aminoacyl0tRNA protein transferases 
Aminoacyl1tRNA protein tranferases are ubiquitous proteins involved in an 
essential cellular process: regulated protein degradation. 
1.2.1.5.1 Biological implication and function 
Intracellular protein degradation plays an essential role in many physiological 
processes by removing either damaged polypeptides or proteins that harbor specific 
destruction tags. No matter in eukaryotes or in prokaryotes, the protein degradation 
is regulated by the N1end rule pathway. The N1end rule defines the stability of 
proteins according to the nature of their N1terminal residues (Mogk et al. 2007). 
Unstable proteins harbor specific degradation signals, termed degrons, which are 
recognized by components of the proteolytic systems and subsequently delivered to 
hydrolyzing proteases. In different organisms, the generation of N1degrons and the 
composed residues show distinct differences (Mogk et al. 2007). One of the strategies 
to create functional N1degrons concerns the aminoacyl1tRNA protein transferases, 
which catalyze the transfer of destabilizing residues to the N1terminal of the proteins 
to be degraded. These destabilizing residues are recognized as destruction tags and 
thereby provoke the protein degradation. For example, in the majority of prokaryotes, 
such as E. coli, the primary destabilizing residues (Phe, Leu) are conjugated to the 
second destabilizing N1terminal residue Arg (or Lys) of unstable proteins by a 
leucyl/phenylalanyl1tRNA protein transferase (L/F transferase) which uses Leu1
tRNALeu or Phe1tRNAPhe as substrate (Tobias et al. 1991). L/F tranferase is widely 
studied in the last decades, including its tridimensional structure. 
1.2.1.5.2 Structure of L/F transferase 
The crystal structure of E. coli L/F transferase was separately resolved in 2006 
(Suto et al. 2006; Dong et al. 2007). It is the first resolved structure of the aminoacyl1
tRNA protein transferase family. L/F transferase forms a compact structure and 
consists of two domains: an NH21terminal domain of 60 residues and a COOH1
terminal domain of 170 residues () (Suto et al. 2006). The COOH1terminal 
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domain consists of the GCN51related N1acetyltransferase fold thus presents a 
structural similarity to domain 2 of W. viridescens FemX (Biarrotte1Sorin et al. 2004) 
and that of S. aureus FemA (Benson et al. 2002) ( ). The topological 
similarity may reflect the similarity of their chemical reactions, where an amino acid 
is transferred from an aminoacyl1tRNA to the amino group of a protein (or peptide). 
Nevertheless, there is no significant amino acid similarity between them, suggesting 
that they might have arisen from a common ancestor, but have divergently evolved 
(Suto et al. 2006). In contrast, no significant topological similarity is identified 
between the NH21terminal domain of L/F transferase and the domain 1 of FemX and 
FemA () (Suto et al. 2006). 
 
Figure 25: Overall architecture of E. coli L/F-transferase (Suto et al. 2006). (A) Stereo view of the E. 
coli L/F-transferase structure. The NH2-terminal domain (residues 2–62) and the COOH-terminal 
domain (residues 63–232) are colored blue and green, respectively. The puromycin (analog of the 3’-
terminus of an aa-tRNA) bound to the hydrophobic pocket is colored yellow. (B) Topology diagram of 
L/F-transferase. The rimmed elements in the COOH-terminal domain (α3–α5) and (β5–β12) are 
common to the GNAT superfamily fold. The α-helices and β-strands in the COOH-terminal domains 
are colored red and yellow, respectively. (C) Comparison of the structures of E. coli L/F-transferase 
(left), W. viridescens FemX (wvFemX; middle) and S. aureus FemA (saFemA; right). The COOH-
terminal domain of L/F-transferase is topologically similar to the domain 2's of wvFemX and saFemA. 
The conserved α-helices and β-strands in L/F-transferase, wvFemX and saFemA, are colored red and 
yellow, respectively. 
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1.2.1.5.3 Recognition of its substrate aminoacyl0tRNA by L/F transferase 
As what is previously described, L/F transferase catalyzes peptide bond 
formation by using Leu1tRNALeu (or Phe1tRNAPhe) and a protein bearing an N1
terminal Arg (or Lys) as donor and acceptor substrates, respectively. But how does 
L/F transferase recognize its substrate aa1tRNA? The structure of its complex with a 
substrate aa1tRNA, combined with site1directed mutagenesis study, could help us 
unveil the recognition mechanism. 
The first complex structure of L/F transferase with an analog of the 3’1terminus 
of an aa1tRNA, puromycin, was published in 2006 (	 and ) (Suto 
et al. 2006). The chemical structure of puromycin is similar to that of the 3’1teminus of 
an aa1tRNA; the carboxyl group of p1methoxyphenylalanine is linked to the 3’1amino 
group of 3’1amino161N,N1dimethyladenosine by an amide bond (	). The p1
methoxybenzyl group and the 61N,N1dimethyladenosine correspond to the side 
chain of an amino acid and the adenosine at the CCA end of an aa1tRNA, 
respectively. Puromycin reportedly inhibits the activity of L/F transferase by 
preventing the aa1tRNA from binding to the enzyme suggesting that puromycin 
binds to the same position in L/F transferase as the 3’1end of an aa1tRNA (Horinishi 
et al. 1975; Abramochkin and Shrader 1996). The complex structure shows that the p1
methoxybenzyl group of puromycin is docked within a deep pocket of L/F 
transferase composed of the side chains of several hydrophobic residues. Thus, the p1
methoxybenzyl group of puromycin should be recognized by L/F transferase 
through a hydrophobic interaction with these hydrophobic residues. The reported 
inhibitory effect by puromycin on L/F transferase activity might reflect the similar 
hydrophobic properties of the p1methoxybenzyl group of puromycin to the side 
chains of phenylalanine and leucine (	). In addition to a series of structure1
based site1directed mutations, it was assumed that the hydrophobic leucyl and 
phenylalanyl moieties of Leu1tRNALeu and Phe1tRNAPhe, respectively, are recognized 
by the highly hydrophobic pocket of L/F transferase (Suto et al. 2006). Furthermore, 
this hydrophobic pocket is well conserved among L/F transferases of different 
organisms. All these results explain why L/F transferase recognizes aa1tRNAs 
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attached to hydrophobic amino acids, and excludes those coupled to hydrophilic or 
charged amino acids. Besides the hydrophobicity, the size and the shape of the 
pocket also restrict the nature of bound amino acid. Taken all these together, only 
Leu and Phe can be perfectly accommodated in the pocket, although Trp and Met 
can barely be docked in the pocket. This is consistent with that Met and Trp can be 
transferred to proteins bearing an N1terminal Arg or Lys by L/F transferase but 
much less efficiently than Leu and Phe (Abramochkin and Shrader 1996). In addition 
to the hydrophobic aminoacyl moiety recognizing pocket, there is a 3’1nucleotide 
recognition site. The present structural and biochemical studies of L/F transferase 
strongly suggest that the 3’1terminus of the aa1tRNA is recognized by the 
combination of the hydrophobic aminoacyl moiety recognizing pocket and the 3’1
nucleotide recognition sitem although the 3’1nucleotide binding site is not specific for 
the adenosine (Suto et al. 2006). Furthermore, the electrostatic potential surface of 
L/F transferase reveals the highly biased distribution of charged residues. A cluster 
of positively charged residues are present and protrude toward the solvent. These 
basic residues are conserved among the eubacterial L/F transferase. Mutations of 
these residues remarkably reduced the L/F transferase activity. Thus, according to a 
tRNA docking model on L/F transferase, the tRNA moiety of the substrate aa1tRNA 
was supposed to interact with the basic patch ( &) (Suto et al. 2006). 
Concerning the aa1tRNA specificity of L/F transferase, studies suggest that it is 
determined by the aminoacyl moiety attached to the 3’1terminus of the tRNA, rather 
than by the tRNA itself (Suto et al. 2006). 
Afterwards, in 2007, the crystal structure of E. coli L/F transferase complex with 
phenylalanyl adenosine (rA1Phe) was published (Watanabe et al. 2007). rA1Phe was 
found located at almost the same position in the hydrophobic pocket of L/F 
transferase as puromycin, an aa1tRNA analog described previously (Horinishi et al. 
1975; Abramochkin and Shrader 1996; Watanabe et al. 2007). The new complex 
structure and a series of site1directed mutagenesis study confirmed the recognition 
mode of aa1tRNA by L/F transferase previously proposed by Suto et al (Suto et al. 
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2006). Besides the new complex structure, Watanabe et al. also proposed a catalytic 
mechanism of L/F transferase in this work. 
 
Figure 26: Recognition of the puromycin by E. coli L/F transferase (Suto et al. 2006). (A) Chemical 
structure of puromycin (left) and that of the 3'-ends of Leu-tRNALeu and Phe-tRNAPhe (middle and 
right, respectively). The amino-acid moiety and the base moiety are colored pink and blue, 
respectively. (B) Recognition of the p-methoxybenzyl group and the puromycin base by the 
hydrophobic pocket, as shown by a surface model. (C) Ribbon model of (B). 
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Figure 27: Model of aminoacyl-tRNA binding to L/F transferase (Suto et al. 2006). Two views of a 
ribbon diagram of the docking model of L/F transferase and tRNA. The tRNA backbone is shown as a 
green line (upper two panels). Two views of the L/F transferase-tRNA complex model, showing the 
surface colored according to its calculated electrostatic potential (lower panel; blue, positively 
charged +8KT; red, negatively charged –8KT). tRNA interacts with a positively charged cluster 
composed of basic residues (blue) of helice α2. 
1.2.1.5.4 Catalytic mechanism of L/F transferase 
When the crystals of L/F transferase were soaked in a solution containing its 
minimal substrates: rA1Phe and a short peptide bearing an N1terminal Arg, which 
respectively mimic the aa1tRNA and the target protein bearing an N1termianal Arg, 
the reaction took place in the crystal and the product peptide bearing an N1terminal 
Phe was observed in the active site of L/F transferase (Watanabe et al. 2007). 
Comparing the structure before the reaction, that is L/F transferase in complex with 
the minimal substrates, and the structure after the reaction, that is L/F transferase in 
complex with the product, acatalytic mechanism of L/F transferase was proposed 
( +	) (Watanabe et al. 2007). Before the reaction, two hydrogen bonds 
respectively form between the α–amino group of the N1terminal Arg of the target 
protein and the Oε atom of Gln 188, and between the Nε atom of Gln 188 and the Oε 
atom of Asp 186. Therefore, Asp 186 helps Gln 188 attract a proton from the adjacent 
α–amino group of the N1terminal Arg. This hydrogen bond network consequently 
facilitates the nucleophilic attack of the α–amino group of the N1terminal Arg on the 
carbonyl carbon of the aa1tRNA. Meanwhile, another hydrogen bond forms between 
Nδ atom of Asn 191 and the carbonyl oxygen of aa1tRNA, which may increase the 
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polarity of the carbonyl oxygen thus enhance the electrophilicity of the carbonyl 
carbon of aa1tRNA for attack by the nucleophile. Moreover, this hydrogen bond 
stabilizes the tetrahedral intermediate of the oxyanion during the peptide bond 
formation by L/F transferase. Finally, the proton abstracted from the α–amino group 
by Gln188 is transferred to the 3’1O of the tRNA, which is liberated with the 
completion of peptide bond formation.In addition, biochemical studies agree with 
the proposed catalytic mechanism of peptide bond formation by L/F transferase 
(Watanabe et al. 2007). 
The proposed catalytic mechanism of peptide bond formation by L/F 
transferase is analogous to the reverse reaction of the acylation step observed in the 
peptide hydrolysis reaction by serine proteases, such as chymotrypsin (Blow et al. 
1969; Steitz and Shulman 1982) ( +
). In the model for the catalytic 
mechanism of L/F transferase, the aa1tRNA corresponds to the acyl1Ser 195 of 
chymotrypsin, and Gln 188 and Asp 186 of L/F transferase correspond to His 57 and 
Asp 102 of chymotrypsin. The role of the Nδ atom of Asn 191 of L/F transferase 
corresponds to that of the main chain of the amide of Ser 195 and Gly 193 of 
chymotrypsin, which stabilizes the tetrahedral intermediate (Watanabe et al. 2007).  
 
Figure 28: Comparison of the catalytic mechanism for peptide bond formation by L/F-transferase (A) 
with the reverse reaction of the acylation step during peptide hydrolysis by chymotrypsin (B) 
(Watanabe et al. 2007). 
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However, a recent study on catalytic mechanism of L/F transferase does not 
agree with the mechanism previously described. The results demonstrate that the 
roles of Asp 186 and Gln 188 are just for proper substrate binding and orientation, 
and are not directly involved in the chemistry of the reaction as previously proposed 
by Watanabe et al. (Fung et al. 2011). 
We just illustrate, through examples of the ribosomal machinery, of 
Fem transferases and aa1tRNA protein transferases, the implication of aa1tRNAs in 
cellular processes. Besides these primary processes, aa1tRNAs are also involved in 
secondary metabolism (von Dohren 2009). This can be illustrated by the CDPS family 
(Gondry et al. 2009) and also a new group of tRNA1dependent peptide bond1forming 
enzymes, represented by the transferase PacB, involved in the biosynthesis of the 
antibiotics “pacidamycins” (Zhang et al. 2011). VlmA, identified from Streptomyces 
viridifaciens, is another tRNA1dependent peptide bond forming enzyme involved in 
the biosynthesis of the antibiotic valanimycin (Garg et al. 2008). 
1.2.1.6 Cyclodipeptide synthases (CDPSs) 
 In the introduction of the manuscript, we have described the primary 
characterization of CDPSs. My thesis work consists of deep studies on CDPSs 
including the molecular bases of the substrate specificity, the catalytic mechanism 
and the kinetics of CDPSs. They will be described in the result chapters (
). 
1.2.1.7 Other tRNA0dependent peptide bond0forming enzymes involved in the 
secondary metabolism: example of PacB 
Besides in the biosynthesis of cyclodipeptides by CDPSs, aa1tRNAs are also 
involved in other biosynthetic pathways of secondary metabolites, such as some 
antibiotics. Taking for example, we will briefly introduce a new group of tRNA1
depending peptide bond1forming enzymes, named PacB, in biosynthesis of 
pacidamycins. 
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Pacidiamycins are a family of uridyl tetra/pentapeptide antibiotics produced 
by streptomyces coeruleorubidus with antipseudomonal activities through inhibition of 
the translocase Mra Y in bacterial cell wall assembly (Chen et al. 1989). They are 
reported to exert antibiotic activities by virtue of functioning as a substrate analog of 
the UDP1MurNAc1pendapeptide of Mra Y in bacterial cell wall assembly of the 
pentapeptidyl1bactoprenaol intermediate (Boojamra et al. 2001; Winn et al. 2010). 
More than 10 related family members have been reported (Chen et al. 1989; Fronko et 
al. 2000). Their common scaffold contains a central Nβ1methyl 2S,3S1diaminoburytic 
acid (DABA) moiety which is α1amino1capped by a ureido dipeptide (C1terminal), β1
amino1capped by a single amino acid or a dipeptide (N1terminal), and carboxy1
linked to a 3′1deoxy14′,5′1enaminouridine ( .). Pacidamycins are of interest 
due to their unusual peptidyl1nucleoside structure features, and for the development 
of next generation antibacterial drugs inhibiting the clinically underexplored cell 
wall enzyme target MraY (Zhang et al. 2011). Studies revealed that the 5’1
aminouridyl1tetrapeptide framework of the pacidamycin family is synthesized by 
nine NRPS enzymes (Zhang et al. 2011) ( .). But what is the biosynthetic 
route to pentapeptides from that set of tetrapeptide scaffolds? In other words, how is 
the alanine added to the N1terminal of the uridyl tetrapeptide? Recently, a NRPS1
unrelated enzyme, PacB, coded by the gene pacB was demonstrated to be responsible 
of this reaction because the deletion of pacB abolished the production of all of the 
pentapeptide compounds in vivo, while uridyl tetrapeptides were produced (Zhang 
et al. 2011). In addition, in vitro experiments showed that PacB catalyzed transfer of 
the alanyl residue to the N1terminal of the uridyl tetrapeptide on NRPS assembly line, 
as the free uridyl tetrapeptide was not converted to the uridyl pentapeptide by PacB 
(Zhang et al. 2011). Moreover, PacB was found prefer Ala1tRNA as a donor over 
other activated alanyl species in transferring the alanyl residue to the NRPS assembly 
line. Thus, PacB is a tRNA1dependent aminoacyltransferase involved in peptide 
bond formation in secondary metabolise, specifically in the addition of an N1terminal 
alanyl residue to a tetrapeptidyl intermediate in the highly dissociated NRPS 
assembly line in pacidamycin biosynthesis (0) (Zhang et al. 2011). 
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Figure 29: Structures of selected pacidamycins, and biosynthetic pathway for uridyl tetrapeptide 
using nine NRPS enzymes (Zhang et al. 2011). Domain notation: T, thiolation; A, adenylation; C, 
condensation; TE, thioesterase. The diamine spacer DABA is shown in red. 
 
Figure 30: peptide bond-forming reaction catalyzed by tRNA-dependent enzyme PacB in the 
biosynthesis of pacidamycin 1 (Zhang et al. 2011). The alanyl residue transferred from Ala-tRNA is 
shown in red. PacH is a NRPS enzyme involved in the catalysis. 
Regarding the structure of PacB, bioinformatic analysis using the program 
HHpred revealed structural homology to W. viridescens FemX (Biarrotte1Sorin et al. 
2004) and S. aureus FemA (Benson et al. 2002). As previously described in this thesis, 
these Fem transferases catalyze the addition of amino acid (FemX: Ala; FemA: Gly) 
on the peptidoglycan precursor using an aa1tRNA as a substrate for subsequent 
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peptide bridge cross1linking to strengthen the cell wall (Hegde and Shrader 2001). 
Thus, in term of amino acid addition to a peptidyl chain, PacB also shows functional 
homologies to the Fem transferases. According to the structural model of PacB 
generated based on the highest scoring template FemX, PacB is presumed to have 
two domains separated by a cleft. One domain is predicted to have a three1
dimensional fold similar to that of the GCN51like N1acetyltransferase superfamily 
(Zhang et al. 2011) (). 
 
Figure 31: Three-dimensional structural model of PacB in comparison to the reported structure of 
FemX (PDB ID 3GKR) (Zhang et al. 2011). Domain 1 is represented in blue and domain 2 in red. 
1.2.2 tRNA0independent peptide bond0forming enzymes 
tRNA1independent peptide bond1forming enzymes have been identified to 
catalyze the nonribosomal peptide formation. These peptides generally show 
interesting biological and pharmacologic activities. Therefore, more and more 
attentions are being paid to their synthetic pathways. Among these enzymes, NRPS 
family is the most important class. This part will be dedicated to the description of 
this enzyme family as well as other relevant enzymes by taking glutathione 
synthetase as an example. 
1.2.2.1 Nonribosomal peptide synthetases (NRPSs) 
Nonribosomally synthesized microbial peptides show remarkable structural 
diversity and constitute a widespread class of the most potent antibiotics and other 
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important pharmaceuticals that range from penicillin to the immunosuppressant 
cyclosporine (Walsh 2007). They are generally produced in the secondary 
metabolism of bacteria and fungi by the consecutive condensation of amino acids, 
which is achieved by a group of multimodular megaenzymes called nonribosomal 
peptide synthetases (NRPSs) (Finking and Marahiel 2004; Walsh 2007). We 
previously presented that several DKPs were synthesized by NRPSs (section 
$$$$). However, nonribosomal peptides synthesized by NRPSs are far more than 
this. They are generally polypeptides with more than two peptide bonds. In addition, 
NRPSs relay not only on the 20 canonical amino acids, but also use several different 
building blocks, including nonproteinogenic amino acids (Caboche et al. 2008). The 
nonproteinogenic building blocks contribute to structural versatility of nonribosomal 
peptides and are likely to contribute substantially to the observed biological activity 
() (Walsh 2007). 
 
Figure 32: Examples of non-ribosomally synthesized bioactive macrocyclic peptides that comprise 
unusual structures (D-configured and N-methylated amino acids, heterocyclic rings, fatty acids, 
sugars and non-proteinogenic amino acids) and exhibit antibiotic activity (1, 2, 4), act as siderophore 
(3), biosurfactant (6), or exhibit immunosuppressive activity (5) (Marahiel 2009). 
Tyrocidin A
(1)
Bacitracin A
(2)
Bacitracin
(3)
Vancomycin
(4)
Cyclosporin
(5) Surfactin
(6)
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Next, we will describe NRPS assembly line, their structure, and their catalytic 
mechanism. 
1.2.2.1.1 Assembly logic of NRPSs 
In principle, NRPSs constitute an array of distinct modular sections, each of 
which is responsible for incorporation and if necessary modification of one defined 
monomer into the final product (Konz and Marahiel 1999; Sieber and Marahiel 2005; 
Caboche et al. 2008). As a consequence, in linear NRPS assembly lines, the number of 
the catalytic modules and their order exactly matches the number and order of amino 
acids incorporated in the backbone of the final peptide product (Marahiel 2009). 
Precisely, the identity and order of a module in an assembly line specifies: first, the 
sequence of monomer units activated and incorporated; second, the chemistry that 
occurs at each way station in the assembly line; third, the length and functionality of 
the product released from the distal end of the assembly line (Fischbach and Walsh 
2006) ( ). The modules can be divided into catalytic domains, each 
responsible for a specific synthetic step during peptide synthesis (Mootz et al. 2002; 
Schwarzer et al. 2003; Felnagle et al. 2008). In each so1called elongation module, three 
domains are ubiquitous in nonribosomal peptide synthesis and essential for peptide 
elongation. The domains are responsible for the activation of the amino acid 
(adenylation (A) domains, ~500 amino acids), the propagation of the growing 
peptide chain (thiolation or peptidyl carrier protein (PCP) domains, 801100 amino 
acids), and the condensation of the amino acids (condensation (C) domains, ~450 
amino acids). A fourth essential NRPS catalytic unit associated with product release 
is the thioesterase (TE) domain (~280 amino acids). The TE domain is located in the 
termination module and catalyzes peptide release by either hydrolysis or 
macrocyclization. In addition, some modification domains could be integrated into 
NRPS modules at different locations in order to modify amino acids incorporated, 
such as epimerization (E) domains and N1methyltransferase domains (Mt) catalyzing 
respectively the generation of D1configurated and methylated amino acids () 
(Kopp and Marahiel 2007; Marahiel 2009; Strieker et al. 2010). 
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However, during the past few years, it has become clear that modules from 
acterial megasynthetases can in fact operate iteratively, resulting in elongated 
products or, in contrast to this, can be skipped during the biosynthetic process to 
yield shortened products. Reports on multimodular assembly lines not following the 
co1linearity rules are emerging, as well as descriptions of deviations from the 
standard modular architecture. This reports illustrate that NRPSs have a much 
greater diversity in their biosynthetic potential than originally expected (Wenzel and 
Müller 2005). 
 
Figure 33: Simplified mechanism of nonribosomal peptide synthesis (Strieker et al. 2010). (1) The 
amino acid is activated as aminoacyl-AMP by the adenylation domain. (2) Transfer of the amino acid 
onto the PCP domain. (3) Condensation of PCP-bound amino acids. (4) Possibility of amino acid 
modifications, for example by epimerization domains. (5) Transesterification of the peptide chain 
from the terminal PCP onto the TE domain. (6) TE catalyzed product release by either hydrolysis or 
macrocyclization. The number of modification domains and modules is very variable. 
Structures of the NRPS domains are necessary to be described in order to clarify 
the catalytic mechanism. 
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1.2.2.1.2 NRPS structures 
So far, the structures of the four essential NRPS domains described above had 
been subsequently determined. The structural information provides profound 
insights into the catalytic mechanisms and dynamics of these multidomain enzymes. 
1.2.2.1.2.1 The adenylation (A) domain 
The A domains catalyze reactions concerning ATP1dependent amino acid 
activation and subsequent transfer to the PCP domain. The first A domain structure, 
Phe A, was published in 1997 (Conti et al. 1997). Each A domain comprises a large N1
terminal core domain (~450 amino acids) and a small C1terminal subdomain (~100 
amino acids), which are connected by a small 5110 residues hinge, with a 
hydrophobic active site in between () (Marahiel 2009; Strieker et al. 2010). 
The A domains show a significant structural similarity to several members of the 
adenylate1forming1superfamily, which include in addition to NRPS A domains the 
firefly luciferase, acetyl CoA synthetase, and yeast 41chlorobenzoate: CoA ligase 
(Marahiel 2009). The core and subdomain organization of A domains is highly 
conserved even in other adenylate generating enzymes just mentioned. It was 
reported that an A domain adopted two different states, open and closed, during 
different catalytic stage. During the catalytic cycle (substrate and ATP binding 
followed by acyl1AMP formation) the small C1terminal subdomain can adopt 
different orientations relative to the large N1terminal subdomain (Yonus et al. 2008). 
This motion ranges from 140° rotation in the open state during substrate loading 
(ATP and amino acid) to a closed state that promotes the adenylation reactions 
( ). Also, extensive biochemical studies combined with structural and 
phylogenetic studies on A domains revealed the so1called “specificity1conferring 
code” of A domains (Stachelhaus et al. 1999). This code is composed of 10 amino acid 
residues, which are responsible for substrate binding within the active site of A 
domains. This code can be easily identified and extracted out of the sequence of any 
A domain and used for in silico studies to make a good prediction on the possible 
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substrate without prior biochemical studies. Different online tools for A domain 
specificity prediction are available (Rausch et al. ; Weber et al. 2009). 
 
Figure 34: An proposed reaction cycle of an A domain showing the conformational movement of the 
small C-terminal subdomain (gray) compared to the large N-terminal core domain (red) upon ATP 
and substrate amino acid binding (Marahiel 2009). During this initial reaction of the A domain, 
aminoacyl-AMP formation and pyrophosphate release, the C-terminal subdomain rotates by some 
140° from an open into a close conformation. In the second half reaction, through a specific PCP/A 
interaction, the activated substrate is then transferred to the reactive thiol group of the cofactor 
bound to the carrier domain PCP (green). 
1.2.2.1.2.2 The peptidyl carrier protein (PCP) domain  
The PCP domain is a small protein containing the binding site of the cofactor 4’1
phospopantetheine (ppant), derived from CoA. Its highly conserved serine residue 
(GGXS1motif) is post1translationnally modified by the 20 Ǻ “swinging arm” ppant, 
which is carried out by ppant1transferases such as the promiscuous Bacillus subtilis 
ppant1transferase Sfp (Reuter et al. 1999; Strieker et al. 2010). The ppant offers a thiol 
group to covalently bind its substrate and synthetic intermediates in the form of acyl1
(core domain)
(subdomain)
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S1PCP (). Like other members of the carrier protein superfamily, PCP shows 
a simple four helix bundle structure. A large loop region (10115 amino acids) located 
between helix 1 and helix 2 contains the conserved serine residue to which the ppant1
cofactor is attached ( ) (Weber et al. 2000; Marahiel 2009). Recent studies 
revealed that PCP forms three different and slowly interconverting conformations, 
that is the A (apo), H (holo), and A/H states, depending on its chemical modification 
states () (Koglin et al. 2006). It was shown that ppant1bound PCP domain 
could be generated only with the A1state PCP. 
 
Figure 35: NMR structures of the PCP conformers (A, A/H, and H states) (Marahiel 2009). 
1.2.2.1.2.3 The condensation (C) domain 
The C domains are the control entities of NRPS elongation (C1A1PCP) modules 
as they catalyze the peptide bond formation between two adjacent PCP molecules 
loaded with their respective amino acids (Linne and Marahiel 2000). An aminoacyl1S1
PCP activated amino acid is bound to the acceptor site of the C domain, whereas its 
donor site accommodates the incoming peptidyl1S1PCP substrate. The overall 
architecture of the C domain revealed a V1shaped form with a canyon1like structure 
in which the two PCP1bound substrates can be positioned from both sides (acceptor 
and donor sites) in close proximity to the active site histidine located in the 
conserved HHxxxDG core motif ( 	). The V1shape C domain structure 
A state A/H state H state
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shows two similar N and C1terminal subdomain folds that both belong to the well1
known chloramphenicol acetyltransferase (CAT) fold. In the C domain structure the 
two CAT1folds build the canyon1like active site with the HHxxxDG1motif located on 
the middle of its floor. In the PCP1C didomain structure ( 	), the PCP 
domain is attached to the donor site of the C domain and has an A/H conformation. 
The flexible linker region between PCP and C is 18 residues in length and show little 
interaction with both folds (Marahiel 2009). 
 
Figure 36: Structures of the PCP-C didomain(A) and of the dissected TE domain (B) from the surfactin 
synthetase (Marahiel 2009). PCP, C and TE domains are respectively shown in green, gray and orange. 
1.2.2.1.2.4 The thioesterase (TE) domain 
TE domains are only found in termination modules. Several structures of 
dissected TE domains have been solved, showing that all have the common fold of 
α/β1hydrolases (
) (Bruner et al. 2002; Samel et al. 2006), such as esterases 
and lipases, and all harbor in the active center a catalytic triad of serine, histidine, 
and aspartate. The serine within this triad plays an important catalytic role, which 
will be detailed later in the catalytic mechanism part. 
A B
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1.2.2.1.2.5 An entire termination module 
Recently, the crystal structure of the surfactin NRPS (SrfA1C) termination 
module composed of the four domains (A1PCP1C1TE, 1274 residues) was determined 
( &) (Tanovic et al. 2008). The folds of the individual domains in SrfA1C 
module were found to be exactly the same as those solved before for the individually 
dissected A, C, PCP, and TE domains. The four domains of SrfA1C termination 
module catalyze the activation and incorporation of the terminal amino acid leucine 
and also the release of the final product as a cyclic lipopeptide lactone. Although the 
structures of these domains had been individually resolved, the entire module 
structure of SrfA1C provided unique information on domain1domain interactions 
within an NRPS module as well as on the nature of the linker regions and on how the 
essential catalytic domains are oriented and connected in space. Overall, the 
structural core of the module is a compact rectangular catalytic platform mainly built 
by the intimate association of the C domain and the large N1terminal part of the A 
domain. The two domains are “glued” together by extensive interactions at their 
interfaces and by the intervening linker region (32 residues) sandwiched in between. 
Both active sites of the A and C domains are arrayed on the same side of the platform. 
The C1terminal lid1region of the A domain (∼100 residues of the C1terminal part) and 
the PCP domains are tethered to each other on top of the platform and connected to 
the large N1terminal region of A by a flexible linker of 15 residues. In this 
arrangement, PCP and A1lid region can easily move relative to the static C–A1
platform. Considering the distances unsuitable for the catalysis between the active 
sites of the module, large structural rearrangements are mandatory during a full 
catalytic cycle (Marahiel 2009; Strieker et al. 2010). 
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Figure 37: Back view or acceptor site view of the termination module of the surfactin NRPS subunit 
SrfA–C (Strieker et al. 2010). The 20 Å radius, which is the reachable region of the carrier-arm, 
around the ppant-attachment site of the PCP domain (S1003A) is depicted as a gray sphere. The PCP 
domain is well positioned to interact with the H144 active site of the C domain. The active sites of the 
TE (S1117) and the A domain substrate leucine cannot be reached. The active site of each domain is 
shown in spheres. Linker regions are shown in blue, the domains are arranged and colored 
corresponding to the schematic illustrations in upper left corner. 
1.2.2.1.3 Catalytic mechanism of NRPSs 
As described previously, an A domain is responsible for activation of its 
cognate amino acid by ATP. The activated amino acid is present in the form of 
aminoacyl1adenylate (+	). Then the activated amino acid is transferred onto 
the PCP by a yet unknown mechanism, forming a thioester via ppant bound to PCP 
(+
). Next, the C domain catalyzes the peptide bond formation between two 
adjacent PCP domains (upstream PCP1 and downstream PCP2) loaded with their 
respective amino acids. The aminoacyl1S1PCP2 activated amino acid is bound to the 
acceptor site of the C domain, whereas the incoming aminoacyl (or peptidyl)1S1PCP1 
substrate is bound to the donor site. The C domain catalyzes the nucleophilic attack 
of the downstream amino acid on the carbonyl group of the upstream amino acid (or 
nascent peptide), thus forming a new peptide bond (+). Then a new peptide 
bond1forming cycle begins and is catalyzed by the downstream NRPS module. In 
this manner, the peptide chain is elongated until the last module containing the TE 
domain. The TE domains catalyzes product release by a two step reaction mechanism: 
transfer of the full length peptide chain attached to the terminal PCP to a highly 
79 
conserved serine residue in the active site of TE by the formation of an acyl1O1TE 
intermediate that is subsequently cleaved by a region1 and stereoselective 
intramolecular macrocyclization using a peptide internal nucleophile (Trauger et al. 
2000; Kopp and Marahiel 2007) ( +). Some TE domains catalyze product 
release either by the generation of cyclic or branched1cyclic products (lactones and 
lactams), whereas others catalyze product release just by hydrolysis. Anyways, 
macrocyclization by TE seems to be the predominant mechanism for product release 
and regeneration of the NRPS (Marahiel 2009). We have previous mentioned that the 
TE domain harbors in the active center a catalytic triad of serine, histidine, and 
aspartate ( 
 and  &). The serine within this triad is the site of 
tetrahedral intermediate formation that is stabilized by an oxyanion hole on the way 
to the acyl1O1TE intermediate. This intermediate breaks down by the nucleophilic 
attack of a peptide internal nucleophile. In this way, a nonribosomal peptide is 
formed by NRPS. 
More and more medically relevant nonribosomal peptides and their synthetic 
mechanisms by NRPSs are being discovered. Nevertheless, although remarkable 
progress regarding the revelation of the mechanisms underlying nonribosomal 
peptide synthesis has been made during the last decade, there are still a lot of 
puzzles. We are still far away from understanding the whole picture. 
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Figure 38:  Reactions catalyzed by the four essential NRPS domains A, PCP, C and TE (Felnagle et al. 
2008; Marahiel 2009). The cofactor ppant attached to PCP domain is shown as a wavy line. 
1.2.2.2 Other peptide synthetases: example of the glutathione synthetase 
Glutathione (GSH) is the most abundant and important low molecular weight 
antioxidant synthesized in cells. GSH play critical roles in protecting cells from 
oxidative damage and the toxicity of xenobiotic electrophiles, and maintaining redox 
homeostasis. Moreover, GSH is also involved in regulation of the cell cycle (Forman 
et al. 2009).  Thus, it is of interest to understand the biosynthetic pathway of the GSH. 
1.2.2.2.1 General introduction to the glutathione biosynthesis 
GSH is a tripeptide, γ1glutamyl1cysteinyl1glycine. The GSH biosynthesis 
consists of two steps of reaction ( .) (Forman et al. 2009). The first step 
TE
Peptidyl-O-TE
(hydrolysis)
(macrocyclization)
(A)
(B)
(C)
(D)
Peptidyl-S-PP-PCP2
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PP-PCP2
Aminoacyl-S-
PP-PCP1
Aminoacyl-S-PP-PCPAminoacyl-Adenylate
Aminoacyl-Adenylate
holo-PCP
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involves the combination of cysteine with glutamate to produce γ1glutamylcysteine. 
This reaction is catalyzed by the enzyme glutamate cysteine ligase, also called γ1
glutamylcysteine synthetase. This enzyme requires coupled ATP hydrolysis to form 
an amide bond between the γ1carboxyl group of glutamate and the amino group of 
cysteine (Huang et al. 1993). The next step involves the enzyme glutathione 
synthetase (GSH synthetase), responsible for adding glycine to the dipeptide to 
produce GSH. This step also requires coupled ATP hydrolysis (Meister 1974). Here, 
we will just briefly describe the structure and the catalytic mechanism of the GSH 
synthetase. 
 
Figure 39: Two-step glutathione synthetic pathway (Forman et al. 2009). 
1.2.2.2.2 Structure of the GSH synthetase  
Up to now, GSH synthetase structures from three different species have been 
determined: E. coli (Yamaguchi et al. 1993), human (Polekhina et al. 1999), and yeast 
(Gogos and Shapiro 2002). Taking for example, we will highlight the human GSH 
Glutamate cysteine ligase
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synthetase, the crystal structure of which was determined at 2.1 Ǻ resolution in 
complex with ADP, two Mg2+, a sulfate ion and GSH ( 0) (Polekhina et al. 
1999). Human GSH synthetase is composed of about 470 amino acid residues. It is a 
compact molecule with the shape of a flat and a central cavity. The ligands 
mentioned above are bound in the central cavity, with ADP stacked between two 
antiparallel β1sheets. The cavity is covered by three loops (designated gray in 
0) projecting from three of the lain structural units of the structure. The first loop, 
named substrate1binding loop, forms interactions with the GSH; the other two loops 
are named the Gly1rich loop and Ala1rich loop. The main structural units are an 
antiparallel β1sheet together with helices packing on either side of the sheet 
(designated blue in 0), a parallel β1sheet together with helices on both sides 
(designated red in  0), and a domain called the lid because of its role in 
providing access to the ATP1binding site (designated green in  0). The lid 
domain consists of an antiparallel β1sheet with helices packed on one side. In 
addition to the three main structural units, residues 3148 form a dimerization unit 
(designated purple in 0) and residues 2951335 make up the helical connection 
(designated orange in  0) between the parallel β1sheet unit and the lid 
domain (Polekhina et al. 1999). 
The structure indicates that the human GSH synthetase belongs to the ATP1
grasp superfamily (Polekhina et al. 1999), the structures of which are characterized 
by an ATP1binding cleft formed by two antiparallel β1sheets and a phosphate1
binding loop (Galperin and Koonin 1997). 
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Figure 40: Structure of human GSH synthetase (Polekhina et al. 1999). The elements are shown 
insecondary structures. GSH and sulfate ions are shown as ball-and-stick and magnesium ions as 
mauve spheres. Major structural units (see text) are shown in different colors. 
1.2.2.2.3 Catalytic mechanism of the GSH synthetase 
We evoke that the GSH synthetase is involved in the second catalytic step of the 
GSH by catalyzing the addition of glycine to the first step1formed dipeptide, γ1
glutamylcysteine.  
Recently, combining the structures of the GSH synthetases and biochemical 
studies, the highly conserved residues that form polar interaction with ATP, Mg2+ 
and GSH were found important even essential to the activity. A catalytic mechanism 
for GSH synthesis in eukaryotes is thus suggested () (Herrera et al. 2007). 
Several amino acid residues of the enzyme were involved in the catalysis. In the first 
part of the reaction ( 	), formation of an electrophilic acylphosphate 
intermediate occurs by transfer of the γ1phosphate of ATP to γ1glutamylcysteine. 
During this step, the residues coordinating the Mg2+ to ATP are required for 
nucleotide binding and for orienting the γ1phosphate group in the active site. Arg 
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132 plays a critical role in catalysis. The guanidyl group of the side chain likely 
stabilizes formation of the pentavalent transition state that yields the phosphorylated 
γ1glutamylcysteine intermediate and ADP. In the second half of the reaction (

), the amino group of glycine acts as a nucleophile to attack the acylphosphate 
intermediate. Arg 132 and Mg2+ bound by Glu 148 and Asn 150 are positioned to 
stabilize the tetrahedral transition state that decomposes to yield glutathione and 
inorganic phosphate. The side chain guanidyl group of Arg 454 interacts with the 
carboxylate moiety of glycine to orient the substrate for attack on the acylphosphate 
intermediate (Herrera et al. 2007). 
 
Figure 41: Proposed reaction mechanism for the GSH synthetase (Herrera et al. 2007). A, formation 
of the acylphosphate intermediate. B, addition of glycine to theγ-glutamylcysteine phosphate 
intermediate. 
We have presented, in  , the DKP family and the biologic peptide 
bond1forming systems. These bibliographic studies will help us understand the 
results of my thesis work, which will now be exposed. 
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2 STRUCTURAL AND MECHANISTIC 
CHARACTERIZATION OF THE CDPSS 
2.1 Introduction 
In the section $ and the introduction of the manuscript, we have illustrated 
numerous interests to study the DKP family and presented the recently discovered 
CDPS family which is dedicated to catalyzing the formation of cyclodipeptides, 
precursors of DKPs. Up to now, eight CDPSs of different bacterial phyla have been 
identified and characterized, including the first characterized CDPS, AlbC from S. 
noursei. AlbC catalyzes the formation of cFL, which is the precursor of the DKP 
albonoursin (Lautru et al. 2002; Gondry et al. 2009). 
This chapter consists of an article describing the structure and site1directed 
mutagenesis studies of AlbC, which provides insight into the catalytic mechanism 
and the interaction between AlbC and aa1tRNA substrates. In the end of the chapter, 
we will present related studies on another CDPS YvmC1Blic published shortly after 
those on AlbC (Sauguet et al. 2011). 
The crystallographic structure of AlbC was determined by Ludovic Sauguet 
during his Ph.D work in our laboratory. Concerning my contribution to the work of 
this article, I participated in the site1directed mutagenesis studies of AlbC in order to 
understand the role of some residues considered relevant to the catalytic activity of 
AlbC. Firstly, I participated in the selection of these residues. Secondly, I participated 
in the construction of the plasmids encoding different variants of AlbC. Then I tested 
the in vivo activities of each of the variants. The variants were expressed in E. coli and 
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the culture supernatants were analyzed by LC1MS/MS in order to identify and 
quantify the various cyclodipeptides produced then secreted in the culture medium. 
I also analyzed the expression levels of the variants by SDS1PAGE and western blot. 
Concretely describing this work, as the crystal structure of AlbC was found to be 
similar to that of the catalytic domain of the class1Ic aaRSs, we compared the 
sequences of the six identified CDPSs with those of three TyrRSs from different 
kingdoms. Among the five conserved CDPS residues located in a surface1accessible 
pocket, three are well superimposed with their corresponding residues in TyrRS. 
Considering the possible positioning of the aminoacyl moiety of an aa1tRNA 
substrate in AlbC pocket, six pocket1forming residues suspected to interact with the 
aminoacyl moiety of the substrate were independently substituted by alanine and, 
where relevant, other amino acids. It included the five conserved CDPS residues and 
another relevant residue located near to the bottom of the pocket. This study allowed 
understanding the role of these residues in the interaction with the aminoacyl moiety 
of the substrate. In addition to AlbC pocket, we also independently substituted with 
alanine the seven residues conserved among CDPSs but located outside the active 
site. They showed different effect on the activity or production amounts of the 
corresponding variants. On the basis of their structural positioning, we gave possible 
explications to their various effects. Moreover, we also studied two patches of basic 
residues suspected to interact with the tRNA moiety of the substrate. All of these 
basic residues were substituted with alanine. The site1directed mutagenesis studies 
on these relevant residues described above allowed understanding the interaction 
mode of aa1tRNA substrates with CDPSs. 
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SUPPLEMENTARY INFORMATIONS
Supplementary Table 1. First hits of the Dali search of the AlbC structure against the Protein Data Bank.
Redundancies, i.e. hits that correspond to the different structures of the same protein, have been removed. Hits
that correspond to the structures of TyrRSs and TrpRSs are indicated by an orange or yellow background,
respectively. TyrRS from M. jannaschii (PDB id: 1j1u) has the Dali number 13 and the protein number 3.
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SUPPLEMENTAL FIGURES 
Supplementary Figure S1. Electron density map in
AlbC pocket. Residues from AlbC pocket are
represented in ball and stick and coloured in green.
A molecule of cyclodithiothreitol and a molecule of
phosphate have been modelled in the residual
electron density observed in the pocket. Water
molecules presented in the pocket are represented in
orange sphere. The electron density corresponds to
a 2Fo-Fc map contoured at one sigma.
Supplementary Figure S2. Positioning of the flexible 27 amino acids extension in the crystal packing.
An AlbC monomer is represented in grey surface with the first four N-terminal residues visible in the
electron density map shown in magenta. Twelve symmetric molecules surrounding the N-terminal region of
AlbC are presented either in cartoon (A) or in surface (B) representation. The AlbC N-terminus is located in
a large cavity that is about 45 Å large in each direction. Three other symmetric molecules have their N-
terminus directed towards this cavity. The dimension of this cavity about 4 105 Å3 is fully compatible with
the presence of four flexible 27 amino acids extensions.
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Supplementary Figure S3. Analysis of AlbC B-factors. (A) Cartoon representation of AlbC with residues
coloured from high B-factors (red) to low B-factors (blue). The four loops with highest B-factors (L1: A38-
K46; L2: A105-E111; L3: R215-R220; L4: A236-A239) are indicated by arrows. The ligands observed in the
active site are represented in sphere mode and coloured in magenta (phosphate) and pink (cDTT). (B) Graph
representing the B-factors along the AlbC sequence. The four loops with highest B-factors are indicated.
tRNA-binding
domain
Catalytic
domain
CP1
domain
N-terminal
domain
Supplementary Figure S4. Superimposition of the structures of AlbC and E. histolytica TrpRS (pdb 3hzr).
The two enzymes are shown in cartoon mode. The Rossmann-fold and the CP1 domains of E. histolytica TrpRS
are coloured in dark blue and blue, respectively, and the corresponding domains of AlbC are coloured in dark
green and green, respectively. Rossmann-fold and CP1 domains of the two proteins have similar rmsd
(respectively 3.07 Å over 91 Ca and 3.17 Å over 55 Ca). E. histolytica TrpRS possesses two additional regions
compared to AlbC: a C-terminal domain involved in tRNA-binding and anticodon recognition coloured in grey,
and a short N-terminal region coloured in light blue.
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Supplementary Figure S5. Comparison of oligomeric states
for AlbC, Rv2275, and TyrRSMj. The enzymes are shown in
cartoon mode. (A) Comparison for TyrRSMJ (PDB id: 1j1u)
and AlbC (PDB id: 3oqv). The TyrRSMj dimer is shown with
the Rossmann-fold and the CP1 domains in dark and light
blue, respectively. The tRNA-binding domain is represented in
grey (top view). The AlbC monomer, with the Rossmann-fold
and the CP1 domains in dark and light green respectively, has
been superimposed on each of TyrRSMj monomer. The
superimposition shows major steric hindrance, coloured in
orange, between helices α5, α6 and α7 of each AlbC monomer
(bottom view). (B) Comparison for Rv2275 (PDB id: 2x9q)
and AlbC (PDB id: 3oqv). The Rv2275 dimer is shown with
the Rossmann-fold and the CP1 domains in dark and light
blue, respectively (top view). The AlbC monomer, with the
Rossmann-fold and the CP1 domains in dark and light green
respectively, has been superimposed on each of Rv2275
monomer. The superimposition shows smaller interface
between AlbC monomer that for that of Rv2275, due in
particular to the absence of helix α1 (bottom view).
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Supplementary Figure S6. Cyclodipeptides synthesized by the wild-type AlbC and the variant L200N
expressed in E. coli. (A) LC-MS analyses of the culture medium of E. coli cells expressing the wild-type
AlbC and the variant L200N; the UV traces (λ = 214 nm) are shown in yellow and blue, respectively. (B)
The EIC peaks corresponding to the wild-type AlbC and the variant L200N are shown in yellow and blue,
respectively. The cyclodipeptides were identified as previously described in Gondry et al1.
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Supplementary Figure S7. Analysis of trypsin-digested AlbC not incubated with Phe-tRNAPhe.
(A) Peptide mass fingerprint analysis. Thick grey arrows indicate the observed m/z of AlbC peptide
fragments containing residue S37 (fragments [29-46] at calculated m/z 1878.94 and [27-46] at
calculated m/z 2163.09). Continuous and dashed line frames are closed views of the m/z regions of the
mass spectrum corresponding to calculated m/z of potential phenylalanylated [29-46] fragment at
2026.01 and phenylalanylated [27-46] fragment at 2310.16, respectively. (B) PSD-MS/MS spectrum of
m/z 1878.91. Both b- and y-ions series identify the amino acids sequence of AlbC fragment [29-46].
(C) PSD-MS/MS spectrum of m/z 2163.04. Both b- and y-ions series identify the amino acids
sequence of AlbC fragment [27-46].
B
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Supplementary Figure S8. Analysis of trypsin-digested AlbC pre-incubated with Phe-
tRNAPhe. Corresponding PMF analysis is shown in Figure 7. PSD-MS/MS spectrum of m/z
2310.17. Both b- and y-ions series identify the amino acids sequence of the modified AlbC
fragment [27-46], and the residue 37 as the phenylalanylated residue.
Supplementary Figure S9. Peptide mass fingerprint analysis of the trypsin-digested variant
S37A pre-incubated with Phe-tRNAPhe. Continuous and dashed line frames are closed views of
the m/z regions of the mass spectrum corresponding to respectively calculated m/z of potential
phenylalanylated [29-46] fragment at 2009.97 and phenylalanylated [27-46] fragment at 2294.16.
None of these modified fragments was detected and identified by PSD-MS/MS analyses.
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Supplementary Figure S10. Analysis of the trypsin-digested variant E182Q pre-incubated
with Phe-tRNAPhe. (A) Peptide mass fingerprint analysis. Continuous and dashed line frames are
closed views of the m/z regions of the mass spectrum corresponding to calculated m/z of
potential phenylalanylated [29-46] fragment at 2026.00, and phenylalanylated [27-46] fragment
at 2310.17, respectively. The y-ions of the phenylalanylated serine residue were detected in both
[29-46] fragment at 2026.00, and [27-46] fragment at 2310.17 (respectively B and C). However,
none of these modified fragments was formed with a sufficient amount to be detected, isolated as
precursor-ion, and sequenced unambiguously by PSD-MS/MS analyses.
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Supplementary Figure S11. Analysis of the trypsin-digested variant Y178F pre-incubated
with Phe-tRNAPhe. (A) Peptide mass fingerprint analysis. Continuous and dashed line frames are
closed views of the m/z regions of the mass spectrum corresponding to calculated m/z of
potential phenylalanylated [29-46] fragment at 2026.00, and phenylalanylated [27-46] fragment
at 2310.17, respectively. The y-ions of the phenylalanylated serine residue were detected in the
[29-46] fragment at 2026.00, but not in the [27-46] fragment at 2310.17 (respectively B and C).
The modified [29-46] fragment was not formed with a sufficient amount to be detected, isolated
as precursor-ion, and sequenced unambiguously by PSD-MS/MS analyses.
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Supplementary Figure S12. Analysis of the trypsin-digested variant Y202F pre-incubated with
Phe-tRNAPhe. (A) Peptide mass fingerprint analysis. Continuous and dashed line frames are closed
views of the m/z regions of the mass spectrum corresponding to calculated m/z of potential
phenylalanylated [29-46] fragment at 2026.00, and phenylalanylated [27-46] fragment at 2310.17,
respectively. (B) PSD-MS/MS spectrum of m/z 2026.00. Both b- and y-ions series identify the
amino acids sequence of the modified AlbC fragment [29-46], and b9 and y10 daugther-ions
confirm that S37 is the phenylalanylated residue. (C) PSD-MS/MS spectrum of m/z 2310.17. Both
b- and y-ions series identify the amino acids sequence of the modified AlbC fragment [27-46], and
y10 daugther-ion confirms that S37 is the phenylalanylated residue.
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Supplementary Figure S13. Analysis of the trypsin-digested variant S37C pre-incubated with
Phe-tRNAPhe. (A) Peptide mass fingerprint analysis. Continuous and dashed line frames are closed
views of the m/z regions of the mass spectrum corresponding to calculated m/z of potential
phenylalanylated [29-46] fragment at 2041.99, and phenylalanylated [27-46] fragment at 2326.15,
respectively. Both modified fragments were detected as indicated by the arrows. (B) PSD-MS/MS
spectrum of m/z 2041.99. Both b- and y-ions series identify the amino acids sequence of the
modified fragment [29-46], and b9 and y10 daugther-ions unambiguously confirm that C37 is the
phenylalanylated residue. (C) PSD-MS/MS spectrum of m/z 2326.15. Both b- and y-ions series
identify the amino acids sequence of the modified fragment [27-46], and b11 and y10 daugther-ion
unambiguously confirm that C37 is the phenylalanylated residue.
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Supplementary Figure S14. Description of the residues
conserved among CDPSs but located outside the active
site. (A) Overall view. The side chains of conserved
residues are in stick representation. They are coloured in
blue if their substitution with alanine does not affect
enzyme activity and protein expression (G79, S120 and
C149). They are coloured in orange if the substitution
affects both enzyme activity and protein expression (H31,
W54, and F59), and in magenta if the substitution affects
enzyme activity but not protein expression (Y128).
Residues G79 and S120 are not visible in this view. (B)
Position of residues H31, W54 and F59. Residues that are
within 4.0 Å of these three residues are represented.
Hydrogen bonds made by H31 are represented in dashed
lines. (C) Position of residues Y128 and S120. Residues that
are within 4.0 Å of these two residues are represented.
Hydrogen bonds are represented in dashed lines.
Supplementary Figure S15. Comparison of the tRNA-binding regions in AlbC and TyrRSMj. (A) Structure
of the TyrRSMj-tRNATyr-tyrosine complex (PDB id: 1j1u). TyrRSMj and tRNATyr are respectively shown in
surface and cartoon representations. The catalytic and tRNA-binding domains are respectively in dark blue and
grey. The TyrRSMj residues involved in acceptor stem binding (see Figure 4) are coloured in magenta. The
amino acid-binding pocket is indicated by a black arrow. (B) Structure of AlbC. AlbC is shown in surface
representation, coloured in green, and oriented as TyRSMJ in (A). The residues forming the basic patch
identified inAlbC are shown in blue; among them, the residues essential for enzyme activity are indicated.
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2.3 Additional information 
Now, the crystal structure of another CDPS named YvmC1Blic from Bacillus 
licheniformisis also available (Bonnefond et al. 2011). Here we will compare the three 
CDPSs: AlbC, Rv2275 and YvmC1Blic. Their structures are respectively determined at 
1.91Ǻ, 2.01Ǻ and 1.712.41Ǻ resolutions. The 3D structures of the three CDPSs (
	) (Belin et al. 2012) superimposed well (rms deviation value of 2.27 Ǻ, 2.2 Ǻ and 
2.46 Ǻ over 196, 211 and 180 matched Cα positions for Rv2275 versus AlbC, for 
Rv2275 versus YvmC1Blic and AlbC versus YvmC1Blic, respectively) despite their 
sequence divergence (only about 27% sequence identity). Strikingly, AlbC and 
YvmC1Blic are monomers whereas Rv2275 is a homodimer. The common monomer 
has a compact α/β fold consisting essentially of a central β1sheet with five parallel β 
strands surrounded by α helices ( 	). Just as class I aaRSs, the common 
monomer of the three CDPSs also contains a Rossmann1fold domain. This motif is 
formed by strands β31β5, helix α2 and the C1terminal part of helix α4, followed by a 
helical region consisting of three helices (α51α7) that is packed against this Rossmann 
fold. Structures of all the three CDPSs are highly similar to that of the catalytic 
domain of class Ic aaRS. They all possess a similar surface1accessible pocket 
containing five of the seven essential residues conserved among the eight 
characterized CDPSs. Four residues (AlbC numbered Gly35, Ser37, Tyr178, and 
Glu182) are well superposed whereas the fifth, Tyr202, adopts an opposed position 
for Rv2275 to AlbC and YvmC1Blic ( 
). In addition, the cluster of basic 
residues of AlbC supposed to interact with the tRNA moiety of aa1tRNA substrate is 
conserved in all CDPSs characterized to date, including Rv2275 and YvmC1Blic. Thus, 
the basic patch of the CDPS may interact with the tRNA moiety of the substrate, 
potentially with the phosphate backbone of the tRNA body. However, there are some 
significant differences between the three CDPSs. First, the N1terminal region (amino 
acids 50177) of Rv2275 is structured (strands β1, β2 and helix α1) whereas the 
corresponding regions of YvmC1Blic (1111) and AlbC (1127) are not observed. 
Conversely, the C1terminal helix α9 is structured in AlbC whereas the corresponding 
regions of Rv2275 (2851289) and YvmC1Blic (2361249) are not observed (	). 
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Second, there are major deviations between the loops containing residues shown to 
be involved in substrate interaction or catalytic mechanism. 
Studies on the three CDPSs all suggest that the surface1accessible pockets in 
CDPSs are the binding sites for the aminoacyl moiety of the aa1tRNA substrate. 
Furthermore, studies on the pocket of AlbC proved this hypothesis via the results 
obtained with the L200N variant of AlbC (Sauguet et al. 2011). These studies not only 
demonstrate the binding of the aminoacyl moiety of the substrate in the pocket, but 
also suggest that the specificity of CDPSs for at least one of the substrates is mainly 
directed at the aminoacyl moiety, and not at the sequence of the tRNA moiety of the 
substrate. Knowing that AlbC, Rv2275 and YvmC1Blic mainly synthesize cFL, cYY 
and cLL, respectively, in addition to the other characterized CDPSs mainly 
synthesizing cLL (Gondry et al. 2009), it is reasonable that the bottom of the pocket 
be found essentially hydrophobic. Nevertheless, the residues of this site are loosely 
conserved among the CDPS family, potentially accounting for their relaxed substrate 
specificity. 
Studies performed on all the three CDPSs suggest that these enzymes use the 
two aa1tRNA substrates in a sequential ping1pong mechanism, with a similar first 
catalytic step: the binding of the first aa1tRNA and the transfer and storage of its 
aminoacyl moiety on the conserved serine residue of the enzyme pocket (e.g. Ser37, 
AlbC numbering), that is the covalent acyl1enzyme intermediate () (Belin et 
al. 2012). However, one divergence among the studies on the three CDPSs is about 
the activation of the catalytic serine. In Rv2275 and YvmC1Blic, the catalytic serine 
(Ser88, in Rv2275 numbering; or Ser37, in YvmC1Blic numbering) is proposed to be 
activated by a sterically adjacent tyrosine (Tyr253, in Rv2275 numbering; or Tyr204, 
in YvmC1Blic numbering). In AlbC, the corresponding tyrosine (Tyr202, in AlbC 
numbering) is proved not to be responsible for serine activation because the Y202F 
variant does not affect the formation of the covalent acyl1enzyme intermediate 
mentioned above. This divergence is also reflected to the conformation of the 
controversial tyrosine, which is located on the highly flexible loop β6 1 α8 (

). In the structures available for Rv2275 and YvmC1Blic, this loop adopts a 
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confirmation narrowing the entrance of the active site and bringing the tyrosine close 
to the active serine (
). Nevertheless, in AlbC, this loop adopts a different 
conformation, making the active site appears more “open” and the Try202 is oriented 
towards the solvent rather than the active Ser37 (
). Nureki and coworkers 
noticed the narrow access to the pocket in both YvmC1Blic and Rv2275 and 
suggested that the solved structures may represent a “closed” state of the enzymes, 
with tRNA binding required to open up the structure (Bonnefond et al. 2011). The 
impact of aminoacyl1tRNA binding on the enzyme structure remains unclear, but the 
structures of both YvmC1Blic and Rv2275 strongly suggested that some remodeling 
of the loops close to the active serine is required to allow access to the catalytic 
pocket. As no relevant residue for activation of the catalytic serine has yet been 
clearly identified, an attractive hypothesis is that the serine activation results from a 
concerted proton shuttling mechanism involving the two adjacent vicinal hydroxyls 
of the nucleotide A76 of the tRNA moiety (Sauguet et al. 2011). 
The steps of the catalytic mechanism occurring after the formation of the 
covalent intermediate remain to be determined. The cyclodipeptides formed by a 
given CDPS enzyme almost invariably have one amino acid in common (Gondry et 
al. 2009). Based on the available data, the most likely hypothesis for this is that only 
the first aminoacyl group, probably the “common” aminoacyl group, binds and 
remains in the catalytic pocket, the second aminoacyl group being accommodated at 
a different site with less stringent recognition that has yet to be characterized. The 
aminoacyl moiety of the second aa1tRNA to form either a dipeptidyl1enzyme or a 
dipeptidyl1tRNA intermediate, which may undergo intramolecular cyclization to 
generate the final cyclodipeptide product () (Sauguet et al. 2011; Belin et al. 
2012). 
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3 NDAS_1148 FROM NOCARDIOPSIS 
DASSONVILLEI, A NEW ACTIVE CDPS WITH 
A PROTEIN SEQUENCE CLOSE TO THAT OF 
ALBC 
3.1 Introduction 
In the databases, characterized CDPSs and putative CDPSs have been detected 
in approximately 50 different bacterial genomes (of the 2019 publicly available) (Belin 
et al. 2012). The evolutionary relationship of these CDPSs in the form of unrooted 
phylogenetic tree (Belin et al. 2012) attracted our attention to a putative CDPS 
Ndas_1148 from the actinobacterium Nocardiopsis dassonvillei because it lies on the 
same branch as the characterized CDPS AlbC from S. noursei. Ndas_1148 is the 
nearest identified putative CDPS to AlbC compared to the others. It should thus be of 
great interest to study this protein in order to have a better understanding of CDPSs.  
This chapter consists of studies on Ndas_1148 by comparison with AlbC. It 
mainly concerns studies of grafting the Ndas_1148 catalytic pocket on AlbC in order 
to elucidate of the molecular bases of the substrate specificity of CDPSs. This work 
will be presented in the form of manuscript of an article. 
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3.2 Article manuscript 
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SUMMARY 
Cyclodipeptide synthases (CDPSs) hijack aminoacyl-tRNAs (aa-tRNAs) to produce 
various cyclodipeptides. They contain a surface-accessible pocket accommodating the 
aminoacyl moiety of one of the two aa-tRNA substrates. We show here that the putative 
CDPS Ndas_1148 identified in Nocardiopsis dassonvillei is an active CDPS. Ndas_1148 
displays a high level of sequence identity to the CDPS AlbC but both enzymes do not have 
the same profile of cyclodipeptide production. We demonstrate that the chimera that 
corresponds to AlbC having the Ndas_1148 pocket has acquired the substrate specificity of 
Ndas_1148. This shows that the difference in residues constituting the two CDPS pockets is 
responsible for the difference in cyclodipeptide production observed for the two enzymes. 
This also indicates that CDPS pockets contain specificity determinants responsible for the 
incorporation of the aminoacyl moiety of the second aa-tRNA substrate into cyclodipeptides. 
 
HIGHLIGHTS 
 Identification of a new active CDPS  
 CDPS engineering  
 Molecular bases of substrate specificities in CDPSs 
 Changing CDPS specificities  
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INTRODUCTION 
Cyclodipeptide synthases (CDPSs) form a family of small enzymes that hijack 
aminoacyl-tRNAs (aa-tRNAs) from their canonical role in ribosomal protein synthesis for 
cyclodipeptide formation (Gondry et al., 2009). Nine CDPSs have been biochemically 
characterized, eight originating from bacteria and one from an animal (Gondry et al., 2009; 
Seguin et al., 2011). Genome mining revealed the presence of putative CDPSs in 
approximately 60 different genomes from bacteria, fungi or animal (Aravind et al. 2010; Belin 
et al. 2012). In bacteria and fungi, CDPSs are associated with cyclodipeptide-tailoring 
enzymes in biosynthetic pathways dedicated to the synthesis of diketopiperazines (DKPs) 
(Belin et al., 2012). Three CDPS-dependent pathways have been fully characterized in terms 
of both the DKPs produced and the enzymes involved. In Streptomyces noursei, the CDPS 
AlbC mostly catalyzes the synthesis of the cyclo(L-Phe-L-Leu) (cFL) intermediate, into which 
the cyclic dipeptide oxidase (CDO) introduces two α,β-dehydrogenations, yielding 
albonoursin that has been shown to have antibacterial activity (Fukushima et al., 1973; 
Gondry et al., 2001; Lautru et al., 2002). In Bacillus subtilis, the CDPS YvmC mostly 
produces the cyclo(L-Leu-L-Leu) (cLL), into which the cytochrome P450 CYP134A1 
catalyzes a DKP ring oxidation, yielding pulcherriminic acid that chelates iron (Cryle et al., 
2010; Gondry et al., 2009; Tang et al., 2006). In Mycobacterium tuberculosis, the CDPS 
Rv2275 mostly synthesizes the cyclo(L-Tyr-L-Tyr) (cYY), into which the cytochrome P450 
CYP121A1 introduces C-C aryl coupling, yielding mycocyclosin that may be essential for M. 
tuberculosis viability (Belin et al., 2009; Gondry et al., 2009; McLean et al., 2008; Vetting et 
al., 2010). 
The crystallographic structures of AlbC, Rv2275 and YvmC have been determined. The 
three CDPSs share a common architecture highly similar to that of the catalytic domain of 
class-Ic aminoacyl-tRNA synthetases, the enzymes catalyzing the activation of amino acids 
and their transfer to cognate tRNAs to produce aa-tRNAs. These structural data combined 
with extensive mutagenesis analyses have provided insight into the molecular bases of the 
interactions between CDPSs and their substrates and the catalytic mechanism used by these 
enzymes (Bonnefond et al., 2011; Sauguet et al., 2011; Vetting et al., 2010). CDPSs contain a 
patch of basic residues that may interact with the tRNA moiety of an aa-tRNA substrate. They 
also have a surface-accessible pocket that accommodates the aminoacyl moiety of the 
substrate. CDPSs catalyze their two-substrate reaction using a sequential ping-pong 
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mechanism. The first catalytic steps correspond to the binding of the first aa-tRNA then the 
transfer and the covalent attachment of its aminoacyl moiety on a conserved serine residue 
located in the pocket. The subsequent steps remain to be demonstrated but it is currently 
assumed that the aminoacyl-enzyme reacts with the aminoacyl moiety of the second tRNA to 
form a dipeptidyl-intermediate that undergoes intramolecular cyclization, yielding the 
cyclodipeptide product (Bonnefond et al., 2011; Sauguet et al., 2011; Vetting et al., 2010). 
CDPSs are promiscuous enzymes as they predominantly produce one major 
cyclodipeptide but also other minor cyclodipeptides. For example, AlbC mostly synthesizes 
cFL but also other L-Phe-containing cyclodipeptides. The other CDPSs produce L-Tyr-, L-
Leu- or L-Trp-containing cyclodipeptides (Gondry et al., 2009; Seguin et al., 2011). The 
molecular bases responsible for the difference in substrate specificities remain poorly 
documented. We show here that the CDPS Ndas_1148 identified in Nocardiopsis dassonvillei 
does not produce cFL as the major cyclodipeptide although this CDPS has a protein sequence 
and a genomic context close to those of AlbC. We also show that the difference in residues 
constituting the two CDPS pockets is responsible for the difference in profiles of 
cyclodipeptides production observed for these two enzymes. Finally, we demonstrate that the 
grafting of the Ndas_1148 pocket on AlbC results in an AlbC chimera having the substrate 
specificity of Ndas_1148.  
 
RESULTS 
The putative CDPS found in Nocardiopsis dassonvillei 
Eight bacterial and one animal members of the CDPS family have been experimentally 
characterized so far (Gondry et al., 2009; Seguin et al., 2011). However, new putative CDPSs 
have been identified in diverse organisms by iterative PSI_BLAST searches (Aravind et al. 
2010; Belin et al. 2012). One putative CDPS, Ndas_1148, has been detected in Nocardiopsis 
dassonvillei. We aligned sequences for Ndas_1148 and the nine characterized CDPSs (Figure 
1). The protein Ndas_1148 (244 residues) is of a similar size to the CDPSs (216-289 residues) 
and displays the highest sequence similarity to the CDPS AlbC (40% identity and 53% 
similarity). The 13 residues conserved among bacterial CDPSs, including the seven residues 
(G35, S37, G79, Y128, Y178, E182, Y202, AlbC numbering) previously shown to be 
involved in CDPS activity (Sauguet et al., 2011), are also found in Ndas_1148. The 
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characterized CDPSs contain a patch of basic residues, suspected to interact with the tRNA 
moiety of an aa-tRNA substrate (Sauguet et al., 2011), which is also present in Ndas_1148 
(Figure 1).  
In S. noursei, AlbC catalyzes the synthesis of cFL, into which the cyclic dipeptide 
oxidase (CDO) introduces two α,β-dehydrogenations leading to the formation of albonoursin 
(cyclo∆Phe-∆Leu) (Gondry et al., 2001; Lautru et al., 2002). The genes encoding the two 
subunits of CDO, AlbA and AlbB, are located immediately upstream from that of AlbC. In N. 
dassonvillei, a similar operon-like structure is found (see Figure S1 available online). Proteins 
encoded by the two genes preceding the Ndas_1148 gene display a significant sequence 
similarity to AlbA (39% identity and 50% similarity) and AlbB (45% identity and 58% 
similarity). Two other genes encoding proteins annotated as methyl transferases are also 
present in the vicinity of the Ndas_1148 gene but absent in that of AlbC (Figure S1 available 
online). 
The similar protein sequence and genomic context of Ndas_1148 and AlbC strongly 
suggest that Ndas_1148 may be member of the CDPS family. 
 
Ndas_1148, a cyclodipeptide-synthesizing enzyme 
We investigated whether Ndas_1148 catalyzes the formation of cyclodipeptides. We 
had previously shown that all characterized CDPSs produced in Escherichia coli synthesize 
cyclodipeptides that are further released into the culture medium (Gondry et al., 2009; Seguin 
et al., 2011). We then introduced a construct encoding Ndas_1148 in this host and analyzed 
the cyclodipeptide content of the culture supernatant of these Ndas_1148 producing cells. We 
compared the UV-chromatograms for the Ndas_1148 sample and the control – consisting of 
the culture supernatant of E. coli cells containing the empty cloning vector. Several peaks 
specific to Ndas_1148-producing cells were observed (Figure 2A). The corresponding 
extracted ion current (EIC) chromatograms (Figure 2B) and MS/MS fragmentation patterns 
(see Figure S2 available online) indicated that Ndas_1148 synthesizes eight cyclodipeptides: 
cFL, cFY, cFF, cFM, cFA, cYL, cYY and cYM. Thus, Ndas_1148 catalyzes the formation of 
various cyclodipeptides in E. coli. It is a new active member of the CDPS family. 
Similarities and differences between Ndas_1148 and AlbC  
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The cyclodipeptides produced by Ndas_1148 are also produced by AlbC (Gondry et al., 
2009). However, although the nature of the cyclodipeptides produced by the two CDPSs is 
almost identical, their quantities and their relative proportions appear different. Concerning 
Ndas_1148, the cyclodipeptides cFY and cFF are predominantly produced (3.5 ± 0.6 and 1.9 
± 0.1 mg l-1 of culture supernatant, respectively), the cyclodipeptides cYL and cYM are 
obtained in lower quantities (about 0.5 mg l-1 of culture supernatant) and the cyclodipeptides 
cFL, cFM, cFA and cYY are hardly detectable (Figure 3A). To accurately compare the 
Ndas_1148 profile of cyclodipeptide production to that of AlbC, we again analyzed the 
cyclodipeptide content of a culture supernatant of AlbC-producing cells. AlbC synthesizes 
cFL (43 ± 5 mg l-1 of culture supernatant), cFY, cFF, cFM, cYL, cYM, cLL, cLM (between 
10 and 4 mg l-1 of culture supernatant), cYY, cYA, cMM (less than 1 mg l-1 of culture 
supernatant) (Figure 3A and Figure S3 available online) and trace amounts of cFA and cLA 
that had not been previously identified (Gondry et al., 2009). Thus, Ndas_1148 synthesizes 
less cyclodipeptides than AlbC, not only in variety but also in quantities, which is consistent 
with its much lower expression in soluble form (Figure 3B). Interestingly, Ndas_1148 does 
not synthesize significant quantities of cyclodipeptides containing a leucyl residue: cFL, the 
major cyclodipeptide produced by AlbC, is almost not synthesized (the decrease in cFL 
synthesis is 99.5% compared to AlbC) and cLL is not at all produced (Figure 3A). The 
quantity of L-Phe-containing cyclodipeptides is also reduced (the decrease in cFY and cFF is 
about 60-70%), but the relative proportion of each of the L-Phe-containing cyclodipeptides is 
almost similar for the two CDPSs (except for cFL). The same conclusion can be made for L-
Tyr-containing cyclodipeptides although their synthesis by Ndas_1148 is further decreased. 
To understand the difference in production profiles of the two CDPSs, we generated a 
homology-based structural model for Ndas_1148 with Modeler software (Sali and Blundell, 
1993), using the crystal structure of AlbC (Protein Data Bank [PDB] id: 3OQV) as a template 
(Figure 4). Superimposition of the three-dimensional structures of AlbC and Ndas_1148 gave 
a root-mean-square deviation value of 0.29 Å over 152 Cα. Comparison of the distribution of 
electrostatic surface potential of the two proteins indicates that the patch of basic residues 
present in AlbC is also present in Ndas_1148 (Figures 4A and 4B). The residues constituting 
the two basic patches are particularly well conserved (see also Figure 1) and most of them 
protrude toward the solvent, consistent with the fact that they may interact with the tRNA 
moiety of an aa-tRNA substrate (Sauguet et al., 2011). For AlbC, the aminoacyl moiety of the 
substrate is accommodated in a surface-accessible pocket that consists of 19 residues (Figure 
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4C). Compared to the AlbC pocket, the Ndas_1148 pocket is constituted of 13 residues that 
are identical and similarly positioned, and six residues that are different (Figure 4D). The 
identical residues contain in particular the five residues (G35, S37, Y178, E182, Y202, AlbC 
numbering) conserved among all known CDPSs and essential for the cyclodipeptide-
synthesizing activity (Sauguet et al., 2011). The different residues are L69, A71 and L186 – 
that respectively correspond in AlbC to the conservative residues V65, V67 and F186 – and 
also H156, C200 and M206 –that respectively correspond in AlbC to the non conservative 
residues M152, L200 and T206 – (Figures 4C and 4D). These residues are positioned at the 
entrance (M206), the side (A71 and H156) and the base (L69, L186 and C200) of the 
Ndas_1148 pocket (Figure 4D).  
 
Exchange of the catalytic pockets of the two CDPSs 
To investigate whether the difference in residues constituting the two CDPS pockets is 
responsible for the difference in profiles of cyclodipeptides production observed for these 
enzymes, we substituted in AlbC all the six residues different in the two CDPSs by their 
corresponding residues in Ndas_1148. Thus, we obtained the AlbC chimera that possesses the 
Ndas_1148 pocket (V65L/V67A/M152H/F186L/L200C/T206M), named AlbC-p(Ndas_1148). 
We produced the resulting chimera in E. coli and compared its properties to those of AlbC 
and Ndas_1148. Its expression profile in soluble form and its profile of cyclodipeptides 
production are both similar to those of Ndas_1148 (Figure 3). The chimera does not 
synthesize significant quantities of cFL (the decrease in cFL synthesis is 99.5% compared to 
AlbC, as observed for Ndas_1148) or other leucyl-containing cyclodipeptides. Thus, the 
grafting of the Ndas_1148 pocket on AlbC results in an AlbC chimera that has almost 
acquired the substrate specificity of Ndas_1148. 
To better identify the specificity determinants located in the two CDPS pockets, we 
independently substituted in AlbC each of the six different residues by their corresponding 
residue in Ndas_1148. The six resulting variants were produced in soluble forms in amounts 
almost similar to that of the wild-type AlbC, with the exception of the variant V65L that is 
less soluble (Figure 5). None of these variants has a profile of cyclodipeptides production 
similar to that of AlbC-p(Ndas_1148), indicating that none of the mutated residues is 
responsible by itself for the change of the substrate specificity (Figure 5A and Figures S4-S9). 
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However, compared to AlbC, each of the mutations induces a decrease in cFL synthesis about 
30 % for the variants V65L, L200C and T206M to about 50-60% for the variants V67A and 
F186L. The largest decrease is observed for the variant M152H (about 90%) but this variant is 
almost inactive. As the residue M152 is located at the entrance of the AlbC pocket (Figure 4), 
we hypothesized that its substitution with histidine could narrow the entrance of the pocket 
and prevent the anchoring of the aminoacyl moieties of substrates. We attempted to construct 
a variant corresponding to AlbC-p(Ndas_1148) without introducing the substitution of M152, 
but the genetic construct (named AlbC-p(Ndas_1148)/M152) was almost not expressed in a 
soluble form (Figure 5B). Concerning the variants F186L, L200C and T206M, besides a 
decrease in the synthesis of L-Leu-containing cyclodipeptides, they have also a significant 
increase in cFY synthesis (between 80 and 100%) that is not observed for the variants V65L 
and V67A (Figure 5). The substitution of residue L200 with asparagine in AlbC was 
previously shown to give a variant that produces mainly cYL instead of cFL (Sauguet et al., 
2011).  Here we show that its substitution with cysteine leads to a significant increase in cFY 
synthesis (Figure 5A). We constructed a variant corresponding to AlbC-p(Ndas_1148) 
containing the L200N substitution (named AlbC-p(Ndas_1148)/L200N) and the variant 
Ndas_1148 C200N. However, these two variantsare only poorly soluble (Figure 5B) and 
almost inactive.  
 
DISCUSSION 
We show here that Ndas_1148 is an active member of the CDPS family. It displays a 
high level of identity to the CDPS AlbC. These two CDPSs differ in specificity from other 
characterized CDPSs as they predominantly synthesize L-Phe-containing cyclodipeptides 
whereas the others produce L-Tyr-, L-Leu- and L-Trp-containing cyclodipeptides (Gondry et 
al., 2009; Seguin et al., 2011). Compared to AlbC, Ndas_1148 is much less soluble and it 
synthesizes less cyclodipeptides in terms of both variety and quantity. In particular, it 
synthesizes almost no cFL, which is the major cyclodipeptide produced by AlbC.  
In S. noursei, the AlbC-dependent biosynthetic pathway has been fully characterized in 
terms of both the DKPs produced and the enzymes involved (Gondry et al., 2009; Lautru et al., 
2002). The gene encoding AlbC is clustered to the two genes encoding the subunits AlbA and 
AlbB of the tailoring enzyme CDO. The cyclodipeptides produced by AlbC are substrates for 
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CDO that catalyzes the α,β-dehydrogenation of the two aminoacyl side chains of a wide 
range of cyclodipeptides (Gondry et al., 2001). The major DKP produced is albonoursin –
cyclo(α,β-dehydroPhe-α,β-dehydroLeu) (c∆F∆L)–, which corresponds to the α,β-
dehydrogenation of cFL, the major cyclodipeptide produced by AlbC. In N. dassonvillei, the 
protein encoded by the two genes preceding the Ndas_1148 gene isa CDO homologue. The 
cyclodipeptides produced by Ndas_1148 are likely to be dehydrogenated by the CDO 
homologue. However, as Ndas_1148 produces much more cFY and other cyclodipeptides (e.g. 
cFF) than cFL, cyclo∆F∆Y and other dehydrogenated cyclodipeptides (e.g. c∆F∆F) but not 
albonoursin are probably the major DKPs synthesized. Two other genes encoding proteins 
annotated as methyl transferases are also present in the vicinity of the Ndas_1148 gene but 
absent in that of AlbC. As methyl transferases are known to be involved in the transfer of 
methyl group on various atoms (C, N, S or O) of various molecules, the final products from 
the Ndas_1148-dependent biosynthetic pathway are likely to be both dehydrogenated and 
methylated. 
Ndas_1148 and the other characterized CDPSs respectively display 40% and 19-27% 
identity with AlbC. Thus, Ndas_1148 has the protein sequence closest to that of AlbC. In 
particular, the residues constituting the pockets of the two CDPSs are well conserved, with 
only six of 19 residues that are different for the two enzymes. However, unlike AlbC, 
Ndas_1148 does not synthesize significant quantities of cyclodipeptides containing a leucyl 
residue. The sequence similarity and the difference in cyclodipeptide-synthesizing activity 
observed for the two CDPSs offer the opportunity to document the molecular bases of their 
specificity, in particular those located in their pockets. We previously demonstrated that the 
AlbC pocket is the binding site of the phenylalanine moiety of its Phe-tRNAPhe substrate, but 
we had no data on the binding of the leucyl moiety of the Leu-tRNALeu substrate, which is 
required for cFL production (Sauguet et al., 2011). Here, we constructed the chimera enzyme 
AlbC-p(Ndas_1148) that corresponds to the CDPS AlbC having the Ndas_1148 pocket. 
AlbC-p(Ndas_1148) has acquired the poor protein solubility and the substrate specificity of 
Ndas_1148. This result indicates that the grafting of the Ndas-1148 pocket is sufficient to 
switch the substrate specificity of AlbC to that of Ndas_1148.  In particular, it shows that 
specificity determinants responsible for the incorporation of a leucyl residue into 
cyclodipeptides are also located in the pocket.   
129 
Moreover, we showed that none of the six substituted residues is responsible by itself 
for the drastic decrease in the incorporation of a leucyl residue into the cyclodipeptides 
produced. This differs from what we previously obtained concerning the incorporation of a 
phenylalanyl residue.  
Indeed, the substitution in AlbC of only one residue, namely L200, with asparagine - its 
equivalent residue in the CDPS Rv2275 that mainly produces cYY - was sufficient to induce 
the synthesis of cYL instead of cFL, probably because the asparagine may form a hydrogen 
bond with the hydroxyl group of the tyrosyl moiety of a tyrosyl-tRNATyr substrate (Sauguet et 
al., 2011). We here substituted L200 with cysteine, which is not favorable for such hydrogen 
bonding, and the resulting variant does not synthesize more cYL. However, this variant 
displays a significant increase in cFY (about 100%). To try to better understand this result, we 
constructed the variant corresponding to AlbC-p(Ndas_1148) containing the L200N 
substitution and the variant Ndas_1148 C200N, butthese two variants are almost inactive, 
which is consistent with their poor expression in soluble form.  
AlbC specifically recognizes the aminoacyl moieties of its aa-tRNA substrates via its 
pocket (this work and (Sauguet et al., 2011)). We previously hypothesized that AlbC also 
recognizes the sequences A76C75C74A73 of the single-strand extremity and C72-G1 of the first 
base pair of the tRNA moieties of its substrates (Sauguet et al., 2011). AlbC and Ndas_1148 
use as substrates the same E. coli tRNA families, namely phenylalanyl-, leucyl-, tyrosyl-, 
methionyl- and alanyl-tRNAs, that possess members sharing these sequences of the acceptor 
stems. This could explain why the change in AlbC specificity is achieved by modifying only 
its aminoacyl moiety-binding pocket. 
Due to their small size, CDPSs are good candidates for protein engineering, and they 
will rapidly receive a large interest to generate a variety of new cyclodipeptide derivatives. 
However, reprogramming CDPSs by altering their substrate specificity still remains a 
challenge. We show here that the grafting of the whole pocket of a given CDPS on another 
CDPS is an interesting option that can be successful. 
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SIGNIFICANCE  
Cyclodipeptide synthases (CDPSs) are a family of small enzymes that hijack 
aminoacyl-tRNAs (aa-tRNAs) to produce various cyclodipeptides, biosynthetic precursors of 
many natural products exhibiting noteworthy biological activities. CDPSs are structurally 
similar to class-I aminoacyl-tRNA synthetases (aaRSs) and contain a surface-accessible 
pocket accommodating the aminoacyl moiety of one of the two aa-tRNA substrates in a way 
similar to that used by class-Ic aaRSs to recognize their amino acid substrates. We show here 
that the putative CDPS Ndas_1148 identified in Nocardiopsis dassonvillei is an active CDPS. 
Ndas_1148 displays a high level of sequence identity to the CDPS AlbC from Streptomyces 
noursei but both enzymes do not have the same profile of cyclodipeptide production. We 
demonstrate that the chimera that corresponds to AlbC having the Ndas_1148 pocket has 
acquired the substrate specificity of Ndas_1148. This shows that the difference in residues 
constituting the two CDPS pockets is responsible for the difference in cyclodipeptide 
production observed for the two enzymes. This also indicates that CDPS pockets contain 
specificity determinants responsible for the incorporation of the aminoacyl moiety of the 
second aa-tRNA substrate into cyclodipeptides. CDPSs are promising enzymes to generate a 
variety of new cyclodipeptide derivatives but reprogramming CDPSs by altering their 
substrate specificity still remains a challenge. However, our findings show that 
reprogramming CDPS specificity can be achieved by swapping the whole pocket of a given 
CDPS by that of another CDPS. 
 
EXPERIMENTAL PROCEDURES  
Structural model of Ndas_1148 
Alignment of protein sequences, obtained with MUSCLE and HHPred (Soding et al., 
2005), was used for model building with Modeler (Sali and Blundell, 1993). The template 
used for the homology modeling was the crystal structure of AlbC (PDB id: 3OQV). The 
quality of the Ndas_1148 model was checked with the Qmean server (Benkert et al., 2009). 
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Cloning and Production of Ndas_1148 
Synthetic gene encoding Ndas_1148 was purchased from GENEART, inserted into the 
pQE60 vector (QIAGEN), and the His6-tagged Ndas_1148 protein was then expressed in E. 
coli as previously described (Gondry et al., 2009). 
 
Construction of expression plasmids encoding AlbC variants 
The primers used in this study are listed in Table S1. The expression plasmid encoding 
AlbC was previously constructed (Gondry et al., 2009). It encodes the full-length AlbC 
(residues 1-239) with the C-terminal addition of two residues (RS) followed by a His6 tag. 
The desired variants with a single mutation were created via PCR mutagenesis according to 
the QuikChange method (Stratagene).  The gene encoding the variant AlbC(p-Ndas_1148), 
which contains six mutations, was obtained by the particular PCR method “gene Splicing by 
Overlap Extension (gene SOEing)” (Ho et al., 1989; Horton, 1995). The desired mutations 
were introduced into the designed primers (Sigma-Aldrich). The gene encoding AlbC(p-
Ndas_1148) was synthesized by two PCR steps. In the first PCR step, four DNA fragments 
containing different mutations (F1, F2, F3 and F4) were generated and amplified by four 
separated PCR reactions by using pQE60-AlbC or pQE60-AlbC-F186L as template. To the 
four DNA fragments, two adjacent fragments shared a segment of identical sequence called 
the overlap region. F1 had 352 bp containing a NcoI restriction site and two mutations V65L, 
V67A; F2 was composed of 297 bp and contained three mutations V65L, V67A and M152H; 
F3 was a DNA fragment of 195 bp containing four mutations M152H, F186L, L200C and 
T206M; F4 was composed of 254 bp containing two mutations L200C and T206M and also a 
HindIII restriction site. The four DNA fragments were purified by agarose gel electrophoresis 
then extracted by using QIAquick Gel Extraction Kit. In the second PCR step, the four DNA 
fragments obtained previously were mixed together, melted and re-annealed. The top strand 
of one DNA fragment could anneal to the bottom strand of another DNA fragment sharing an 
overlap region in such a way that the two strands acted as primers on one another. Extension 
of this overlap by DNA polymerase generated a new longer DNA product connected by the 
two mother DNA fragments. After several cycles of reaction, the four DNA fragments F1, F2, 
F3 and F4 were joined together, so was obtained a full gene of AlbC(p-Ndas_1148) 
containing the six desired mutations and two restriction sites (NcoI and HindIII) to extremities. 
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The latter was then inserted into the pQE60 vector via the two restriction sites described 
above. The DNA sequence was checked by DNA sequencing using Sanger method. One unit 
of Phusion® High-Fidelity DNA Polymerase was used in each PCR reaction. The 
amplification of genes by PCR was realized by the following cycle profile: 35 main cycles; 
98°C, 10 sec (denaturation), 60°C, 10 sec (annealing), 72°C, 15 sec (extension).  
 
Analysis of cyclodipeptide synthesis by Ndas_1148, AlbC or AlbC variants 
In vivo assays for cyclodipeptide-synthesizing activity were performed as described by 
((Gondry et al., 2009). Briefly, E. coli cells expressing the selected CDPSs were grown in M9 
liquid medium supplemented with a solution of vitamins and each culture supernatant was 
analyzed for cyclodipeptide content by LC-MS/MS. Cyclodipeptides were detected and 
identified from both their m/z value (MS) and their daughter ion spectra (MS/MS), as a result 
of their common fragmentation patterns. The nature of the detected cyclodipeptides was 
unambiguously confirmed by comparison with authentic standards. Cyclodipeptides were 
quantified on the basis of their peak area at 214 nm using calibration curves performed with 
the standards. 
 
ACKNOWLEDGMENTS 
We thank Robert Thai and Steven Dubois for helpful advice on mass spectrometry. We 
thank Alain Lecoq for the synthesis of cyclodipeptide standards. This work was supported by 
the CEA and the ANR (ANR 2010 BLAN 1501 01). Y.L. holds a doctoral fellowship from 
the CEA. The authors have no conflict of interest to declare. 
 
 
 
 
 
133 
REFERENCES 
Aravind, L., de Souza, R.F., and Iyer, L.M. (2010). Predicted class-I aminoacyl tRNA 
synthetase-like proteins in non-ribosomal peptide synthesis. Biol Direct 5, 48. 
Belin, P., Le Du, M.H., Fielding, A., Lequin, O., Jacquet, M., Charbonnier, J.B., Lecoq, 
A., Thai, R., Courcon, M., Masson, C., et al.(2009). Identification and structural basis of the 
reaction catalyzed by CYP121, an essential cytochrome P450 in Mycobacterium tuberculosis. 
Proc Natl Acad Sci U S A 106, 7426-7431. 
Belin, P., Moutiez, M., Lautru, S., Seguin, J., Pernodet, J.L., and Gondry, M. (2012). 
The nonribosomal synthesis of diketopiperazines in tRNA-dependent cyclodipeptide synthase 
pathways. Nat Prod Rep doi:10.1039/C2NP20010D 
Benkert, P., Kunzli, M., and Schwede, T. (2009). QMEAN server for protein model 
quality estimation. Nucleic Acids Res 37, W510-514. 
Bonnefond, L., Arai, T., Sakaguchi, Y., Suzuki, T., Ishitani, R., and Nureki, O. (2011). 
Structural basis for nonribosomal peptide synthesis by an aminoacyl-tRNA synthetase paralog. 
Proc Natl Acad Sci U S A 108, 3912-3917. 
Braud, S., Moutiez, M., Belin, P., Abello, N., Drevet, P., Zinn-Justin, S., Courcon, M., 
Masson, C., Dassa, J., Charbonnier, J.B., et al.(2005). Dual expression system suitable for 
high-throughput fluorescence-based screening and production of soluble proteins. J Proteome 
Res 4, 2137-2147. 
Cryle, M.J., Bell, S.G., and Schlichting, I. (2010). Structural and biochemical 
characterization of the cytochrome P450 CypX (CYP134A1) from Bacillus subtilis: a cyclo-
L-leucyl-L-leucyl dipeptide oxidase. Biochemistry 49, 7282-7296. 
Fukushima, K., Yazawa, K., and Arai, T. (1973). Biological activities of albonoursin. J 
Antibiot (Tokyo) 26, 175-176. 
Gondry, M., Lautru, S., Fusai, G., Meunier, G., Menez, A., and Genet, R. (2001). Cyclic 
dipeptide oxidase from Streptomyces noursei. Isolation, purification and partial 
characterization of a novel, amino acyl alpha,beta-dehydrogenase. Eur J Biochem 268, 1712-
1721. 
Gondry, M., Sauguet, L., Belin, P., Thai, R., Amouroux, R., Tellier, C., Tuphile, K., 
Jacquet, M., Braud, S., Courcon, M., et al.(2009). Cyclodipeptide synthases are a family of 
tRNA-dependent peptide bond-forming enzymes. Nat Chem Biol 5, 414-420. 
Ho, S.N., Hunt, H.D., Horton, R.M., Pullen, J.K., and Pease, L.R. (1989). Site-directed 
mutagenesis by overlap extension using the polymerase chain reaction. Gene 77, 51-59. 
134 
Horton, R.M. (1995). PCR-mediated recombination and mutagenesis. SOEing together 
tailor-made genes. Mol Biotechnol 3, 93-99. 
Lautru, S., Gondry, M., Genet, R., and Pernodet, J.L. (2002). The albonoursin gene 
Cluster of S. noursei: biosynthesis of diketopiperazine metabolites independent of 
nonribosomal peptide synthetases. Chem Biol 9, 1355-1364. 
McLean, K.J., Carroll, P., Lewis, D.G., Dunford, A.J., Seward, H.E., Neeli, R., 
Cheesman, M.R., Marsollier, L., Douglas, P., Smith, W.E., et al. (2008). Characterization of 
Active Site Structure in CYP121: a cytochrome P450 essential for viability of Mycobacterium 
tuberculosis H37Rv. J Biol Chem 283, 33406-33416. 
Sali, A., and Blundell, T.L. (1993). Comparative protein modelling by satisfaction of 
spatial restraints. J Mol Biol 234, 779-815. 
Sauguet, L., Moutiez, M., Li, Y., Belin, P., Seguin, J., Le Du, M.H., Thai, R., Masson, 
C., Fonvielle, M., Pernodet, J.L., et al.(2011). Cyclodipeptide synthases, a family of class-I 
aminoacyl-tRNA synthetase-like enzymes involved in non-ribosomal peptide synthesis. 
Nucleic Acids Res 39, 4475-4489. 
Seguin, J., Moutiez, M., Li, Y., Belin, P., Lecoq, A., Fonvielle, M., Charbonnier, J.B., 
Pernodet, J.L., and Gondry, M. (2011). Nonribosomal Peptide synthesis in animals: the 
cyclodipeptide synthase of nematostella. Chem Biol 18, 1362-1368. 
Soding, J., Biegert, A., and Lupas, A.N. (2005). The HHpred interactive server for 
protein homology detection and structure prediction. Nucleic Acids Res 33, W244-248. 
Tang, M.R., Sternberg, D., Behr, R.K., Sloma, A., and Berka, R.M. (2006). Use of 
transcriptional profiling & bioinformatics to solve production problems. Ind Biotechnol 2, 66-
74. 
Vetting, M.W., Hegde, S.S., and Blanchard, J.S. (2010). The structure and mechanism 
of the Mycobacterium tuberculosis cyclodityrosine synthetase. Nat Chem Biol 6, 797-799. 
 
 
 
 
 
135 
FIGURE LEGENDS 
Figure 1. Structure-based alignment of the nine characterized CDPSs and the 
Ndas_1148 protein from N. dassonvillei 
The secondary-structural elements of AlbC of S. noursei (entry 3OQV), Rv2275 of M. 
tuberculosis (entry 2X9Q) and YvmC of B. licheniformis(YvmC-Blic) (entry 3OQJ) are 
indicated above the alignment. The residues constituting the aminoacyl moiety-binding pocket 
are colored in pink. The residues that are not visible in X-ray structures are indicated in gray. 
The regions of the three CDPSs that do not superimpose well are shown with a gray 
background. The other CDPSs used in the alignment are YvmC from B. subtilis (YvmC-
Bsub), YvmC from B. thuringiensis (YvmC-Bthu), pSHaeC06 from S. haemolyticus, Plu0297 
from P. luminescens, Jk0923 from C. jeikeium and Nvec-CDPS2 from N. vectensis. The 
strictly conserved residues are indicated by a red (for the ten CDPSs) or orange (for the nine 
bacterial CDPSs) background. The basic residues suspected to interact with the tRNA moiety 
of the substrate are indicated by a blue background. Black stars above the AlbC sequence 
indicate the residues that were modified by site-directed mutagenesis in this study. 
 
Figure 2. LC-MS/MS analyses of the cyclodipeptides secreted into the culture 
supernatant of E. coli cells producing Ndas_1148  
 (A) UV traces (λ = 214 nm) of the culture medium of Ndas_1148-producing cells (blue) and 
cells containing the empty cloning vector (gray). (B) Corresponding EIC chromatograms with 
the same color codes. The identity of the cyclodipeptides produced is indicated. 
Cyclodipeptides were identified by MS/MS (see Figure S2 for an example).  
 
Figure 3. Comparison of cyclodipeptide-synthesizing activities and protein expression 
profiles for Ndas_1148, AlbC and AlbC-p(Ndas_1148). 
(A) Histogram of the amounts of the various cyclodipeptides synthesized by Ndas_1148 
(blue), AlbC (red), and AlbC-p(Ndas_1148) (green).  Cyclodipeptide amounts are shown with 
errors bars because the values are obtained from at least two independent experiments, except 
for cLL for which only one experiment allowed its quantification. (B) Western blot analysis 
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of soluble (S) and insoluble (I) protein fractions after bacterial lysis with an Eaton press 
(Braud et al., 2005).  
 
Figure 4. Comparison of the Ndas_1148 model with the crystal structure of AlbC 
Electrostatic surface potential of AlbC (A) and Ndas_1148 (B), mapped on their solvent-
accessible surfaces at contouring levels of 5 kTe-1. Positive charge is in blue and negative 
charge in red. Surface-accessible pockets of AlbC with the phenylalanyl moiety of a Phe-
tRNAPhe (C) and Ndas_1148 (D). Residues at the base, the side and the entrance of the 
pockets are colored with green, orange and yellow carbons, respectively. The name of the 
corresponding residues that are different in the two pockets is written in pink in the 
Ndas_1148 pocket.  
 
Figure 5. Comparison of cyclodipeptide-synthesizing activities and protein expression 
profiles for AlbC and its variants. 
(A) Histogram of the amounts of the various cyclodipeptides synthesized by AlbC (red), AlbC 
T206M (gray), AlbC V65L (green), AlbC L200C (purple), AlbC F186L (blue), AlbC V67A 
(orange) and AlbC M152H (light blue).  Cyclodipeptide amounts are shown with errors bars 
because the values are obtained from at least two independent experiments, except for cLL for 
which only one experiment allowed its quantification. (B) Western blot analysis of soluble (S) 
and insoluble (I) protein fractions after bacterial lysis with an Eaton press (Braud et al., 2005). 
P1 and P2 represent AlbC-p(Ndas_1148)/M152 and AlbC-p(Ndas_1148)/L200N, respectively. 
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Figure 1 
β4 β3 β1 β2 α1 α2 α3 
 
 
 
 
 
3OQV AlbC 
2XQ9 Rv2275 
3OQJ YvmC-Blic 
                                                                               * * 
AlbC           MLAGLVPAPDHGMREEILGDRSRLIRQRGEHALIGISAGNSYFSQKNTVMLLQWAGQRFERTDVVYV-DTHIDEMLIAD 78            
Rv2275     RFQLGRRIPEATAQEGFLVRPFTQQCQIIHTEGDHAVIGVSPGNSYFSRQRLRDLGLWGLTNFDRVDFVYT-DVHVAESYEAL 129 
YvmC-Blic      MTELIMESKHQLFKTETLTQNCNEILKRRRHVLVGISPFNSRFSEDYIHRLIAWAVREFQSVSVLLA-GKEAANLLEAL 78 
YvmC-Bsub      MTGMVTERRSVHFIAEALTENCREIFERRRHVLVGISPFNSRFSEDYIYRLIGWAKAQFKSVSVLLA-GHEAANLLEAL 78 
YvmC-Bthu      MTNAIAVRNVRKFSSQPLSTNCAEILKRSKHAIIGISPFNSRFSDEYINRLIEWALHTFDDVSVLLA-GKEAANLLEAL 78 
pSHaeC06       ---------MQNFKVDFLTKNCKQIYQRKKHVILGISPFTSKYNESYIRKIIQWANSNFDDFSILLA-GEESKNLLECL 69 
Plu0297        ----MLHENSPSFTVQGETSRCDQIIQKGDHALIGISPFNSRFSKDYVVDLIQWSSHYFRQVDILLPCEREASRLLVAS 75 
Jk0923         -----------------------MGESKQEHLIVGVSPFNPRFTPEWLSSAFQWGAERFNTVDVLHP-GEISMSLLTST 56 
Nvec-CDPS2     ----MPLKHEHHQDGGLIFTTGDRVLEEKGVVLFGMSPGNPYYKQPIIEQYVEFLGKEPRKIVVFVP-QQPSVHTYRAM 74 
Ndas_1148  MSSPTELEPPPEPEDAFDVLPFTGSCRRVFERGEHALIGISAGNSYFSQERIAQLLRWAQRHFAEVDVLYA-DLHLDTMYMAS 82 
 
 
  
3OQV AlbC 
2XQ9 Rv2275 
3OQJ YvmC-Blic 
                                                                                            * 
AlbC           GRSAQEAERSVKRTLKDLRRRLRRSLESVG----DHAERFRVRSLSELQETPEYRAVRERTDRAFEEDAEFATACEDMV 153 
Rv2275         GDSAIEARRKAVKNIRGVRAKITTTVNELD----PAGARLCVRPMSEFQSNEAYRELHADLLTRLKDDEDLRAVCQDLV 204 
YvmC-Blic      GTPHGKAERKVRKEVSRNRRFAEKALEAHG------GNPEDIHTFSDFANQTAYRNLRMEVEAAFFDQTHFRNACLEMS 151 
YvmC-Bsub      GTPRGKAERKVRKEVSRNRRFAERALVAHG------GDPKAIHTFSDFINK-AYQLLRQEVEHAFFEQPHFRHACLDMS 150 
YvmC-Bthu      G-HQSKRKEKLGKKISRNRRSAEKALKEHG------GNVNAIHTFSDFNDNNAYSCMRAEAEHIFLSETVFRNACLEMS 150 
pSHaeC06       GYSSSKANQKVRKEIKRQIRFCEDEIIKCN-----KTITNRIHRFSDFKNNIYYIDIYKTIVDQFNTDSNFKNSCLKMS 143 
Plu0297        GIDNVKAIKKTHREIRRHLRNLDYVISTAT----LKSKQIRVIQFSDFSLNHDYQSLKTQVENAFNESESFKKSCLDMS 150 
Jk0923         GTPLGRAKRKVRQQCNRDMRNVEHALEISG----IKLGRGKPVLISDYLQTQSYQCRRRSVIAEFQNNQIFQDACRAMS 130 
Nvec-CDPS2     GSK--DAVKRAKKHADYLRAHCKRAIKKLSKLRELPGDFHFVDWPREVATHVVYQEKLEEMTRLYHTHALFRQDAVREV 151 
Ndas_1148      GGSREHASSRANRALKDVRRRIRRAVEAAA----PDAGNVRVRALSQCTGLPGYRDVAYRLDREHATDPRVRRACEEHV 157 
 
 
  
 
3OQV AlbC 
2XQ9 Rv2275 
3OQJ YvmC-Blic 
                                                          *             *     * 
AlbC           RAVVMNRPGDGV-----------GISAEHLRAGLNYVLAEAPLFADSPGVFSVPSSVLCYHIDTPITAFLSRRETGFRA 221 
Rv2275         RRFLSTKVGPR-----------QGATATQEQVCMDYICAEAPLFLDTPAILGVPSSLNCYHQSLPLAEMLYARGSGLRA 272  
YvmC-Blic      HAAILGRARGT-------RMDVVEVSADMLELAVEYVIAELPFFIAAPDILGVEETLLAYHRPWKLGEQISRNEFAVKM 223 
YvmC-Bsub      REAIIGRARGV-------SLMMEEVSEDMLNLAVEYVIAELPFFIGAPDILEVEETLLAYHRPWKLGEKISNHEFSICM 222  
YvmC-Bthu      HAAILGRARGT-------NIDIDQISNDMLNIAVEYVIAELPFFIGGAEILGTQEAVLIYHKPWELGEQIVRNDFSIRM 222 
pSHaeC06       LQALQSKGKNV--------NTSIEITDETLEYAAQYVLAELPFFLNANPIINTQETLMAYHAPWELGTNIINDQFNLKM 214 
Plu0297        FQAIKGRLKGT-------GQYFGQIDLQLVYKALPYIFAEIPFYLNTPRLLGVKYSTLLYHRPWSIGKGLFNGSYPIQV 221 
Jk0923         RAACQSRLRVT-----------NVNIEPDIETAVKYIFDELPAYTHCSDLFEYETAALGYPTEWPIGKLIESGLTSLER 198  
Nvec-CDPS2     ARVLGKTPRDEMSDKESADFYPDLYNDDSIREAVLYIIEEFAYILASKALYDADEVTFIYHRSWPILEKLINGEYDGKP 230 
Ndas_1148      RHVIGAQPDPD---------------GARLRAGLAYLRAELPLLLSTPRVLGLPSSVCCYHALMPILSRLRGATSCFHP 221 
 
 
 
  
3OQV AlbC 
2XQ9 Rv2275 
3OQJ YvmC-Blic 
  
AlbC           AEGQAYVVVRPQELADAA-------- 239  
Rv2275         SRNQGHAIVTPDGSPAE--------- 289 
YvmC-Blic      RPNQGYLMVSEADERVESKSMQEERV 249 
YvmC-Bsub      RPNQGYLIVQEMAQMLSEKRITSEG- 247 
YvmC-Bthu      KPNQGYLMVQEMENLS---------- 238   
pSHaeC06       NEKQGYIILTEKGDNYVKSV------ 234    
Plu0297        ADKQSYGIVTQL-------------- 234 
Jk0923         DPNSSFIVIDFEKELIDD-------- 216   
Nvec-CDPS2     --RQGYGFCIIC-------------- 240 
Ndas_1148      GQGHVILRPVDRHLASPETVGSP--- 244 
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SUPPLEMENTARY FIGURES 
 
Table S1. Primers used in this study. 
For construction of the mutant AlbC-p(Ndas_1148): 
AlbC V65L V67A 5’-TTCGAGCGCACCGATGTCCTCTATGCCGACACCCACATCGAC 
AlbC M152H 5’-ACCGCCTGCGAGGACCATGTGCGGGCCGTGGTG 
AlbC F186L 5’-AGGCCCCGCTCCTCGCTGACTCGCCCGGA 
AlbC L200C T206M 5’-GTCCCCTCCTCGGTGTGCTGCTACCACATCGACATGCCGATCACGGCGTTC 
 
For construction of other AlbC mutants and the mutant Ndas_1148: 
AlbC V65L 5’-GAGCGCACCGATGTCCTCTATGTCGACACCCAC 
AlbC V67A 5’-ACCGATGTCGTCTATGCTGACACCCACATCGAC 
AlbC L200C 5’-GTCCCCTCCTCGGTGTGCTGCTACCACATCGAC 
AlbC T206M 5’-CTCTGCTACCACATCGACATGCCAATCACGGCGTTC 
AlbC-p(Ndas_1148)/M152 5’-CACCGCCTGCGAGGACATGGTGCGGGCCGTGGTG 
AlbC-p(Ndas_1148)/L200N 5’-GTCCCCTCCTCGGTGAACTGCTACCACATCGAC 
Ndas_1148 C200N 5’-GGTCTGCCGAGCAGCGTTAATTGTTATCATGCACTGATG 
 
 
 
 
Figure S1. Genomic contexts showing the neighboring genes of the genes encoding AlbC and 
Ndas_1148. The CDPS genes, the genes encoding the two subunits of CDO and the genes encoding 
proteins annotated as methyl transferases are shown in brown, green and gray, respectively. 
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Figure S2. MS/MS of the major compound produced by Ndas_1148, identified as cFY. The 
fragmentation pattern is characteristic of a cyclodipeptide and red labels at 120.0 ± 0.1 and 136 ± 0.1 
match the immonium ions of Phe (iPhe) and Tyr (iTyr), respectively. 
 
 
Figure S3. LC-MS/MS analysis of the cyclodipeptides secreted into the culture supernatant of E. coli 
cells producing AlbC. (A) UV traces (λ = 214 nm) of the culture medium of AlbC-producing cells 
(orange) and cells containing the empty cloning vector (gray). (B) Corresponding EIC chromatograms 
with the same color codes. This experiment was duplicated and gave similar results. 
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Figure S4. LC-MS/MS analysis of the cyclodipeptides secreted into the culture supernatant of E. coli 
cells producing AlbC V65L. (A) UV traces (λ = 214 nm) of the culture medium of AlbC V65L-producing 
cells (red) and cells containing the empty cloning vector (gray). (B) Corresponding EIC chromatograms 
with the same color codes. This experiment was duplicated and gave similar results. 
 
Figure S5. LC-MS/MS analysis of the cyclodipeptides secreted into the culture supernatant of E. coli 
cells producing AlbC V67A. (A) UV traces (λ = 214 nm) of the culture medium of AlbC V67A-
producing cells (blue) and cells containing the empty cloning vector (gray). (B) Corresponding EIC 
chromatograms with the same color codes. This experiment was duplicated and gave similar results. 
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Figure S6. LC-MS/MS analysis of the cyclodipeptides secreted into the culture supernatant of E. coli 
cells producing AlbC M152H. (A) UV traces (λ = 214 nm) of the culture medium of AlbC M152H-
producing cells (green) and cells containing the empty cloning vector (gray). (B) Corresponding EIC 
chromatograms with the same color codes. This experiment was duplicated and gave similar results. 
 
Figure S7. LC-MS/MS analysis of the cyclodipeptides secreted into the culture supernatant of E. coli 
cells producing AlbC F186L. (A) UV traces (λ = 214 nm) of the culture medium of AlbC F186L-
producing cells (pink) and cells containing the empty cloning vector (gray). (B) Corresponding EIC 
chromatograms with the same color codes. This experiment was duplicated and gave similar results. 
20 25 30 35 40 45
0
2
4
6
8
Time (min)
B
In
te
n
si
ty
x 
10
5
-50
0
50
100
In
te
n
si
ty
(m
AU
)
A
cFF
295.1
cFL
261.1
cLL
227.2
cFM
279.1cLM
245.1
cFY
311.1
cMM
263.1
cYL
277.1
20 25 30 35 40 45
0.0
0.5
1.0
1.5
Time (min)
B
In
te
n
si
ty
x
 
10
6
0
100
200
300
400
500
A
In
te
n
si
ty
(m
AU
)
cFF
295.1
cFL
261.1
cLL
227.2
cFM
279.1cLM
245.1
cFY
311.1
cMM
263.1
cYL
277.1
cYY
327.1
cLA
185.1
cYM
295.1
cYA
235.1
cFA
219.1
146 
 
 
Figure S8. LC-MS/MS analysis of the cyclodipeptides secreted into the culture supernatant of E. coli 
cells producing AlbC L200C. (A) UV traces (λ = 214 nm) of the culture medium of AlbC L200C-
producing cells (light blue) and cells containing the empty cloning vector (gray). (B) Corresponding 
EIC chromatograms with the same color codes. This experiment was duplicated and gave similar 
results. 
 
Figure S9. LC-MS/MS analysis of the cyclodipeptides secreted into the culture supernatant of E. coli 
cells producing AlbC T206M. (A) UV traces (λ = 214 nm) of the culture medium of AlbC T206M-
producing cells (light green) and cells containing the empty cloning vector (gray). (B) Corresponding 
EIC chromatograms with the same color codes. This experiment was duplicated and gave similar 
results. 
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3.3 Additional information 
In the manuscript of the article, we have described the cyclodipeptides 
produced by the recombinant Ndas_1148 expressed in E. coli. Although we supposed 
that the final products from the Ndas_11481dependent biosynthetic pathway could 
be dehydrogenated and methylated cyclodipeptides because in N. dassonvillei, 
Ndas_1148 is clustered with genes encoding a CDO homologue and methyl 
transferases ( 4 of the section $), it should still be of great interest to 
experimentally determine the DKPs produced by Ndas_1148 and the putative 
cyclodipeptide1tailoring enzymes in N. dassonvillei. However, N. dassonvillei is a 
pathogen and can induce infections in humans (González1López et al. 2011). The 
order of the strain is thus a complicated procedure because of the strict eximination. 
Now, our collaborative team directed by Jean1Luc Pernodet (IGM, CNRS UMR 8621, 
Université Paris1Sud 11) has received the strain N. dassonvillei and has carried out the 
cultivation. We can thus analyze the culture supernatants by LC1MS/MS very soon 
so as to identify the final DKPs produced through the Ndas_11481dependent 
biosynthetic pathway. These results will be added in the article manuscript before 
submission. 
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4 ALBC0IMI FROM STREPTOMYCES SP. 
IMI 351155, A NEW CDPS TO FURTHER 
EXPLORE THE INTERACTIONS BETWEEN 
CDPSS AND THEIR SUBSTRATES AND THE 
MECHANISM USED BY CDPSS 
4.1 Introduction 
CDPSs have been proved to use a sequential ping1pong mechanism to catalyze 
the formation of cyclodipeptides (Vetting et al. 2010; Bonnefond et al. 2011; Sauguet 
et al. 2011). Vetting and his coworkers have reported the kinetic parameters of 
Rv2275 for E. coli substrate (Vetting et al. 2010). However, they are the apparent 
kinetic parameters for Tyr1tRNATyr which is not only the first substrate, but also the 
second one because Rv2275 produces cYY (Gondry et al. 2009). Thus, it is not 
possible to discriminate the binding of the two ordered substrates and in particular 
to determine the kinetic parameters for the first and the second substrates. In order to 
solve this problem, such a CDPS is needed: a protein which does not use the same aa1
tRNA as the two ordered substrates in the reaction, and consequently does not 
produce the cyclodipeptide composed of the same amino acid residue. Unfortunately, 
no CDPS characterized to date meets the condition. Only AlbC from S. nousei mainly 
synthesizes a cyclodipeptide composed of two different amino acids, that is cFL, but 
it also produces a lot of cFF and significant amounts of cLL (Gondry et al. 2009). 
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However, such CDPS with the characteristic listed above was recently 
identified by the Jean1Luc Pernodet’s team. They were particularly interested by the 
strain Streptomyces sp. IMI 351155 described to produce 11N1methylalbonoursin 
(Gurney and Mantle 1993) ( 	). By using a PCR approach with highly 
degenerated primer, they cloned a fragment of an albC homologue from Streptomyces 
sp. IMI 351155. By probing a cosmid genomic library of strain Streptomyces sp. IMI 
351155, they isolated DNA fragments susceptible to contain the complete 
methylalbonoursin biosynthetic gene cluster from Streptomyces sp. IMI 351155. These 
fragments have been sequenced and their sequence analyzed and compared to the 
one of Streptomyces noursei. Comparisons of cluster organization and percentage of 
sequence identity are given in 
 (non published data). 
 
Figure 44: Structure of 1-N-methylalbonoursin (Gurney and Mantle 1993) with the methyl group 
shown in red (A), and comparison of cluster organization between S. noursei and S. sp. IMI 351155 
with percentages of sequence identity indicated. 
Besides, our laboratory analyzed by LC1MS/MS the culture supernatant of the 
strain Streptomyces sp. IMI 351155 and we have detected the presence of 11N1
methylalbonoursin. We have shown that the strain was also producing albonoursin 
N
NH
O
O
A
B S. noursei
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but cyclo(MPhe1MPhe) or its methylated derivative were not detected. This 
observation made us suppose that the CDPS AlbC1IMI produce cFL but not cFF. We 
thus decided to study this CDPS and by using its characteristics, to better understand 
its interaction with each of the two substrates as well as the mechanism of CDPSs. 
In this chapter, we will present our preliminary results obtained so far, which 
concern the characterization of the in vivo activity of AlbC1IMI, the purification of the 
enzyme, as well as the preliminary work on substrate order used by AlbC1IMI. These 
results are significant because they allow performing a complete study on AlbC1IMI 
in the future. 
4.2  Materials and methods 
4.2.1 Expression of recombinant AlbC0IMI in E. coli and analysis of its in 
vivo activity 
The pQE60 vector (Qiagen) was used to construct the plasmid pQE601AlbC1IMI, 
as previously described in (Gondry et al. 2009). AlbC1IMI was expressed in E. coli 
M15 [pREP4] cells (Invitrogen) transformed with the plasmid pQE601AlbC1IMI. The 
culture supernatant was then analyzed by LC1MS/MS. Cells were disrupted and 
expression of the protein AlbC1IMI was analyzed by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS1PAGE) and western blot. Proteins on SDS1
PAGE gel were revealed by Coomassie brilliant blue whereas protein transferred to 
the Polyvinylidene fluoride (PVDF) membrane is revealed by an immuno1reaction. 
Meanwhile, the same experiments were carried out to the pQE60 vector without 
AlbC1IMI gene, which was taken as a control. The experimental detail was described 
by Gondry et al (Gondry et al. 2009). 
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4.2.2 Purification of AlbC0IMI 
4.2.2.1 Expression of AlbC0IMI in E. coli  BL210AITM 
The competent strain E. coli BL211AITM is transformed with the plasmid pQE601
AlbC1IMI by mixing 50 ng of the plasmid with 100 ll of competent E. coli BL211AITM 
cells. The mixture is incubated for 30 minutes in the ice. A thermal choc of 45 seconds 
at 42 °C is performed in order to make the plasmid penetrate into the bacterium. 
After that, the mixture is incubated for another 2 minutes in the ice. Then the 
transformation product is incubated in 250 ll of SOC medium for one hour at 37 °C 
with stir (200 rpm). 
Preculture of AlbC1IMI is then performed by adding 150 ll of the transformed 
product in 50 ml of LB medium containing 100 lg l11 ampicillin (Amp). The 
preculture lasts over night (about 15 hours) at 37 °C/200 rpm. The next morning, we 
inoculate 2 liters of LB/Amp so as to obtainan initial OD600 of 0.1. The culture 
mixture is incubated at 37 °C/200 rpm until OD600 reaches 0.6 1 0.7. Then, expression 
of AlbC1IMI is induced with 1 mM Isopropyl β1D111thiogalactopyranoside (IPTG). 
The culture is incubated for 20 hours at 20 °C. Then the culture product is 
centrifuged for 40 minutes at 3500 g. The cell pellets are stored at 180 °C. 
4.2.2.2 Extraction of soluble AlbC0IMI protein from E. coli  BL210AITM cells 
The cell pellets are resuspended in the lysis buffer consisting of Tris1HCl 100 
mM (pH 8), 150 mM NaCl, 5% glycerol and a reducing agent (10 mM β1
mercaptoethanol). Meanwhile, 1 mM PMSF and 10 lM phosphoramidon are added 
to inhibit activities of proteases. The bacterial cells were broken in the Eaton press to 
recover the recombinant AlbC1IMI protein. Eaton press allows to shatter the frozen 
cells by passing in a hole of small diameter by the application of a pressure up to six 
tons. Add again 1 mM PMSF and 10 lM phosphoramidon in the homogenate 
obtained. The homogenate was then treated with Benzonase® (a phosphodiesterase) 
of 250 U/ll in the presence of 10 mM MgCl2 to degrade cellular DNA and RNA. The 
mixture is incubated in the cold room (4 °C) until the homogenate becomes fluid, 
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which indicates total degradation of nucleic acids. This process normally lasts 30 
minutes to 1 hour. After that, the fluid homogenate is centrifuged for 30 minutes 
(4000 g, 4°C) to separate the soluble and insoluble fractions. The supernatant, that is 
the soluble fraction, is used to the purification procedure described below. The 
purification system is ÄKTA design (GE Healthcare). The purification process is 
monitored by UV detection at 280 nm and 260 nm. 
4.2.2.3  Step one: immobilized metal ion affinity chromatography (IMAC) 
His1tagged recombinant AlbC1IMI is firstly purified by IMAC with a 
precharged nickel column (HisTrap HP 5 ml, GE Healthcare). The column is 
equilibrated with 50 ml of 55	 (40 mM imidazole, 150 mM NaCl, 100 mM Tris1
HCl (pH 8), 5% glycerol, 10 mM β1mercaptoethanol, and 1mM PMSF). The 
supernatant previously obtained is loaded onto the column at a flow rate of 1 
ml/min. The column is then washed with 55	at a flow rate of 3 ml/min until 
the UV detector shows a path back to its baseline. Then the elution is carried out with 
a linear gradient from 40 to 1000 mM imidazole at a flow rate of 1 ml/min. The 
fraction showing UV absorption is collected and analyzed with SDS1PAGE, then 
passed to the second step of purification. 
4.2.2.4 Step two: heparin affinity chromatography 
The UV spectrum of the fraction collected from the nickel column indicates a 
significant contamination by nucleic acids. In order to eliminate this contamination, 
the protein is further purified with a column charged with heparin (HiTrap Heparin 
HP 5ml, GE Healthcare). The column is equilibrated with 50 ml of 55 (50 mM 
NaCl, 100 mM Tris1HCl (pH 8), 5% glycerol, 10 mM β1mercaptoethanol, and 1 mM 
PMSF). The protein obtained from the first step of purification is loaded onto the 
heparin column at a flow rate of 1 ml/min. The column is then washed with 55 
at a flow rate of 3 ml/min until the UV detector shows a path back to its baseline. 
The elution is carried out with a linear gradient from 50 to 1000 mM NaCl at a flow 
rate of 1 ml/min. The protein eluted is collected and analyzed with SDS1PAGE. The 
UV spectrum of the protein indicates the contamination of nucleic acids is removed. 
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4.2.2.5 Step three: size exclusion chromatography (SEC) 
SEC is also called gel filtration chromatography or gel permeation 
chromatography. In order to obtain pure protein, the protein eluted from the second 
step is further purified by SEC with the column Sephacryl S1200 Hiprep 26/60 (GE 
Healthcare). In order to determine the apparent molecular weight of proteins eluted, 
the column is regularly calibrated from a calibration curve made after injection of 
standard proteins, the molecular masses of which are known. Before purification, the 
column is equilibrated with at least two column volumes (2 x 340 = 680 ml) of 55
 (20 mM Tris1HCl (pH 8), 150 mM NaCl, 5% glycerol, 1mM DTT, and 1 mM PMSF) 
at a flow rate of 1 ml/min. The protein eluted from the second step is concentrated to 
less than 6 ml then loaded onto the column at a flow rate of 1 ml/min. The elution is 
carried out with 55 . AlbC1IMI is eluted at 160 ml, which corresponds to its 
molecular mass. 
4.2.2.6 Concentration and conservation of the protein 
The protein is concentrated with Amicon® Ultra115 10K centrifugal filter device 
(Millipore) by centrifugation at 5000 g with a fixed angle rotor. Every 10 minutes, the 
protein is homogenized to avoid the aggregation. Then the concentration of the 
protein is determined by absorption of UV at 280 nm. The pure protein is analyzed 
with SDS1PAGE and western blot then conserved at 180 °C. The protein should 
beforehand be frozen in liquid nitrogen before conservation at 180 °C.   
4.2.3 Substrate order of AlbC0IMI 
As described in Gondry et al. (Gondry et al. 2009), the experiment is globally 
carried out in three steps (): firstly, the acyl1enzyme1forming reaction takes 
place in appropriate reaction medium in vitro which contains radioactivity labeled 
amino acid ([14C]Phe or [14C]Leu). Secondly, the reaction medium is deposited on 
two SDS1PAGE gels and AlbC1IMI is separated from the other components of 
reaction by electrophoresis. Finally, one gel is stained in silver nitrate in order to 
reveal proteins whereas the proteins on the other gel are transferred onto a PVDF 
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membrane by western blot. The latter one is analyzed by a radioactivity analyzer “β1
Imager” so as to reveal the 14C labeled acyl1enzyme. In this way, we show which aa1
tRNA interacts with AlbC1IMI as the first substrate. 
It should be noted that tRNAPhe and tRNALeu used in our in vitro experiments    
are obtained by in vitro transcription (Villet et al. 2007) performed by M. Fonvielle 
(UMR S 872, INSERM UPMC UPD) on the basis of the sequences of E. coli tRNAs. In 
E. coli, there exist six tRNALeu isoacceptors. A manuscript dealing with the 
recognition of each of these isoacceptors by AlbC from S. nousei is being prepared in 
the laboratory. This study showed that the tRNALeu CAG isoacceptor is the best 
substrate for AlbC from S. nousei compared to the other five isoacceptors. We thus 
used this tRNALeu isoacceptor for the study of AlbC1IMI after having made sure that 
it is a good substrate for AlbC1IMI, which means, in the presence of this tRNALeu 
isoacceptor and tRNAPhe, AlbC1IMI produces cFL (data not shown). 
156 
 
Figure 45: Procedure of acyl-enzyme experiment. 
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4.2.3.1 Acyl0enzyme0forming reaction 
The formation of acyl1enzyme is realized by a coupled reaction. The total 
volume of one reaction is 10 nl. In the reaction medium, we mix 50mM Hepes1KOH 
(pH 7.5), 150 mM KCl, 14 mM MgCl2, 2 mM ATP, 10 mM β1mercaptoethanol, 0.1 mM 
EDTA, 1.5 nM tRNA, 50 nM radioactivity labeled amino acid from PerkinElmer 
([14C]Phe or [14C]Leu, the specific radioactivities of which are respectively 90 and 153 
nCi/nmol), and RNase free H2O. The aminoacylation reaction is initiated by adding 
1 nM cognate aaRS. The reaction medium is then incubated at 30 °C during 10 min. 
The formation of acyl1enzyme is initiated by adding 5 ll of 3 lM pure AlbC1IMI. So 
the final concentration of AlbC1IMI in the reaction medium is 1 lM. The reaction 
lasts for 20 s at room temperature. Then the reaction is stopped by adding 5 ll of 
Laemmli buffer 5X at 50°C for 2 min. The Laemmli buffer 5X contains 0.1% (w/v) 
SDS, 10% (v/v) glycerol, 50 mM Tris1HCl (pH 6.8) and 100 mM DTT. 
4.2.3.2 SDS0PAGE 
The reaction medium is firstly mixed with a blue solution containing 62.5 mM 
Tris1HCl (pH 6.8), 0.02% (w/v) bromophenol blue, 2% (w/v) SDS, 2% (v/v) β1
mercaptoethanol and 20% (v/v) glycerol. The sample is denatured at 95 °C for 5 min. 
Then 9 ll of denatured sample is deposited on two SDS1PAGE gels containing 12% 
acrylamide for two different revelation methods (silver nitrate staining and β1Imager) 
described later. 3 ll of protein marker from Bio1Rad (Precision Plus ProteinTM All 
Blue Standards) is deposited on each gel. The migration is performed with the 
system Mini1Protean3 DodecaTM Cell (Bio1Rad) at 200 volt during 45 min. 
4.2.3.3 Silver nitrate staining of SDS0PAGE gel 
One of the two SDS1PAGE gels is stained in silver nitrate. Le gel is firstly 
incubated for 30 min in the fixing solution (50% methanol, 10% acetic acid, and 100 
mM ammonium acetate), then washed twice with H2O for 30 min each time. The gel 
is incubated with 0.005% (w/v) sodium thiosulfate solution for 30 min then with 0.1% 
(w/v) silver nitrate solution for another 30 min. After that, the gel is washed with 
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H2O for several seconds. Then the gel is soaked in a developer (0.036% formaldehyde, 
2% sodium carbonate) for several minutes until the protein bands appear. The 
staining is stopped by incubating the gel with 50 mM EDTA during 30 min. Finally, 
the gel is washed twice with H2O. 
4.2.3.4 Transfer to the PVDF membrane and revelation by β0Imager 
The protein bands of the other SDS1PAGE gel are transferred to a PVDF 
membrane. Firstly, the membrane is activated by 100% ethanol for 5 seconds then 
rinsed in the transfer buffer composed of 25 mM Tris1HCl (pH 7.5), 192 mM glycine 
and H2O. The transfer is performed with a semi1dry transfer cell (Trans1Blot® SD) 
from Bio1Rad at 400 mA during 30 min. After transfer, the membrane is rinsed with 
H2O then with a solution composed of 5% TCA and 0.5% casamino acids three times 
with 10 min each time in order to remove the non1specific fixation of amino acid. 
Finally, the membrane is dried with a hair dryer. 
Before analysis of the membrane by β1Imager, the bands of molecular weight 
standard are highlighted by toothpicks with a 14C labeled solution in order that the 
protein marker can be revealed by β1Imager. After that, the membrane is analyzed 
for 4 hours with Biospace Beta imager 2000 digital system for auto1radiography 
which records every beta particle and generates images on screen in real time at low 
levels of radioactivity. 
4.3 Results 
4.3.1 AlbC0IMI, an active member of the CDPS family 
AlbC1IMI (279 residues) is a little longer than most of the ten characterized 
CDPSs (2161249 residues in general, with only one CDPS having 289 residues). It 
displays 35% identity and 48% similarity to AlbC from S. noursei. In addition, the 
isolated gene cluster containing albCIMI from S. sp. IMI 351155 shows albCIMI has a 
similar genetic environment to albC of S. noursei ( 
). As mentioned in the 
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introduction section ($), AlbC1IMI was supposed to synthesize cFL but not cFF. In 
order to confirm this hypothesis, recombinant C1terminal histidine1tagged AlbC1IMI 
was expressed in E. coli, and then the culture supernatant was analyzed by LC1
MS/MS as previously described (Gondry et al. 2009). 
Five cyclodipeptides were detected by LC1MS/MS in the culture supernatant of 
AlbC1IMI ( ). They are: cFL (21.2 ± 3.0 mg l11 of culture supernatant), cFM 
(1.6 ± 0.4 mg l11), cYL (0.2 ± 0 mg l11), cLM (0.2 ± 0.1 mg l11) and trace amounts of cFF 
(< 0.1 mg l11) (&	). Thus, the result demonstrated that AlbC1IMI is an active 
CDPS that predominantly synthesizes cFL and produces almost no cFF. Analysis of 
the total expression of AlbC1IMI by SDP1PAGE and western blot showed that AlbC1
IMI was much less produced than AlbC in E. coli (&
). It could explain that 
AlbC1IMI synthesizes less cFL than AlbC does (44.5 ± 5.7 mg l11 of culture 
supernatant) (&	). 
 
Figure 46: LC-MS/MS analyses of the cyclodipeptides secreted into the culture supernatant of E. coli 
cells producing AlbC-IMI. (A) UV traces (λ = 214 nm) of the culture medium of AlbC-IMI-producing 
cells (red) and cells containing the empty cloning vector (gray). (B) Corresponding EIC chromatograms 
with the same color codes. 
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Figure 47: Comparison of cyclodipeptide-synthesizing activities and protein expression profiles for 
AlbC-IMI and AlbC. (A) Histogram of the amounts of the various cyclodipeptides synthesized by AlbC-
IMI (red) and AlbC (blue). Cyclodipeptide amounts are shown with errors bars because the values are 
obtained from at least two independent experiments, except for cLL for which only one experiment 
allowed its quantification. (B) Expression levels of AlbC-IMI and AlbC in E. coli revealed by a western 
blot with an immunorevelation.  
4.3.2 Purification of AlbC0IMI 
AlbC1IMI was expressed in E. coli BL211AITM cells (Invitrogen) transformed 
with the plasmid pQE601AlbC1IMI. We replaced E. coli M15 [pREP4], used for 
expression of AlbC from S. noursei, by E. coli BL211AITM cells in order to increase the 
expression level of AlbC1IMI (data not shown). The expressed histidine1tagged AlbC1
IMI protein was purified with a three1step chromatographic procedure as describe by 
Gondry et al. (Gondry et al. 2009). However, some precaution should be taken 
because AlbC1IMI is susceptible to proteolysis. Addition of the protease inhibitors, 
phenylmethylsulfonyl fluoride (PMSF) and phosphoramidon, is indispensable 
during the purification procedure (see below). 
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The purification results of AlbC1IMI protein is shown in  +. Analysis 
with SDS1PAGE and western blot showed that AlbC1IMI was well expressed in E. 
coli BL211AITM and well soluble ( +, lanes “Homogenate” and “Soluble 
fraction”). The first step of purification by HisTrap allowed separating His1tagged 
AlbC1IMI from other proteins in the cellular soluble fraction but it was contaminated 
by nucleic acids because the absorbance of the fraction eluted at 260 nm was greater 
than that at 280 nm ( +	 and  +, lane 1). The chromatogram of 
Heparin (+
) showed that nucleic acids were eliminated during the washing 
process and AlbC1IMI protein was eluted from the column during the NaCl gradient. 
The absorbance of the protein eluted at 280 nm was about 1.5 folds of that at 260 nm, 
which indicated no nucleic acid contamination was present. The protein was further 
purified with a gel filtration column and only one peak was observed. The elution 
volume (160 ml) corresponded to that expected for AlbC1IMI. SDS1PAGE and 
western blot analysis confirmed the purity of the protein ( +, lane 4). It 
should be noted that proteolysis of AlbC1IMI was efficiently inhibited by PMSF and 
phosphoramidon. The precise molecular mass of the protein was obtained by Maldi1
Tof (31535.2 Da). It corresponded to the mass of AlbC1IMI. Finally, we harvested 5.3 
mg pure AlbC1IMI from two liters of culture. 
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Figure 48: Three-step purification procedure of AlbC-IMI and analysis with SDS-PAGE and Western 
blot. Chromatograms of purification on columns HisTrap (A), Heparin (B) and Gel filtration (C). Blue 
and red lines indicate UV absorptions at 280 and 260 nm, respectively. Expression of AlbC-IMI and 
fractions eluted from the three purification steps are analyzed by SDS-PAGE and Western blot (D).1, 
2, 3, and 4 lanes indicate the fractions eluted from HisTrap, Heparin, concentrated fraction from 
Heparin, and Gel filtration, respectively. 
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4.3.3 Substrate order of AlbC0IMI 
Our in vivo experiments in E. coli have demonstrated that cFL is the 
predominant product of AlbC1IMI. AlbC1IMI should use Phe1tRNAPhe and Leu1
tRNALeu as substrates to catalyze the formation of cFL via a ping1pong mechanism. In 
order to know which aa1tRNA is the first substrate to interact with the protein, that 
means which amino acyl residue is covalently bound to AlbC1IMI to form the 
aminoacyl1enzyme intermediate, we carried out in vitro experiments with each of the 
radioactivity labeled substrates. As described in the section “materials and methods” 
(section $$), the tRNALeu isoacceptor used in the experiments is tRNALeu CAG.  
The results of the experiments are shown in the  .. The silver nitrate1
stained gel confirmed the presence of AlbC1IMI in the two reaction media (
.	). The PVDF membrane analyzed by β1Imager showed that AlbC1IMI incubated 
with [14C]Phe1tRNAPhe retained a high amount of the radiolabel, whereas AlbC1IMI 
incubated in the presence of [14C]Leu1tRNALeu did not retain any radiolabel (
.
). These results demonstrate that AlbC1IMI forms acyl1enzyme with the 
phenylalanine but not with the leucine. So it reveals that Phe1tRNAPhe is the first 
substrate of AlbC1IMI in its catalysis. 
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Figure 49: Acyl-enzyme-forming experiments. Enzymes were incubated with [14C]Phe-tRNAPhe or 
[14C]Leu-tRNALeu, as described in “Materials and Methods” section, separated on SDS-PAGE. One gel 
was stained with silver nitrate and AlbC-IMI bands were highlighted with white frame (A). Enzymes 
on the other gel were transferred onto a PVDF membrane which was then analyzed with β-Imager 
(B). 
4.4 Discussion 
We have shown that, as expected, AlbC1IMI essentially synthesizes cFL with 
cFF produced in trace amounts and no cLL produced at all. This CDPS is therefore 
appropriate for subsequent studies. AlbC1IMI has proven difficult to obtain in large 
quantity and without proteolysis. Nevertheless, we have still developed suitable 
conditions to obtain it. We were also able to start in vitro studies especially to 
determine the order of the two substrates used by AlbC1IMI. With this done, the 
kinetic characterization studies can be considered and performed. 
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5 XP_001636126 FROM NEMATOSTELLA 
VECTENSIS, THE FIRST ACTIVE CDPS 
IDENTIFIED IN ANIMAL 
5.1 Introduction 
With studies on the CDPS family going on, we are aware that members of the 
family are persistently growing. In addition to the bacterial members of the CDPS 
family described above, several other putative members of this family have been 
detected in various bacterial, and even in eukaryotes (Aravind et al. 2010; Seguin et al. 
2011). In this chapter, we will mainly describe, in the form of article, the first 
characterized eukaryotic CDPS (XP_001636126) from the sea anemone Nematostella 
vectensis in our laboratory. We have named it Nvec1CDPS2. A homology1based 
structural model for Nvec1CDPS2 is generated by using the crystal structure of AlbC 
as a template. By comparing with the structure of AlbC, the structural model gives us 
preliminary structural knowledge on Nvec1CDPS2. The cyclodipeptides produced by 
recombinant Nvec1CDPS2 in vivo are also identified. In addition, we will present the 
results of experiments carried out in vitro to characterize Nvec1CDPS2. 
My participation in this work concerned analysis by LC1MS/MS of the in vivo 
activity of Nvec1CDPS2. 
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5.2 Article 
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SUPPLEMENTAL INFORMATION
Supplemental Data
Gene encoding
Nvec-CDPS1
Gene encoding
Nvec-CDPS2
Gene encoding
Nvec-CDPS3
1141 nt 3360 nt
3489 nt 3580 nt
3481 nt 3389 nt
Figure S1, related to Figure 1. Schematic representation of the three genes encoding Nvec-CDSP1-3
The coding regions of the three genes are represented by lines. Their relative positions correspond to the
alignment of their sequences. The positions of the introns, indicated by inverted triangles, are the same in the
three sequences and the lengths of the introns are given. The sequences of the genes, of partial mRNAs and of the
deduced proteins are available in GenBank (Nvec-CDPS1: accession numbers for the gene NW_001834372
region 1122446..1128760, mRNA XM_001636075, protein XP_001636125; Nvec-CDPS2 accession numbers for
the gene NW_001834372 region 1133497..1141771, mRNA XM_001636076, protein XP_001636126; Nvec-
CDPS3: accession numbers for the gene NW_001833027 region 6667..14036, mRNA XM_001621161, protein
XP_001621211).
Figure S2, related to Figure 2. Nvec-CDPS2 model reliability by Qmean Server
The quality of the model of Nvec-CDPS2 was checked with Qmean server (Benkert et al, 2009). (A) The QMEAN
score of the query model is related to the scores of a non-redundant set of high-resolution X-rays structures of
similar size and a Z-score is calculated. The QMEAN score is a global score of the whole model reflecting the
predicted model reliability ranging from 0 to 1. (B) The estimated residue error is visualized using a color gradient
from blue (more reliable regions) to red (potentially unreliable regions, estimated error above 3.5 Å).
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Figure S3, related to Figure 3. Expression of Nvec-CDPS1 and Nvec-CDPS2 in E. coli
Analysis of soluble (S) and insoluble (I) protein fractions after bacterial lysis and centrifugation. Protein
separations were performed on 12% acrylamide gels. Then, the proteins were stained by Coomassie blue
(A) or transferred onto a polyvinylidene fluoride (PVDF) membrane visualized using alkaline phosphatase-
conjugated anti-His antibody and NBT/BCIP solution (Sigma) (B). Arrows indicate the expected position
of Nvec-CDPS1 at 36 kDa, and of Nvec-CDPS2 at 28 kDa. Molecular weight standards (MW) are in kDa.
Figure S4, related to Figure
3. Analyses of in vivo assays
for Nvec-CDPS2 activity
(A)Histogram of the amounts
of the various
cyclodipeptides
synthesized by Nvec-
CDPS2 after 20 hrs
(orange) and 44 hrs (blue)
of expression in E. coli.
Cyclodipeptides were
quantified on the basis of
their peak area at 214 nm
using calibration curves
obtained with authentic
standards, as previously
performed in Gondry et al
(2009). The amounts of
cWM and cWA (light blue
and light orange) were
estimated using cWL
calibration.
(B) Characterization of cWM
by MS/MS. Signals
specific for Trp are in red.
The loss of 48.0 is specific
for methionine’s
fragmentation.
(C) MS/MS/MS of the major
daughter ion resulting from
cWM fragmentation. The
fragmentation pattern is
characteristic for the
cyclodipeptide structure.
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Supplemental Experimental Procedures 
Purification of N. vectensisNvec-CDPS2  
The His6-tagged protein Nvec-CDPS2 was expressed and purified as previously 
described (Braud et al. 2005; Gondry et al. 2009), except that the HiPrep Sephacryl S-200 
column was replaced by a Superdex HR 75 column (GE- Healthcare Bio-Sciences). Protein 
production was followed by SDS-PAGE analyses; the proteins were stained by Coomassie 
blue or transferred onto a polyvinylidene fluoride (PVDF) membrane visualized using 
alkaline phosphatase-conjugated anti-His antibody and NBT/BCIP solution (Sigma). 
Analysis of cyclodipeptide synthesis by Nvec-CDPS2 
In vivo assays for Nvec-CDPS2 activity were performed as previously described(Gondry 
et al. 2009), except that culture durations were respectively 20 hrs and 44 hrs after addition of 
IPTG. The control strain was M15[pREP4] (Qiagen) harboring the empty vector pQE60. 
Cyclodipeptides were detected and identified by both their m/z value (MS) and their daughter 
ion spectrums (MS/MS), as a result of their common fragmentation patterns. The nature of the 
Figure S5, related to Figure 4. Analysis of the oligomeric state of the purified Nvec-CDPS2
280nm-chromatogram obtained when Nvec-CDPS2-containing fractions were submitted to a size exclusion
chromatography. Fractions were loaded onto a Superdex 75 HR 10/30 column (GE-Healthcare BioSciences).
Nvec-CDPS2 eluted as a single peak, with estimated Mr of 21 kDa, a value very close to its theorical Mr of
28 kDa, revealing a monomeric state of the enzyme.
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detected cyclodipeptides was unambiguously confirmed by comparison with authentic 
standards except for cWM and cWA. The standards cWL and cWF were obtained from 
Bachem, cLA from Sigma-Aldrich, and others have already been described (Gondry et al. 
2009). 
Detection of Nvec-CDPS2 activity 
cFF-forming activity of Nvec-CDPS2 was measured by a coupled assay detailed 
in(Sauguet et al. 2011). Assay mixtures contained 2 mM L-Phe, 1.2 µM E. coli tRNAPhe 
(Sigma), 1 µM of E. coli PheRS, in 50 mM Hepes-KOH, pH 7 containing 50 mM KCl, 10 
mM ATP, 1 mM DTT and 20 mM MgCl2. After 20 min of incubation at 30°C, reactions were 
initiated by the addition of Nvec-CDPS2 (125 nM-1 µM). 90 µl aliquots were withdrawn at 
different times and quenched by the addition of 2 µl of TFA. After addition of 10 µl of a 12.5 
µM 13C9,15N-labeled cFF solution (see below), 90 µl of these aliquots were injected in LC-MS 
on the same system as in vivo assays, with a linear gradient from 20 to 40% (v/v) acetonitrile 
in 0.1% (v/v) formic acid for 20 min (flow rate, 0.6 ml min-1). The detection of cFF 
synthesized was achieved by mass spectrometry using 13C9,15N-labeled cFF as a stable isotope 
internal standard. The synthesis of the standard was performed according to (Jeedigunta et al. 
2000), with the exception that Boc-Phe-OH 13C9,15N was used instead of Boc-Phe-OH. The 
resulting 13C9,15N-labeled cFF (m/z = 305.1) and cFF (m/z = 295.1) have a difference of 10 
mass units.  
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5.3 Additional information 
We have described the first active CDPS, Nvec1CDPS2, identified in animal. 
Nvec1CDPS2 is probably not the only eukaryotic member of the CDPS family. Up to 
now, except in the sea anemone Nematostella vectensis, iterative PSI1BLAST searches 
have detected other four putative CDPSs in eukaryotes: the annelid 
Platynereisdumerilii, the fungi Gibberella zeae and Fusarium oxysporum, and the 
protozoa Ichthyophthirius multifiliis (Aravind et al. 2010; Belin et al. 2012). Not only in 
eukaryotes, are more and more bacterial putative CDPSs also being discovered in 
different phyla. A further 25 putative CDPSs have been recently identified, most of 
which belong to actinobacteria and proteobacteria. Aravind et al. had already noted 
the large number of parasitic bacteria among CDPS1encoding organisms, which are 
not specialized in the synthesis of secondary metabolites (Aravind et al. 2010). 
Taking for example, Rv2275 is a CDPS from a human pathogen M. tuberculosis which 
persists within the macrophage through a complex host1pathogen relationship. 
Knowledge on these CDPSs from the parasitic organisms along with their 
cyclodipeptide products could help us in studies of related diseases. 
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6 CONCLUSIONS AND PERSPECTIVES 
At the beginning of this manuscript, we have emphasized the developing 
interest in the drug discovery research of the diketopiperazines (DKPs) which 
include the cyclodipeptides and their derivatives. The structural complexity and 
diversity of this molecule family make it difficult to synthesize some DKPs with 
complex modifications via chemical approach. It is thus of great interest to elucidate 
the biosynthetic pathways of the DKPs. However, our knowledge on this aspect is 
still poor. Nonribosomal peptide synthetases (NRPSs) were the first enzymes 
discovered of being responsible for the synthesis of some DKPs. In the , we 
listed several DKP biosynthetic pathways dependent of NRPSs as examples, and 
detailed structures of NRPSs as well as their involvement in the nonribosomal 
peptide bond formation. Lately, the cyclodipeptide synthases (CDPS) family was 
discovered to be dedicated to the formation of cyclodipeptides (Gondry et al. 2009). 
Studies on CDPSs are thus of great interest to elucidate the biosynthesis of DKPs.  
The first part of our results on AlbC (), which is published in Nucleic 
Acid Research journal, reveals that AlbC displays high structural similarity to the 
catalytic domain of class1I aminoacyl1tRNA synthetases (aaRSs), especially class1Ic 
TyrRSs and TrpRSs. AlbC contains a catalytic pocket which is highly conserved 
among CDPSs. Our studies indicate that this pocket accommodates the aminoacyl 
moiety of the aa1tRNA substrate whereas the tRNA moiety interacts with AlbC via at 
least one patch of basic residues. Moreover, we have demonstrated that AlbC 
catalyzes its two1substrate reaction via a sequential ping1pong mechanism with a 
covalent intermediate in which Phe is shown to be transferred from Phe1tRNAPhe to 
an active serine situated in the catalytic pocket. A mechanism of covalent 
phenylalanyl1enzyme formation is also proposed. All these findings provide insight 
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into the molecular bases of the interactions between CDPSs and their aa1tRNA 
substrates, and the catalytic mechanism used by CDPSs to achieve the nonribosomal 
synthesis of cyclodipeptides. 
The following part of my thesis work was, by using the newly characteraized 
CDPSs, to deepen our knowledge on specificity of CDPSs and their catalytic 
mechanism. 
The second part of our results ( ) is on Ndas_1148, a recently 
characterized CDPS in Nocardiopsis dassonvillei. Compared to the other nine identified 
CDPS (Gondry et al. 2009; Seguin et al. 2011), Ndas_1148 has the closest protein 
sequence to AlbC and a genomic context similar to those of AlbC. However, in spite 
of all these similarities, the two CDPSs do not have the same substrate specificity. 
Ndas_1148 produces cFY as the major cyclodipeptide instead of cFL, which is the 
major product of AlbC. After a series of studies, we showed that their difference in 
profiles of cyclodipeptide production is mainly due to the difference in residues 
constituting the two CDPS pockets because the AlbC chimera obtained by grafting 
the Ndas_1148 pocket on AlbC has the substrate specificity of Ndas_1148. We also 
showed that the CDPS pocket contains specificity determinants responsible for the 
incorporation of a leucyl residue into cyclodipeptides. These findings are significant 
for understanding of the molecular bases of CDPS specificity, especially those located 
in the pockets. The chimera that corresponds to AlbC having the Ndas_1148 pocket 
has acquired the substrate specificity of Ndas_1148, suggesting that reprogramming 
of CDPS specificity can be achieved by replacing the entire pocket of a given CDPS 
with that of another one. 
The third part of our results ( ) consists of studies on AlbC1IMI, a 
CDPS identified in Streptomyces sp. IMI 351155. AlbC1IMI is a good study model for 
its sole cyclodipeptide produced, cFL, in the presence of Phe1tRNAPhe and Leu1
tRNALeu substrates. As CDPSs have been shown to use a sequential ping1pong 
mechanism, the two different substrate1binding sites on AlbC1IMI can thus be 
distinguished. According to results on acyl1enzyme intermediate1forming 
181 
experiments, we demonstrated that Phe1tRNAPhe is the first substrate to interact with 
AlbC1IMI rather than Leu1tRNALeu substrate. Our preliminary results demonstrate 
that the CDPS AlbC1IMI is of great interest and studies on it should pursue. 
The last part of our results ( ) concerns published work on the first 
characterized CDPS from an animal, that is Nvec1CDPS2 identified in the sea 
anemone Nematostella vectensis. Nvec1CDPS2 mostly produces in vivo Trp1containing 
cyclodipeptides, thus exhibits a different specificity than other characterized bacterial 
CDPSs which synthesize Phe1, Tyr1, and Leu1containing cyclodipeptides. This 
difference in specificity could be attributed to residues constituting the catalytic 
pocket because Nvec1CDPS2 contains in the pocket a higher proportion of aromatic 
residues than the other characterized CDPSs. This finding also suggests that the 
substrate specificity of CDPSs is related to their catalytic pockets. The 
characterization of Nvec1CDPS2 is of great significance because we have 
experimentally proved the existence of CDPS in the animal. Otherwise, other four 
eukaryotic genomes have been found to encode CDPSs: the fungi Gibberella zeae and 
Fusarium oxysporum, the annelid Platynereis dumerilii and the protozoa Ichthyophthirius 
multifiliis (Aravind et al. 2010; Belin et al. 2012).  
Genome mining revealed the presence of putative CDPSs in approximately 60 
different genome from bacteria, fungi or animal ( 0), including numerous 
parasitic bacteria (F. oxysporum, Candidatus Glomeribacter gigasporarum and 
Candidatus Odyssella thessalonicensis, for example) (Aravind et al. 2010; Belin et al. 
2012). It was suggested that cyclodipeptides might enable the parasite to reside 
within the host (Aravind et al. 2010). The earliest isolations of CDPSs included that of 
Rv2275 from Mycobacterium tuberculosis, which is a human pathogen that persists 
within the macrophage through a complex host1pathogen relationship. Rv2275 and 
its associated tailoring enzyme, CYP121, are highly conserved among the other 
pathogenic tuberculosis1causing mycobacteria of the tuberculosis complex (M. 
africanum, M. bovis, M. canetii and M. microti). Research on CDPSs originated from 
pathogens could be useful for studies on related diseases. 
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Figure 50: The developing CDPS-encoding organisms shown in the form of phylogenetic tree. The 
eight bacterial organisms and the eukaryotic organism encoding characterized CDPSs are shown in 
blue and in red, respectively. The organisms colored in black represent those encoding putative 
CDPSs. 
In bacteria, cyclodipeptides produce by CDPSs are usually precursors of more 
complex DKPs generated by tailoring reactions. The genes encoding the CDPSs and 
the associated cyclodipeptide1tailoring enzymes are clustered. Only three CDPS1
dependent pathways haven been fully elucidated so far, in which the cyclodipeptide1
tailoring enzymes are responsible for α,β–dehydrogenation, C1C aryl coupling, and 
DKP ring oxidation (Belin et al. 2012), as described in the introduction of the 
manuscript. New putative cyclodipeptide1tailoring enzymes are being discovered 
such as methyl1transferases, oxydoreductases, acyl1CoA and hypothetical proteins 
not yet related to any known function (Belin et al. 2012). For example, genes 
encoding methyl transferases have been seperetely found in the vicinity of the genes 
encoding Ndas_1148 and AlbC1IMI (sections 3and ). These proteins may catalyze 
0.1
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alternative modifications of cyclodipeptides, thereby enlarging the diversity of DKPs 
synthesized through CDPS1dependent pathways. 
As previously described, in addition to the CDPS family, NPRS systems are also 
used to synthesize DKP metabolites in nature (sections $$$$ and $$$). 
However, these two enzyme families are very different. One of the obvious 
differences is their size: CDPSs (about 26 kDa) are about ten times smaller than 
NRPSs involved in DKP biosynthesis. CDPSs are simple systems whereas NRPSs are 
complex, multimodular enzymes. This size difference probably reflects the different 
strategies used to activate the amino acid carboxyl group required for peptide bond 
formation: NRPSs use adenylation and pepetidyl carrier protein (PCP) domains to 
recognize and activate amino acids in the form of PCP1bound aminoacyl thioesters 
(section $$$), whereas CDPSs directly use activated amino acids in the form of aa1
tRNAs, thereby eliminating the need to activate amino acids (Belin et al. 2012). For 
that reason, CDPSs can only use the 20 canonical L1amino acids charged on tRNAs as 
substrates. However, amino acids incorporated by NRPSs are not restricted to the 20 
canonical L1amino acids. They can also incorporate some unusual amino acids 
(section $$$,  ) such as 41nitrotryptophan (Johnson et al. 2009) into 
thaxtomin A () biosynthesis (Belin et al. 2012). In addition, NRPS substrates 
can be altered on the enzyme by accessory domains introducing chemical 
modifications, such as methylation (methylation domains, thaxtomin synthetase) or 
configuration changes (epimerization domains, erythrochelin synthetase), whereas in 
CDPS1dependent pathways, chemical modifications can only be introduced after 
cyclodipeptide formation by cyclodipeptide1tailoring enzymes. Consequently, it 
coud lead to a wider structural complexity of DKPs synthesized through NRPS1
dependent pathways than that produced via CDPS1dependent pathways (Belin et al. 
2012). 
Otherwise, It is interesting to note that all the NRPS1dependent DKP 
biosynthetic pathways characterized to date are only found in bacteria and fungi, 
whereas CDPS1dependent pathways have been identified in bacteria, fungi (G. zeae, 
F. oxysporum), protozoa (I. multifiliis), and animals (N. vectensis, P. dumerilii) (Belin et al. 
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2012), as described above. The first characterized animal1originated CDPS from N. 
vectensisis has been experimentally demonstrated to be involved in nonribosomal 
cyclodipeptide synthesis (Seguin et al. 2011). Furthermore, the functions of the DKPs 
known to be synthesized by NRPS pathways are usually identified (roles of 
siderophores or toxins involved in pathogenicity), whereas those from CDPS 
pathways are poorly known (Belin et al. 2012). Interestingly, it is noted that in the 
marine annelid Platynereis dumerilii (Aravind et al. 2010), the expression of the CDPS 
gene increases in response to septic injury (Altincicek and Vilcinskas 2007). A role in 
immunity can thus be suggested for the DKP produced via the CDPS pathway (Belin 
et al. 2012). 
Regarding the reprogramming of enzymes, NRPS genes are particularly 
amenable to genetic engineering to modify the sequence or the nature of the peptide 
synthesized because of the modular architecture of the NRPS enzymes (Belin et al. 
2012), knowing that each module of NRPS, divided into domains, is responsible for 
the incorporation of one amino acid (section$$$). Several groups have succeeded 
in deleting, inserting or replacing modules, and site directed mutagenesis has been 
used to modify the substrate specificity of some adenylation domains (Eppelmann et 
al. 2002; Mootz et al. 2002; Hahn and Stachelhaus 2004; Lautru and Challis 2004; Miao 
et al. 2006; Nguyen et al. 2006; Wilkinson and Micklefield 2007).  
Studies on CDPSs began much latter than NRPSs. Our knowledge on CDPSs is 
still limited. However, the small size of CDPSs makes them good candidates for 
enzyme engineering. Such small proteins are generally easy to produce and to 
manipulate and could therefore be used to synthesize new cyclodipeptides. With our 
deepening understanding on molecular bases of the substrate specificity, it is 
conceivable to reprogram CDPSs by altering their substrate specificity. We already 
succeeded in modifying the nature of the cyclodipeptides produced by the CDPS 
AlbC by mutating a residue of its amino acyl1binding pocket (Sauguet et al. 2011). In 
the , we also demonstrated that the specificity of AlbC can be switched to 
that of Ndas_1148 by grafting the pocket of the latter on AlbC. Furthermore, the 
structural homology of CDPSs with class1Ic aaRSs is a precious source of information 
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for such a reprogramming since extensive work has been done on aaRSs, especially 
on the amino acid1binding pocket of TyrRSs to accommodate non natural amino 
acids (Liu and Schultz 2010). The strategies developed for TyrRSs could thus be 
adapted to CDPSs (Belin et al. 2012). In addition, in bacteria, the CDPS1dependent 
biosynthetic pathways are organized into gene clusters, providing useful information 
for combinatorial approaches. The characterization of new and versatile CDPSs and 
of various cyclodipeptide1tailoring enzymes, combined with CDPS engineering, 
opens up new possibilities for pathway engineering and combinatorial approaches to 
increase the natural diversity of DKPs, thus to generate products with interesting 
biological or pharmaceutical properties (Belin et al. 2012). 
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